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1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD), including the most common forms Crohn’s disease 
(CD) and ulcerative colitis (UC), are idiopathic diseases with a dysregulated immune 
response to the intestinal microbiota, which leads to mucosal inflammation and 
destruction of the mucosal integrity (1). In the last decades, especially in industrialized 
nations the prevalence of IBD increased dramatically (2). CD and UC are clinically 
relevant with a prevalence rate of 322 per 100,000 and 505 per 100,000 persons in 
Europe, respectively (3). Both subtypes of IBD show specific gender-dependent incidence 
rates. In the case of CD, female individuals have a higher incidence rate than male 
individuals (female:male ratio 1.31:1) (4). Conversely, UC is more common in male 
individuals compared to female individuals (female:male ratio 1:1.5) (5). Moreover, the 
incidence and prevalence rates of IBD differ depending on the geographic location. For 
example, in Europe are the highest annual incidences of UC and CD with 24.3 and 19.2 
cases per 100,000 persons and year, respectively. In comparison, in Asia and the Middle 
East the annual incidence rates of UC and CD are lower with 6.3 and 5 cases per 100,000 
persons and year, respectively (3). The higher incidence rates in Europe suggest that the 
lifestyle of Western industrial societies is a relevant factor contributing to an increased 
pathogenesis of IBD. Moreover, the incidence rates are age-dependent, although IBD can 
occur at any age. The peak age of IBD manifestation is between the ages of 16 and 24 
years (6,7).  
The differentiation between the two major forms of IBD, CD and UC, can be made by the 
distribution and nature of the inflammatory changes. CD may affect segments of the entire 
gastrointestinal tract from the mouth to the anus, whereas UC is limited to the colon. The 
discontinuous inflammation in CD is transmural and affects all layers of the intestine (8). 
UC is characterized by diffuse mucosal inflammation with extensive superficial mucosal 
and submucosal ulcerations (9). Many clinical symptoms of both IBD subtypes are quite 
similar, including persistent and chronically relapsing diarrhea, abdominal pain, fever and 
loss of appetite. Blood in the stool, rectal bleeding and body weight loss may also occur 
(10,11). Furthermore, IBD patients with severe and long-term active disease have an 
increased risked for colon cancer (12). About 36 % of patients with IBD are additionally 
burdened by extra-intestinal manifestations, such as arthritis, fatty liver or growth 
retardation in children (13). For both diseases currently no cure is available (14,15). Many 




patient suffering. However, due to the fact that IBD is a lifelong disease and the incidence 
rates increase worldwide, new therapeutics for better and more effective treatments of UC 
and CD patients are needed. If the symptoms cannot be controlled by medications 
anymore, surgeries are performed. Three quarters of CD and one quarter of UC patients 
require surgery during their life (16). The complication rates of these resectional surgeries 
are high with 57 % and 31 % for CD and UC, respectively (17). The disease symptoms 
and the limited medications result in a reduced quality of life. 
The human body contains ten-fold more microbial cells than human cells (18). These 
microorganisms colonize at the boundary surfaces, such as the skin, respiratory or 
gastrointestinal tract. In the gastrointestinal tract microorganisms reach the highest 
density (19). For that reason, the intestinal homeostasis highly depends on a complex 
interaction between gut microbiota, intestinal epithelium and the host immune response 
(20). The intestinal epithelium participates in the coordination of appropriate immune 
responses and fulfills the barrier function with a tightly sealed cell layer covered by a 
mucus biofilm secreted from goblet cells (21). This mucus biofilm is essential for the 
intestinal homeostasis as suggested by decreased expression levels of the MUC1 gene in 
CD patients (22). Paneth cells are highly specialized intestinal epithelial cells (IEC) of the 
small intestine located in the crypt bottom between the intestinal stem cells. These cells 
secrete antimicrobial peptides, such as α-defensins, in response to bacterial antigens 
(23). The secretion of antimicrobial peptides into the crypt lumen protects crypt cells from 
colonization of pathogens and protects against enteric infections (24). In addition, a 
variety of different innate immune cells in the epithelium and lamina propria recognize 
microbe associated patterns such as lipopolysaccharide, peptidoglycan-derived muramyl 
dipeptide, lipoteichoic acid, single and double stranded RNA and methylated DNA through 
pattern recognition receptors, including Toll-like receptors (TLR) and nucleotide binding 
domain (NOD) like receptors (NLR) (1). The essential roles of TLRs and NLRs during 
intestinal inflammation were demonstrated in several studies (25–27). In IBD patients the 
tolerance towards the commensal gut microbiota seems to be impaired and the immune 
response is dysregulated. 
Although there have been many studies on this field, the mechanisms of disease 
manifestation are not fully understood at the moment (28). However, it has been shown 
that multiple non-genetic and genetic risk factors are involved in the pathogenesis and 
manifestation of the complex diseases CD and UC (29,30). It is thought that CD and UC 
arise due to non-genetic factors in genetically predisposed individuals (31). Additionally, 
epigenetic mechanisms, such as DNA methylation (32) and histone modification (33), can 




1.1.1 Non-genetic risk factors for IBD 
Non-genetic risk factors have an important impact on the manifestation of IBD, as 
demonstrated by concordance rates among monozygotic twins of only 10-15 % for UC 
and 30-50 % for CD (34,35). Furthermore, studies with migrants from countries with low 
incidents rates to countries with high incidents rates revealed increased risk of these 
individuals to develop IBD (36). Thus, non-genetic, environmental factors contribute to the 
development and manifestation of IBD in genetically predisposed individuals.   
One of the identified environmental risk factor is smoking (37). Smoking can function as a 
disease-specific environmental risk factor that exacerbate CD while being protective in UC 
(38). Also high levels of hygiene and the lack of exposure to enteric pathogens in 
childhood predispose individuals to CD (39). For example, exposure to pets in early life 
decreases the risk of IBD (40). Additionally, the dietary intake influences the disease risk 
of IBD (41). High intakes of total fats, total polyunsaturated fatty acids, omega-6 fatty 
acids and meat increase the risk of IBD, whereas high fiber and fruit intake decrease the 
risk of CD and high vegetable intake decreases the risk of UC (42). Furthermore, a 
protective effect of breastfeeding on the risk of IBD was noticed. The risk decreased by 
33 % and by 23 % for CD and UC, respectively (43).  
1.1.2 Genetic risk factors for IBD 
Genetic studies, including linkage mapping and genome-wide association studies 
(GWAS), identified genetic risk factors that contribute to the pathogenesis of IBD. In 1996, 
linkage mapping studies discovered the first genetic risk factor for CD at the IBD1 locus 
on chromosome 16 (44). This region was later identified to encode the nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2) (45). Today, NOD2 is known as one 
of the strongest susceptibility genes associated with CD (46). However, mutations in a 
single gene are usually not sufficient to induce IBD, indicating that CD and UC are 
complex, multi-genetic diseases (47). The search for novel genetic risk factors was 
revolutionized by high-throughput technologies. GWAS enabled the discovery of a broad 
range of genetic risk factors associated with IBD. Due to a meta-analysis of GWAS and 
Immunochip data the number of susceptibility loci increased to 163 for IBD (48), which 
explain approximately 20-25 percent of the disease risk (49). Twenty-eight of the identified 
risk loci are shared between CD and UC, such as the interleukin 23 receptor (IL23R), 
X-box binding protein 1 (XBP1) or orosomucoid 1 (Saccharomyces cerevisiae)-like protein 
3 (ORMDL3) (50,51). Other genetic risk loci are only associated with either CD or UC. For 




(ATG16L1), are unique for CD (52), whereas genetic variants in tyrosine-protein 
phosphatase non-receptor type 2 (PTPN2), probable E3 ubiquitin-protein ligase (HERC2) 
and signal transducer and activator of transcription 3 (STAT3) were linked only to the 
pathogenesis of UC (53). The identified susceptibility loci for CD and UC reveal that 
alterations in a variety of pathways are involved in the pathogenesis of IBD, for instance 
the genetic risk loci NOD2 elucidated that defects in proper microbial sensing and the 
innate immune system are associated with the development of CD. Other genetic risk loci, 
including XBP1, AGR2 (encoding the anterior gradient protein-2) and ORMDL3, identified 
endoplasmic reticulum (ER) stress and alterations in the unfolded protein response (UPR) 
as a pathogenic mechanism in IBD. Over the last decade, further studies supported the 
link between dysregulated UPR and the pathogenesis of IBD. 
1.2 The unfolded protein response (UPR) 
ER can be found in all eukaryotic cells and is composed of a continuous membrane 
system that forms a dynamic network of tubules and cisternae with a single lumen. The 
membrane of the ER represent more than half of the total membrane of an average 
mammalian cell (54). In the cell, the ER plays a crucial role in the biosynthesis, maturation 
and transport of lipids and proteins. Only properly folded proteins are transported from the 
ER to the Golgi apparatus for further modifications, while incompletely folded proteins 
remain in the ER until they are properly folded. However, incompletely folded proteins 
may also be delivered to the cytosol to undergo ER-associated protein degradation 
(ERAD) through ubiquitination and degradation by the 26S proteasome (55). Under 
physiological conditions, the protein load of the ER and the protein folding capacity are 
well balanced. However, the protein folding and maturation function is highly sensitive to 
disturbances of the ER homeostasis, including virus infection, inflammation, alteration in 
ER calcium homeostasis, changes in temperature or pH, oxidative stress, glucose 
deprivation as well as high-fat diet (56). These disturbances alter the function of the 
organelle and induce the accumulation of unfolded or misfolded proteins inside the ER. 
This cellular condition is termed ER stress, which activates the evolutionarily conserved 
mechanism of the UPR (57). The UPR signal transduction gets induced when unfolded 
proteins exceed the capacity of the ER chaperones leading to the activation of three 
transmembrane ER signaling proteins, including activating transcription factor 6 (ATF6), 
double-stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum kinase 
(PERK) and inositol-requiring enzyme-1 (IRE1) (58) (Fig. 1.1). The most common theory 
about the activation of the UPR signal transduction is that the key chaperone 78-kDa 




signaling proteins, which prevents the activation of the UPR. When unfolded proteins 
accumulate in the ER to a larger amount, GRP78 gets released from the three ER 
signaling proteins in order to support proper protein folding. The release of GRP78 
enables unfolded proteins to bind directly to ATF6, PERK and IRE1 resulting in the 
activation of the three UPR signaling branches (59). The main intent of this signal 
transduction pathway is to restore the ER homeostasis and its protein-folding function by 
transcriptional upregulation of ER chaperones and expansion of the ER (60). The UPR is 
an adaptive mechanism and plays a crucial role especially in secretory highly active cell 
types, such as pancreatic β cells, plasma cells, hepatocytes, goblet cells and Paneth cells. 
However, if the load of unfolded proteins in the ER is prolonged or severe, the UPR 
induces apoptosis (61) and probably also autophagy (62). 
 
Fig. 1.1: Overview of the UPR with its three signaling pathways. 
Cellular stress conditions result in the accumulation of unfolded proteins inside the ER leading to the release 
of the chaperone 78-kDa glucose-regulated protein (GRP78) from the three transmembrane ER signaling 
proteins activating transcription factor 6 (ATF6), protein kinase-like ER kinase (PERK) and inositol-requiring 
enzyme-1 (IRE1). Unfolded proteins bind directly to the ER signaling proteins, which results in the activation of 
the three UPR pathways to induce chaperone transcription, apoptosis and protein degradation. See text for 



































1.2.1 Activation of the IRE1 signaling pathway 
The evolutionarily most conserved and best-investigated branch of the mammalian UPR 
signaling pathway involves IRE1 (64). Already in yeast cells, Ire1p senses ER stress and 
mediates UPR by upregulation of genes involved in protein folding and secretion (65). 
Homologous proteins of the other two UPR signaling pathways, ATF6 or PERK, are not 
present in the yeast genome (66). In mammalian cells, two homologues for IRE1 are 
found, IRE1α and IRE1β, which are expressed in a variety of tissues (67) or only in the 
intestinal (68) and airway mucous cells (69), respectively. In contrast to IRE1β, IRE1α is 
essential for placental development and embryonic viability (71). During ER stress, mainly 
IRE1α mediates the UPR response and the activation of UPR target genes (72). IRE1 is a 
100 kDa type I ER transmembrane protein with a serine/threonine kinase (73) and an 
endoribonuclease (74) activity in its cytosolic region. 
Under unchallenged conditions, the N-terminal luminal domain of IRE1 is bound by 
GRP78. In response to ER stress, GRP78 dissociates from IRE1, causing its 
oligomerization, trans-autophosphorylation and a conformational change that activates its 
endoribonuclease domain. This activation of IRE1 enables a unique UPR signaling 
mechanism through the unconventional splicing of the messenger ribonucleic acids 
(mRNA) encoding XBP1 (Fig. 1.1). This splicing event removes 26 intronic nucleotides 
from the mRNA of XBP1 and consequently alters its reading frame (75). The spliced form 
of XBP1 functions as a potent transcription factor activating the unfolded protein response 
element (UPRE) (76) and its target genes which control ER protein folding, glycosylation, 
membrane expansion, phospholipid biosynthesis and ERAD (77).  
Additionally to XBP1 splicing, the RNase activity of IRE1 is also involved in a conserved 
mechanism termed regulated IRE1-dependent decay of mRNA (RIDD) (78). This rapid 
degradation mechanism of ER-localized mRNAs supports the folding machinery by 
stopping the production of new proteins that challenge the ER. The cleavage events occur 
at consensus sequences similar to the XBP1 splicing sites (74). The resulting mRNA 
fragments are further degraded by the exosome. The RIDD activity of IRE1β is stronger 
compared to IRE1α (72). Furthermore, IRE1 was identified to form complexes with the 
tumor necrosis factor receptor-associated factor 2 (TRAF2) and subsequently activates 
the c-Jun amino-terminal kinase (JNK) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathway through the recruitment of the IκB kinase (79,80). 




1.2.2 Activation of the ATF6 signaling pathway 
The ATF6 signaling pathway leads mainly to the induction of a pro-survival transcriptional 
program during ER stress (81). ATF6 is a type II ER transmembrane protein with its 
C-terminal domain inside the ER lumen and a cytosolic N-terminal domain (82,83). Its 
N-terminus contains a basic leucine zipper motif responsible for the activation of UPR 
target genes (84). In C. elegans ATF6 is present as a single gene, whereas two closely 
related isoforms, ATF6α (90 kDa) and ATF6β (110 kDa), exist in mammalian cells (85). 
However, mainly ATF6α mediates the UPR signaling pathway and the transcription of ER 
chaperones (86).  
Under physiological conditions, the ER chaperone GRP78 binds to the luminal domain of 
ATF6α and blocks its two Golgi apparatus localization signals (87). During ER stress, 
GRP78 releases ATF6α, which can be transported by COPII-coated vesicles from the ER 
to the Golgi apparatus, where ATF6α is cleaved by site 1 and site 2 proteases (S1P and 
S2P) (88) (Fig. 1.1). The cleavage events proceed as a sequential action of the serine 
protease S1P at the ER luminal domain of ATF6α, followed by the metalloprotease S2P-
mediated cleavage at the transmembrane region of ATF6α (89). The resulting cytosolic 50 
kDa fragment of ATF6α (p50ATF6α) enters the nucleus, binds to the ER stress response 
element (ERSE) sequence through binding to the nuclear transcription factor Y (NF-Y) 
and activates gene transcription (90). The consensus sequence of ERSE is CCAAT-N(9)-
CCACG and acts in cis of many UPR-regulated genes (91). The transcription of UPR 
target genes, including ER chaperones such as the GRP78, the 94 kDa glucose-regulated 
protein (GRP94) and the protein kinase inhibitor of 58 kDa (p58IPK), are strongly induced 
to support protein folding and restore the ER homeostasis (92). The ERSE promoter and 
its target genes are also inducible by XBP1, however to a much lesser extent (93). 
Despite this functional overlap, in mammalian cells, ATF6α is induced and has an 
essential role during protein folding, modification and secretion, especially during ER 
stress conditions. Experiments with ATF6α-/- mouse embryonic fibroblasts (MEFs) 
revealed attenuated upregulation of the main ER chaperones GRP78 and GRP94 upon 
ER stress (85). Especially, persistent and recurring ER stress resulted in reduced survival 
rates of ATF6α-/- MEFs. This protective role of ATF6α was also observed in vivo, where 
ATF6α-/- mice were not able to survive intraperitoneal injections with the ER stress-




1.2.3 Activation of the PERK signaling pathway 
The main function of the PERK signaling pathway is to modulate translational activity 
within the cell. However, this pathway is also capable of inducing pro-apoptotic signals in 
case of chronic or severe ER stress conditions. PERK is a type I transmembrane protein 
with its C-terminal domain inside the ER lumen and its N-terminal domain towards the 
cytosol (95). The C-terminal domain functions as an ER stress sensor and the N-terminal 
domain is required for the oligomerization of PERK during ER stress (96).  
Similar to ATF6α, the ER-luminal domain of PERK is bound to GRP78 under physiological 
conditions. Upon ER stress, GRP78 dissociates from PERK resulting in the activation of 
the PERK signaling pathway (Fig. 1.1). The release of GRP78 initiates oligomerization 
and autophosphorylation of PERK, which induces the phosphorylation of the eukaryotic 
translation initiation factor 2α (eIF2α) on serine residue 51 (97). The phosphorylated form 
of eIF2α inhibits the translation initiation to alleviate ER stress induced by the influx of new 
synthesized proteins into the ER, hence reduces the protein folding load (98). 
Paradoxically, some mRNAs are able to bypass this inhibition and are even upregulated 
by p-eIF2α. These mRNAs contain an internal ribosome entry site (IRES) sequence in the 
5’ untranslated region, such as ATF4 that encodes the activating transcription factor 4 
(99). The transcriptional induction of ATF4 induces the transcription of CCAAT-enhancer-
binding homologous protein (CHOP), a transcription factor that facilitates ER stress-
induced apoptosis by repressing Bcl2 expression (100). Additionally, CHOP increases the 
expression of the growth-arrest DNA damage gene 34 (GADD34), which forms a complex 
with protein phosphatase 1 (PP1) and functions then as a phosphatase that 
dephosphorylates the serine residue 51 of p-eIF2α (101). This mechanism provides a 
negative feedback to the PERK signaling pathway and controls the duration of the 
inhibitory effect on the translation initiation. 
Furthermore, the PERK signaling pathway is also involved in the phosphorylation and, 
therefore, activation of the transcription factor NF-κB (102) and nuclear factor erythroid 
2-related factor (NRF2) (103). The pathway member CHOP plays an essential role in 
regulating IL-23 protein levels (104). Thus, components of the PERK pathway may affect 
the regulation of redox homeostasis and inflammatory processes. 
1.2.4 Cross-talk events between the three UPR signaling pathways 
The UPR is an adaptive network that allows cross-talk events between the three major 
signaling branches to enable a fine-tuned ER stress response dependent on the type and 




three branches coordinates the ER stress response to restore the ER homeostasis or to 
undergo cell death.  
Cross-talk events were identified between all three UPR branches. For example, the 
activated cleaved form of ATF6α also induces the transcription of XBP1 in addition to its 
typical target genes such as the ER chaperones GRP78 and GRP94 (105). This 
mechanism allows the ATF6α signaling pathway to influence the IRE1 branch without 
being able to bind directly to the UPRE sequence (106). In contrast, the spliced form of 
XBP1 can directly influence the ATF6α signaling pathway by binding directly to the ERSE 
sequence, the typical target of ATF6α (65). This event enhances the transcription of ER 
chaperones. The connection between the ATF6α and the IRE1 pathway acts efficiently 
during ER stress conditions depending on its duration. The ER chaperone induction of 
ATF6α functions faster compared to the XBP1 signal transduction, because the activation 
of ATF6α depends only on cleavage events, whereas XBP1 needs to be translated from 
its mRNA to induce the target genes. Furthermore, ATF6α heterodimerizes with the 
spliced form of XBP1 to control the expression of genes involved in ERAD through the 
URPE (85). During late stages of ER stress, the dimerization of the cleaved ATF6 
fragments and the unspliced form of XBP1 facilitate the degradation of both proteins to 
reestablish physiological conditions in the cell (107).  
The ATF6α and IRE1 branches are also linked to the PERK pathway. The PERK pathway 
member CHOP is strongly induced by ATF4 but can also be stimulated by ATF6α and 
XBP1 (108,109). Further support of the communication between the three UPR signaling 
pathways was provided by PERK-deficient cells, which were still able to induce its 
downstream target CHOP, however more slowly (110). 
1.3 Role of ER stress in intestinal epithelial cell homeostasis and IBD 
Unresolved ER stress and a disrupted UPR in IECs have been implicated in the 
development of intestinal inflammation (51). Especially the intestinal epithelium relies on 
an intact UPR, because it contains highly secretory cell types that are constantly exposed 
to environmental antigens and commensal microorganisms. The main cell types in the 
intestinal epithelium are absorptive enterocytes, goblet cells, Paneth cells and 
enteroendocrine cells (111). Beside their function as a physical barrier, these cells types 
secrete hormones, highly glycosylated mucins or defensins to protect the host (21). In 
particular, goblet and Paneth cells appear particularly sensitive towards unresolved ER 




The first indication of a connection between a disrupted UPR and the development of 
intestinal inflammation was given by GWAS from IBD patients. These studies identified 
disease susceptibility loci within or in close proximity to several genes including XBP1, 
AGR2 and ORMDL3 that encode proteins associated with functions in the ER or in the 
UPR signaling pathways (113). Additionally, mucosal tissues of patients with active forms 
of CD or UC revealed increased expression levels of the ER chaperone GRP78 (114) and 
upregulated phosphorylation of eIF2α (115). Furthermore, in vivo studies were performed 
to investigate the role of a properly functioning UPR on the IEC homeostasis. One of the 
first animal studies, which linked ER stress to the development of spontaneous intestinal 
inflammation, was performed with IEC-specific Xbp1-deficient (Xbp1ΔIEC) mice. The 
absence of XBP1 in IECs resulted in ER stress with increased protein levels of the ER 
chaperone GRP78 and spontaneous enteritis characterized by crypt abscesses and 
infiltrations of immune cells. In addition, the small intestine of Xbp1ΔIEC mice revealed 
strongly reduced numbers of Paneth cells and goblet cells, resulting in impaired mucosal 
defense against oral Listeria monocytogenes infection. Xbp1ΔIEC mice are also more 
susceptible to the colitis-inducing agent dextran sodium sulfate (DSS). Moreover, Xbp1 
deficiency in IECs induces IRE1α hyperactivation and increased JNK phosphorylation 
(51). This hyperactivation of IRE1α results in the activation of the IκB kinase, which 
phosphorylates IκB proteins and targets them for polyubiquitination (116). The subsequent 
degradation by the 26S proteasome causes the release of NF-κB that induces the 
transcription of pro-inflammatory cytokines and enzymes to modulate inflammatory 
processes (117). Another genetic risk factor for IBD that impacts the UPR is the protein 
disulfide isomerase AGR2 (118). Under physiological conditions AGR2 regulates 
developmental processes and functions as a survival factor that stimulates cell 
proliferation, cell adhesion, cell migration and inhibits apoptosis (119,120). However, 
increased expression levels of AGR2 result in several types of metastatic 
adenocarcinomas (121–123), whereas decreased expression levels were associated with 
increased risk for CD and UC (118). Another study revealed that the deficiency of Agr2 in 
mice affects the intestinal homeostasis characterized by elevated ER stress, decreased 
Mucin 2 expression in goblet cells and multiple Paneth cell abnormalities resulting in 
spontaneousterminal ileitis and colitis (124). Also ORMDL3 has been associated with IBD 
and ER stress (125). However, Ormdl3-deficient or IEC-specific Ormdl3-deficient mice are 
not yet described in the literature. Therefore, the exact role of this ER transmembrane 
protein in IBD remains to be elucidated (126). 
In addition to the mentioned susceptibility genes that have been associated with human 




the role of unresolved ER stress in the development of intestinal inflammation. These 
studies revealed that also components of the ATF6 pathway are involved in maintaining 
the intestinal homeostasis. For example, the deletion of the main regulator of ER 
chaperone gene expression, Atf6α, resulted in an increased disease activity during a 
DSS-induced colitis in mice. During this treatment, Atf6α-/- mice suffered from severe body 
weight loss, rectal bleeding, mucosal damage and reduced expression of ER chaperones, 
including GRP78, GRP94 and p58IPK. The same study also showed an increased 
sensitivity of p58IPK-/- mice to DSS, along with increased protein levels of the ER 
chaperone GRP78 and the pro-apoptotic protein CHOP (127). Furthermore, an inducible 
deletion of the ATF6α target Grp94 in mice compromises the intestinal homeostasis, 
resulting in severe body weight loss, profound loss of intestinal villus structure and death 
(70). Additional evidence for the importance of the ATF6 branch in regulating the level of 
susceptibility to DSS-induced colitis was given by a mouse model with a hypomorphic 
allele of the membrane-bound transcription factor S1P-encoding gene, Mbtps1. This 
missense mutation in mice, which is also termed woodrat because of the effect of this 
mutation on the coat color (128), resulted in increased susceptibility to DSS-induced colitis 
(129). Due to the indispensable role of S1P during the cleavage and the resulting 
activation of Atf6α, woodrat mice exhibited reduced levels of the ER chaperones GRP78 
and GRP94 in the colon upon DSS administration (129). All of these studies demonstrate 
the importance of the ATF6 branch in maintaining the intestinal homeostasis especially 
during DSS-induced colitis. Also the role of the PERK pathway on the pathogenesis of 
intestinal inflammation was investigated in vivo. The investigation of mice with a 
non-phosphorylatable Ser51A1a mutant of eIF2α in IECs (eIF2αA/A_IEC mice) revealed 
dysregulated UPR signaling pathways in IECs and disrupted protein secretion functions of 
Paneth cells in the small intestine under physiological conditions. The loss of p-eIF2α 
resulted in an increased sensitivity of eIF2αA/A_IEC mice to DSS and oral infection of 
Salmonella Typhimurium, demonstrating the important role of epithelial p-eIF2α in 
mucosal homeostasis (130). In contrast to other evaluated UPR components, the deletion 
of the pro-apoptotic factor Chop, which functions as a downstream target of PERK and 
p-eIF2α via ATF4, resulted in an improved course of the disease during DSS- and TNBS 
(trinitrobenzene sulfonic acid)-induced colitis (131). Moreover, mouse studies were 
performed to investigate the role of the IRE1 pathway in maintaining the intestinal 
homeostasis. Besides the described Xbp1ΔIEC mice, Ern1 (encodes IRE1α) conditional 
knockout mice were studied to get a better insight into the impact of this UPR pathway on 
the development of intestinal inflammation. These conditional knockout mice provide 
Ern1-deficient embryos with functionally normal placentas to circumvent embryonic 




placenta, Xbp1 mRNA was not spliced and the protein expression of GRP78 was 
reduced. In contrast to Xbp1ΔIEC mice, goblet cells of Ern1-/- mice were inconspicuous 
(132). Interestingly, NF-κB phosphorylation and enteritis was diminished in mice with 
deletions of Xbp1 and Ern1 in intestinal epithelial cells compared to Xbp1ΔIEC mice, 
indicating that NF-κB activation and ileitis is controlled by IRE1α (133). Additionally, the 
second isoform of IRE1, IRE1β (encoded by Ern2), was investigated in vivo. In contrast to 
the ubiquitously expressed IRE1α, IRE1β is only expressed in intestinal and airway 
mucous cells (69). Under physiological conditions, colonic mucosa tissues of Ern2-/- mice 
exhibit elevated levels of the ER stress marker GRP78. Upon DSS treatment, GRP78 
levels were even further increased in colonic tissues of Ern2-/- mice and these mice were 
more susceptible to DSS-induced colitis than wild-type mice (68). IRE1β was also 
identified to promote efficient protein folding and secretion of mucin 2 in goblet cells by 
degrading Mucin 2 mRNA (132). Thus IRE1β plays an important role in protecting the 
colonic epithelium, because Mucin 2 is the most prominent protein secreted from goblet 
cells and contributes to the barrier between the intestinal epithelium and the lumen (134). 
For many components of the UPR the mentioned studies identified an important role in 
maintaining the intestinal homeostasis and regulating inflammatory processes. Beside 
pattern recognitions receptors (e.g. NOD2), immune signaling molecules (e.g. STAT3) or 
autophagy (e.g. ATG16L1), failures or disturbances in the UPR of IECs were identified to 
induce intestinal inflammation and may contribute to the pathogenesis of IBD in humans. 
1.4 The ORMDL protein family 
1.4.1 ORMDL genes belong to an evolutionary conserved gene family 
In 2002, the orosomucoid 1 (Saccharomyces cerevisiae)-like (ORMDL) gene family was 
described for the first time by Hjelmqvist et al. (135). This gene family is highly 
evolutionarily conserved between yeast, plants and human. In the genome of vertebrates 
three ORMDL genes were identified, termed ORMDL1, ORMDL2 and ORMDL3. Each of 
the three genes is localized on a different chromosome in mammalian cells. In the human 
genome, ORMDL1 is located on chromosome 2, ORMDL2 on chromosome 12 and 
ORMDL3 on chromosome 17. The comparison of the encoded proteins revealed high 
positional identities. 77 % of the amino acid residues were conserved throughout the three 
human sequences (Fig. 1.2). The pairwise comparison between human and murine 
ORMDL orthologs revealed even 95 % positional identities. Two conserved homologues 
of the ORMDL gene were also identified in the genome of plants (including Arabidopsis 




ORMDL gene is present in the genome of microsporidias (Encephalitozoon cuniculi), 
invertebrates (including Drosophila melanogaster) and urochordates (Ciona intestinalis). 
However, in the genome of the nematode Caenorhabditis elegans no homologous 
sequence was found (135).  
 
Fig. 1.2: Alignment of the human ORMDL amino acid sequences using the CLUSTALW2 program. 
 
1.4.2 Association of ORMDL3 with several diseases 
Single nucleotide polymorphisms (SNPs) in close proximity to the ORMDL3 gene were 
identified by association studies as risk variants for a variety of diseases, including 
bronchial asthma (136), CD (137), UC (138), type 1 diabetes (139), glioma (140), primary 
biliary cirrhosis (141), rheumatoid arthritis (142) and ankylosing spondylitis (143). In both 
bronchial asthma and CD genetic variants were shown to elevate ORMDL3 expression 
levels (125,137). In the case of CD, the most significant disease associated expression 
quantitative trait locus (eQTL) affects ORMDL3 (137). The association of ORMDL3 with 
bronchial asthma and IBD are interesting as lung and intestine are composed of partially 
similar surface cell types, such as epithelial cells and goblet cells. Additionally, both 
tissues are exposed to potential harmful antigens and highly depend on an intact immune 
system that controls the balance between antigen responsiveness and non-
responsiveness (144). These associations of ORMDL3 with diseases involved in 
dysregulated immune response provide evidence of the participation of ORMDL3 in 
inflammatory processes. In contrast to ORMDL3, ORMDL1 and ORMDL2 were not 
associated with IBD by GWAS. However, analysis of gene expression associated SNPs 
identified ORMDL1 as a promising eQTL influencing hypertension (145), whereas 




1.4.3 ORMDL proteins regulate the ER homeostasis  
ORMDL proteins are ER-resident transmembrane proteins with a molecular mass of 
17.4 kDa. These proteins contain two transmembrane domains, with a loop into the ER 
lumen and the N- and C-terminus facing the cytoplasm (146). ORMDL proteins are 
ubiquitously expressed in fetal as well as adult tissues (135). Although ORMDL proteins 
lack characteristic functional domains, these proteins were identified to influence several 
cellular pathways and processes in the cell, including UPR, Ca2+ signaling, sphingolipid 
and ceramide synthesis, which are thought to affect the ER homeostasis or to be induced 
by elevated or dysregulated ER stress. 
1.4.3.1 ORMDL proteins affect components of the UPR 
The first study of ORMDL proteins by Hjelmqvist et al. implied a role of ORMDL proteins in 
the UPR (135). The absence of both Orm proteins in yeast activated the UPR 
constitutively (147,148). Additionally, deletions of the ORM genes in yeast affected their 
cell growth and ability to respond to chemically induced ER stress using dithiothreitol 
(DTT), a strong reducing agent, or tunicamycin (TM), a glycosylation inhibitor. Mutants 
with only one functional ORM gene were able to respond comparable to the wild-type 
strain to DTT or tunicamycin, suggesting partial functional redundancies of the two yeast 
homologues. Interestingly, the phenotype of the double knockout mutants could also be 
rescued by functional complementation with the human ORMDL3, indicating functional 
and structural evolutionary conservations of this gene family (135).  
For ORMDL proteins further in vitro studies indicated a role in regulating components of 
the UPR also in mammalian cells, however these data are inconsistent. Cantero-
Recasens et al. demonstrated an influence of ORMDL3 on the PERK pathway (146). 
Their study revealed that overexpression of ORMDL3 in HEK-293 cells resulted in 
elevated p-eIF2α protein levels without affecting XBP1 splicing. In contrast, 
overexpression of ORMDL3 in fibroblast-like cells (Cos-7) reduced the UPRE promoter 
activity, indicating less XBP1 splicing (138). However, Miller et al. reported increased 
ERSE promoter activities in ORMDL3 overexpressing lung epithelial cells (A549), 
whereas the IRE1 and the PERK signaling branch were left unchanged (149). An 
additional study observed no differences in UPR activation in SV40-transformed normal 
human airway epithelial cells (1HAE) treated with ORMDL3 siRNA (small interfering RNA) 
(125). Whether these discrepancies are a result of the strength of the ER stress, the 




In summary, there is no common understanding of the functional principle of ORMDL3 on 
the three UPR signaling branches so far.  
1.4.3.2 Regulation of the Ca2+ homeostasis by ORMDL proteins 
Alterations in the Ca2+ homeostasis of the ER result in ER stress and activate the UPR 
signaling pathway (150). ORMDL3 was identified to regulate ER-mediated Ca2+ 
homeostasis, which is crucial during protein folding (146). Appropriate Ca2+ levels in the 
ER are essential for proper protein assembly and folding, whereas abnormal Ca2+ levels 
can induce the pathophysiology of many diseases (151). The homeostasis in the ER is 
maintained by Ca2+ release channels and pumps that enable the exit of Ca2+ from the ER 
to the cytoplasm or return Ca2+ to the ER, respectively (152). In this process ORMDL3 
was shown to interact and affect the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA). 
Overexpression of ORMDL3 revealed elevated cytosolic Ca2+ levels and reduced 
ER-mediated Ca2+ signaling in HEK-293 cells. Knockdown of endogenous ORMDL3 
reinforced the release of ER Ca2+ (146). Thus, ORMDL3 was found to function as a 
negative regulator of SERCA. Controversial results were demonstrated by Miller et al., 
whereby  overexpression of ORMDL3 induced SERCA2b mRNA expression in lung 
epithelial cells (A549) (149). A recent study from Miller et al. in 2014 supported their 
previous in vitro results by showing increased mRNA expression level of Serca2b in 
transgenic mice overexpressing human ORMDL3 (153). Furthermore, the effect of 
ORMDL3 on the Ca2+ homeostasis was also shown to modify lymphocyte activation in 
vitro, which provides an additional indication for the connection of ORMDL3 and 
inflammatory processes (154). Thus, ORMDL3 regulates the ER Ca2+ levels and 
maintains the ER homeostasis.  
1.4.3.3 ORMDL proteins regulate sphingolipid synthesis 
In response to ER stress, the sphingolipid synthesis is thought to be modulated by 
ORMDL proteins (155). Studies in yeast, plants and human cells identified a fundamental 
role of ORMDL proteins in the sphingolipid synthesis and homeostasis. In yeast, 
increased expression levels of ORM1 or ORM2 reduced levels of the long-chain base 1 
(LCB1) and LCB2, whereas cells with deletions of ORM1 or ORM2 showed highly 
elevated levels of LCB1 and LCB2 (156). LCB1 and LCB2 encode the serine 
palmitoyltransferase (LCB1/2 in yeast and  SPTLC1/2/3 in mammals), an essential 
enzyme in the first and rate-limiting step in sphingolipid synthesis (157). Sphingolipids are 
important components of eukaryotic cell membranes and play vital roles in cell signaling 




form a complex with the serine palmitoyltransferase. Additionally, Orm proteins act directly 
on Lcb1 and Lcb2, suggesting that Orm1 and Orm2 negatively regulate sphingolipid 
synthesis. Loss of Orm1 and Orm2 increased the activity of the serine 
palmitoyltransferase, resulting in toxic accumulations of sphingolipids (156). As a potential 
regulatory mechanism of Orm proteins on the serine palmitoyltransferase activity the 
phosphorylation status of this protein was identified in yeast (159). However, ORMDL 
proteins in mammalian cells lack the sequence, which is phosphorylated in yeast (160). 
Similar results were also obtained in plants. ORMDL genes were identified to control 
sphingolipid homeostasis in plants, as shown for the example of rice plants (161). Main 
metabolites of complex sphingolipids are ceramides, which are also de novo synthesized 
by serine palmitoyltransferase (162). Similar to sphingolipid levels, ceramide levels were 
also elevated upon siRNA-mediated knockdown of all three ORMDL genes in mammalian 
cells (156,160,163). Based on these findings, ORMDL proteins are thought to be negative 
regulators of the ceramide and sphingolipid synthesis and this function is even more 





1.5 Objective of the study 
IBD with its major subtypes, CD and UC, are complex multigenic disorders with several 
identified risk loci, including an eQTL affecting ORMDL3. The role and the function of 
ORMDL3 in vitro and in vivo with regard to the pathogenesis of chronic intestinal 
inflammation are incompletely understood and investigated. Thus, the general objective of 
this study is to analyze the effect of ORMDL proteins on the three UPR signaling branches 
during ER stress and its impact on the intestinal homeostasis and regeneration under 
baseline and challenging conditions. 
Major questions: 
1. Effect of ER stress on ORMDL proteins:
2. 
 Determination of ORMDL protein 
expression levels during chemically-induced ER stress in several cell lines and 
primary murine cells in order to investigate whether ORMDL protein levels are 
influenced by ER stress.  
Regulatory capacity of ORMDL proteins on the UPR:
1.4.3
 At the moment there is no 
common understanding of the functional mechanism of ORMDL3 on the three 
UPR signaling branches. Previous investigations have shown controversial roles of 
ORMDL3 on the UPR, ranging from no effect to affecting one or another signaling 
branch only (as referred in chapter ). Detailed in vitro investigation of the 
impact of human ORMDL proteins on the UPR signaling branches should clarify 
several questions:  
a. Do ORMDL proteins modify the UPR?  
b. In case that ORMDL proteins affect the UPR, which components and UPR 
signaling branches are regulated?  
c. How could ORMDL proteins be able to regulate the UPR signaling 
branches? 
3. Role of ORMDL proteins in vivo: For a detailed in vivo analysis of the association 
of ORMDL3 as genetic risk loci for human IBD, there is a high demand for the 
generation and investigation of Ormdl3-deficient mice. Since the high amino acid 
identity of 84 % between ORMDL1 and ORMDL3 points to functional redundancies 
of these proteins, a comparable phenotype analysis of Ormdl1-deficient mice is of 
fundamental interest too. The deficient mice provide an opportunity to examine the 




a. Does the depletion of Ormdl1 or Ormdl3 affect the basal phenotype and in 
particular the intestinal homeostasis? 
b. How does the deficiency of Ormdl1 or Ormdl3 in mice affect the 
susceptibility to DSS-induced colitis? 
c. Are Ormdl1- and Ormdl3-deficient mice more susceptible to intraperitoneal 












2.1 Cell biological methods 
2.1.1 Cell lines 
Cell lines used for in vitro investigation were purchased from the Leibniz-Institute 
DSMZ-German Collection of Microorganisms and Cell Cultures or from the American 
Type Culture Collection (ATCC) (Table 2.1). All applied cell lines were cultured at 37 °C 
and 5 % (v/v) carbon dioxide in their appropriate nutrition media (Gibco/Life Technologies, 
Darmstadt, Germany). 
Table 2.1: Overview of applied cell lines 
Cell line Company Product nr. Species Cell type Nutrition medium 
HeLa DSMZ ACC-57 human cervix carcinoma RPMI, 10 % (v/v) FCS 
HEK-293 DSMZ ACC-305 human embryonal kidney DMEM, 10 % (v/v) FCS 
HT-29 DSMZ ACC-299 human colon adenocarcinoma DMEM, 10 % (v/v) FCS 
RAW 264.7 ATCC TIB-71  murine macrophage-like DMEM, 10 % (v/v) FCS 
 
The cell lines were passaged twice per week for maintenance. Cells were washed with 
PBS and treated with a trypsin/EDTA solution (Life Technologies, Darmstadt, Germany) 
for 5 min at 37 °C. The resulting cell suspension was centrifuged at 300 g for 5 min. The 
cell pellet was resuspended in 5 ml fresh nutrition medium. A dilution of cells was 
transferred into new culture flasks for maintaining cultured cells or sowed with a defined 
cell number for experiments (Table 2.2). All steps were performed under sterile conditions 
using a laminar flow workbench (Thermo Scientific, Bremen, Germany). 
 
Table 2.2: Overview of applied cell culture dishes for experiments with cell lines 
Experiment Cell culture dish Cell number/well Medium volume [ml] 
Cell fractionation  10 cm dish  5 x 106  10 
Co-immunoprecipitation  10 cm dish  5 x 106  10 
Protein lysates  6-well plate  2 x 105  2 
RNA isolation  6-well plate  2 x 105  2 
FACS measurement  6-well plate  2 x 105  2 
Fluorescence microscopy  6-well plate  2 x 105  2 






2.1.2 Transient transfection of plasmid DNA 
Plasmid DNA was transiently transfected into cultured eukaryotic cells by lipofection using 
FuGENE® 6 transfection reagent (Promega, Mannheim, Germany). The cationic liposome 
formulation FuGENE® 6 forms complexes with negatively charged plasmid DNA. This 
complex can fuse with the cell membrane which allows plasmid DNA to enter the cell.  
The appropriate amount of FuGENE® 6 was diluted in Opti-MEM® (Life Technologies, 
Darmstadt, Germany) and incubated for 5 min at room temperature (Table 2.3). Plasmid 
DNA was added to the transfection mix and incubated for additional 15 min. After 
incubation, the transfection mix was added dropwise to the cells. The transfection mix was 
distributed by gently shaking the cell culture dish horizontally. The cells were placed back 
into the incubator for 24 h. All steps were performed under sterile conditions. 
 
Table 2.3: Overview of formats and volumes of plasmid DNA transfections  
Cell culture dish Opti-MEM® volume [µl] DNA [µg] FuGENE® [µl] 
 10 cm dish  500  5  15 
 6-well plate  100  1  3 
 96-well plate  5  0.05  0.15 
 
2.1.3 Transfection of siRNA 
Transfection of small interfering RNA (siRNA) into cultured eukaryotic cells was performed 
using siPORTTM Amine transfrection reagent (Life Technologies, Darmstadt, Germany). 
The positively charged lipid-based formulation of siPORTTM Amine forms complexes with 
negatively charged siRNA which can fuse with the cell membrane and enables the siRNA 
to enter the cell. 
For the transfection of siRNA the appropriate volume of siPORTTM amine was diluted in a 
1.5 ml reaction tube with Opti-MEM® (Table 2.4). Target-specific siRNA was mixed with 
Opti-MEM® in a second 1.5 ml reaction tube. Both tubes were incubated separately for 
10 min at room temperature. The solutions of both tubes were combined and incubated 
for additional 10 min. After incubation, the solution was added dropwise to the cells and 
distributed in the well by gently shaking the plate horizontally. Cells were placed back into 
the incubator for 24 h. All steps were performed under sterile conditions. 
 
Table 2.4: Overview of formats and volumes of siRNA transfections 
Cell culture dish Opti-MEM® volume [µl] siPORTTM [µl] siRNA [µM] 
 6-well plate  100  5  7.5 




2.1.4 Life cell XBP1 splicing assay using a XBP1-venus reporter construct 
ER stress induces the UPR which consists of three distinct signal pathways including 
ATF6α, IRE1 and PERK. Activation of IRE1 causes mRNA splicing of the transcription 
factor XBP1. This splicing event can be monitored in life cells using a XBP1-venus 
construct (164). A green fluorescent protein variant, called venus, was fused to the 
C-terminus of the human XBP1 sequence (Fig. 2.1). Under baseline conditions, XBP1 
splicing does not occur. The translation of XBP1 ends at its stop codon which is localized 
upstream of the venus fusion. Hence, the venus construct is not in the open reading frame 
of XBP1, thus not translated. Under ER stress conditions, 26 nucleotides are spliced out 
of the XBP1 mRNA introducing a frame shift. Due to this frame shift, the translation of the 
spliced XBP1 mRNA ends only at the stop codon of the venus protein fused in frame. To 
prevent induction of UPR target genes by overexpression of XBP1-venus, a 
pCAX-XBP1ΔDBD-venus plasmid was used. In this construct the DNA-binding domain 
(DBD) of XBP1 is deleted and therefore this construct cannot induce UPR target genes. 
The expressed green fluorescent XBP1-venus fusion protein can be detected by 
fluorescence microscopy or fluorescence-activated cell sorting (FACS) technique. 
For detection of XBP1 splicing HEK-293 cells were co-transfected with 
pCAX-XBP1ΔDBD-venus and either pCMV-HA, pCMV-HA-ORMDL1 or 
pCMV-HA-hORMDL3 as described in chapter 2.1.2. In an additional approach, HEK-293 
cells were treated with a mix of siRNA for hORMDL1, hORMDL2 and hORMDL3 or control 
scrambled siRNA (allStars negative control siRNA, Qiagen, Hilden, Germany) and 
transfected with pCAX-XBP1ΔDBD-venus to detect XBP1 splicing as described. 24 h after 
transfection, cells were treated with DMSO as a control or 20 µg/ml tunicamycin diluted in 
DMSO for 24 h. Fluorescence intensity was investigated by fluorescence microscopy and 
quantified by FACSCalibur cell analysis system (BD Biosciences, Heidelberg, Germany) 






Fig. 2.1: Functional principle of the life cell XBP1 splicing assay using a XBP1-venus reporter 
construct. 
Fusion of XBP1 and venus, a variant of green fluorescence protein, enables life cell monitoring of XBP1 
splicing. Under normal conditions, splicing of XBP1 mRNA does not occur, leading to the translation into the 
XBP1 protein without venus fusion. During ER stress 26 nucleotides are spliced out of the XBP1 mRNA 
resulting in a frame shift expressing fluorescent XBP1-venus fusion protein. Figure was adapted from (164). 
2.1.5 Promoter-mediated luciferase reporter assay 
Each of the three UPR branches can activate specific intracellular response elements, 
which was analyzed using the dual-luciferase reporter assay system (Promega, 
Mannheim, Germany). Each promoter region of the response elements was cloned 
upstream of the luciferase from firefly (Photinus pyralis). The luciferase from Renilla 
(Renilla reniformis) was used as an internal transfection and cell viability control. The 
activation of the response elements was quantified by normalizing the firefly 
bioluminescence to the Renilla bioluminescence.   
HEK-293 cells were sowed on 96-well plates at a density of 2 x 104 cells per well. After 
24 h, cells were transfected with 12 ng of one of the ER stress firefly luciferase reporter 
constructs and 3 ng of the Renilla luciferase plasmid pRL-TK. For the measurement of the 
luciferase activity, cells were lysed using 25 µl of 1X passive lysis buffer and subjected to 
a freeze-thaw cycle for complete cell lysis. Substrate addition and luminescence 
measurement was automatized by Tecan Infinite F200 pro plate reader using the i-control 
software (Tecan, Männedorf, Switzerland). The quotient of response element dependent 
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2.1.6 Flow cytometric analysis 
Cell surface expression of interferon gamma (IFNγ) target genes, including the major 
histocompatibility complex (MHC) class I (MHCI) and class II (MHCII), were investigated 
by flow cytometry. 1 x 105 cell from the lamina propria fraction of Ormdl3-/- and wild-type 
mice were preincubated with anti-CD16/32 to block Fc receptors and prevent unspecific 
antibody binding, washed with FACS wash buffer and incubated with the indicated 
antibody conjugates for 30 min at 4°C in a final volume of 10 µl FACS wash buffer. After 
the staining, cells were washed three times with FACS wash buffer and fixed using 
1 % paraformaldehyde solution. The appropriate isotype-matched control antibodies were 
included in the experiment to determine the level of background staining. Flow cytometric 
analyses were performed on a FACSCalibur cell analysis system (BD Biosciences, 
Heidelberg, Germany) using BD CellQuest ProTM software (BD Biosciences, Heidelberg, 
Germany). All applied antibodies are listed in the supplementary information (Table 8.12). 
2.2 Molecular biological methods 
2.2.1 Isolation of total RNA  
Murine tissue samples were ground using mortar and pestle in liquid nitrogen to prevent 
RNA degradation. The grounded samples were lysed in 700 µl RLT buffer (Qiagen, 
Hilden, Germany) containing 1% 2-mercaptoethanol. Resulting sample lysates were 
applied to QIAshredder columns for homogenization. The RNA extraction was performed 
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
protocol. An incorporated on-column DNase step was carried out to avoid contaminations 
by genomic DNA. The purified RNA was eluted in 50 µl RNase-free water and the RNA 
concentration was determined using the NanoDrop ND-1000 spectrophotometer (PeqLab 
Biotechnologie GmbH, Erlangen, Germany). RNA samples were stored at -80 °C. 
2.2.2 cDNA synthesis 
For reverse transcriptase the Maxima H Minus First Strand cDNA Synthesis Kit (Thermo 
Scientific, Bremen, Germany) was selected to generate complementary DNA (cDNA) from 
an RNA template. According to the manufacturer’s protocol, 500 ng to 1 µg total RNA was 
used as template for the generation of cDNA. In a first step, the RNA was incubated with 
Oligo(dt)18 oligonucleotide, dNTP mix and water at 65 °C for 5 min (Table 2.5). 
Subsequently, 5X RT buffer and Maxima H Minus reverse transcriptase (RT) was added 
to the mixture and incubated as indicated. The synthesized cDNA was diluted 1:10 with 




Table 2.5: Components and incubation conditions of a reverse transcription reaction mixture 
Step Component Quantity  Incubation 
1. 
 RNA  500 ng 
5 min at 65 °C 
 Oligo(dt)18 oligonucleotide  0.125 µl 
 dNTP mix (10 mM each)  0.5 µl 
 nuclease-free water  to 7.5 µl 
2. 
5X RT buffer 2 µl 10 min at 25 °C 
15 min at 50 °C 
5 min at 85 °C Maxima H Minus RT 0.5 µl 
 
2.2.3 Endpoint polymerase chain reaction (PCR) 
Endpoint polymerase chain reactions (PCRs) were performed for semi-quantitative mRNA 
analyses of transcripts of interests. cDNA samples were used as starting material for 
endpoint PCRs. Levels of mRNA expression were determined by target-specific 
oligonucleotides, which amplificated exon spanning PCR products with sizes between 150 
and 500 bp. All applied oligonucleotides were designed with annealing temperatures of 
60 °C and were synthesized by Microsynth AG (Balgach, Switzerland). The full list of used 
oligonucleotides is given in the supplementary material (Table 8.8). The amplification was 
carried out by PCR using GoTaqTM polymerase (Promega, Mannheim, Germany) in a 96-
well thermocycler (Applied Biosystems, Carlsbard, USA). PCR components and the 
cycling protocol are given in Table 2.6. The amplification of target genes were conducted 
with low cycle numbers to ensure amplifications in the unsaturated PCR phase.  
 
Table 2.6: Components and cycling protocol for endpoint PCRs 
PCR component Volume [µl]   Temperature [°C]  Time Cycles 
 cDNA  2   95  3 min 1 
 dNTPs mix (10 mM each)  1   95  30 sec 
28-33  Oligonucleotide mix (10 µM each)  1   Tanneal  30 sec 
 5X GoTaqTM buffer  5   72  30 sec 
 GoTaqTM  polymerase  0.4   72  7 min 1 
 Nuclease-free water  ad 20   4  hold 1 
 
For the semi-quantitative analyses, PCR products were separated by agarose gel 
electrophoresis (2.2.4). The intensity of the PCR products was visualized upon exposure 
to UV light in the Molecular Imager ChemiDoc XRS Imaging System (Bio-Rad, Munich, 
Germany). The housekeeper gene GAPDH was used as an internal control for gene 




2.2.4 Agarose gel electrophoresis 
DNA fragments and PCR product sizes were verified by agarose gel electrophoresis. This 
method separates negatively charged DNA fragments according to their size in an electric 
field. Agarose gel electrophoresis was performed with a gel concentration of 1 % LE 
agarose and 0.5 % TAE buffer. A constant voltage of 120 V and a maximum current of 
300 mA were applied using Bio-Rad Power Pac 300 power supply (Bio-Rad, Munich, 
Germany). Due to the addition of 2 µl SYBR Safe DNA gel stain, a DNA-intercalating 
agent, the size of DNA fragments can be visualized upon exposure to UV light in the 
Molecular Imager ChemiDoc XRS Imaging System (Bio-Rad, Munich, Germany). The 
SmartLadder MW-1700-10 (Eurogentec, Cologne, Germany) was used as a DNA 
fragment size marker. 
2.2.5 Quantitative real-time polymerase chain reaction 
Quantitative real-time PCRs (qPCRs) enabled the quantification of mRNA levels using 
target-specific oligonucleotides. The qPCR method is based on the PCR technique with 
an additional DNA quantification step at the end of each amplification cycle. SYBR Green, 
a DNA intercalating fluorescent dye, was used for quantification. 
For qPCR, oligonucleotides were designed based on the coding region of the gene of 
interest with annealing temperatures of 60 °C and amplicon lengths of 150 to 350 bp. The 
oligonucleotides were synthesized by Microsynth AG (Balgach, Switzerland). All employed 
oligonucleotides are listed in the supplementary information (Table 8.8). The SYBR® 
Select Master Mix (Life Technologies, Darmstadt, Germany) was used for qPCR 
according to the manufacturer’s protocol. 5 µl of sample cDNA was mixed with 5 µM of 
each oligonucleotide and 4.5 µl SYBR® Select Master Mix. The reaction was carried out 
on 384-well plates using the 7900 HT Fast Real-Time PCR System (Applied Biosystems, 
Carlsbard, USA). All results were normalized to their respective GAPDH housekeeper 
mRNA level and shown as foldchange relative to a reference. 
In some experiments predesigned TaqMan probes were applied, which were obtained 
from Applied Biosystems (Carlsbard, USA). The employed TaqMan probes and their order 






2.2.6 Generation of expression constructs 
An overview of all employed plasmids is located in the supplementary material (Table 
8.7). Plasmids were either generated by Gateway® cloning or by traditional restriction 
enzyme-based cloning. 
Gateway® cloning 
Plasmids, such as pCMV-HA-EGFP, pCMV-HA-hORMDL1 or pCMV-HA-hORMDL3, were 
constructed using the Gateway® cloning system (Life Technologies, Darmstadt, 
Germany). In a first step, the target sequence was generated by a hot start PCR (Table 
2.7) using specific oligonucleotides with overhangs containing attB-recombination sites. 
The hot start PCR technique was applied to avoid the generation of non-specific PCR 
amplicons due to the inhibition of the Phusion Hot Start II polymerase activity at low 
temperatures. The resulting PCR product was analyzed by gel electrophoresis and 
isolated from the gel using the QIAquick Gel Extration Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol. 
Table 2.7: Reaction mixture and cycling protocol for a cloning hot start PCR 





 DNA template  200 ng   98  30 sec  1 
 10 mM dNTPs  0.5 µl   98  10 sec 
 30  Oligonucleotide mix (10 µM each)  1 µl   Tanneal  20 sec 
 5X Phusion HF buffer  5 µl   72  30 sec/kb 
 Phusion Hot Start II polymerase  0.25 µl   72  7 min  1 
 Nuclease-free water  ad 25 µl   4  hold  1 
 
The purified PCR product was inserted into the donor vector (pDONR221) by a BP 
Clonase II reaction (Table 2.8) (Life Technologies, Darmstadt, Germany), which replaced 
the negative selection marker ccdB with the PCR product. The reaction was incubated at 
25 °C for 1 h, followed by digestion of phage enzymes using Proteinase K treatment at 
37 °C for 15 min.  
For the transformation, one shot TOP10 Escherichia coli cells (Life Technologies, 
Darmstadt, Germany) were thawed and 2 µl of the Proteinase K-treated BP Clonase II 
reaction were added. The mixture was incubated on ice for 30 min, applied to a 42 °C 
water bath for 30 sec and placed back on ice for 3 min. After the treatment, cells were 
supplied with 250 µl of S.O.C. medium (Life Technologies, Darmstadt, Germany) and 




kanamycin containing agar plates. Due to the negative selection marker ccdB, which 
codes for a growth inhibiting protein (165), only positively recombinated clones grew 
overnight at 37 °C. Single clones were picked using sterile pipette tips, purified (as 
described in chapter 2.2.7) and verified by Sanger sequencing (as described in chapter 
2.2.8) employing M13 oligonucleotides. Plasmids containing the target sequence were 
called entry plasmid. 
The second cloning step using the LR Clonase II (Life Technologies, Darmstadt, 
Germany) was performed to obtain plasmids, which contain N-terminal GFP or HA 
sequences upstream of the target sequence. The plasmids pDEST53 or pCMV-HA-GW 
were used as destination plasmids. The LR Clonase II reaction (Table 2.8) was incubated 
on ice for 30 min and transformed into one shot TOP10 Escherichia coli cells. Plasmids 
were prepared as described in chapter 2.2.7. 
Table 2.8: Gateway cloning: Components for BP and LR Clonase II reactions   









PCR product  150 ng  Entry plasmid  150 ng 
pDONR221  150 ng  Destination plasmid  150 ng 
TE buffer  ad 10 µl  TE buffer  ad 10 µl 
BP Clonase II  2 µl  LR Clonase  II  2 µl 
 
Restriction enzyme-based cloning 
Restriction enzyme-based cloning was performed to generate plasmids such as 
pGL3-ATF4 and pGL3-ERSE. The cloning method was performed as described 
exemplary for the pGL3-ERSE construct. 
The target sequence was amplified by PCR with target-specific oligonucleotides, which 
contained overhangs with sequences for selected restriction enzymes. The 
5’ oligonucleotide carried the sequence for the restriction enzyme KpnI and the 
3’ oligonucleotide for BglII. A hot start PCR was performed on cDNA from HeLa cells 
applying the protocol shown in Table 2.7. To validate the correct PCR product by size, 5 µl 
of the PCR reaction were loaded on an agarose gel and visualized by UV light using the 
Molecular Imager ChemiDoc XRS Imaging System (Bio-Rad, Munich, Germany). The 
remaining PCR reaction was cleaned up by the QIAquick PCR Purification Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. 
The purified PCR product served as the insert for the target-vector pGL3-Basic. For the 




KpnI and BglII containing restriction enzyme mix (Table 2.9) at 37 °C for 1 h. The 
digestion resulted in an insert and a target-vector with sticky ends. The digested 
sequences were separated on an agarose gel and purified using the QIAquick Gel 
Extration Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
Table 2.9: Exemplary components of double digest reactions 
Component Insert Target-vector 
 DNA  0.3 µg  1 µg 
 10X NEB buffer  2 µl  2 µl 
 KpnI (10 U/µL)  1 µl  1 µl 
 BglII (10 U/µL)  1 µl  1 µl 
 Aqua bidest.  ad 20 µl  ad 20 µl 
 
To increase the number of positive clones, the backbone of the target-vector was treated 
with FastAP thermosensitive alkaline phosphatase (Thermo Scientific, Bremen, 
Germany). The enzyme removes 5’- and 3’-phosphate groups from DNA. Due to this 
treatment, the backbone of the target-vector was not able to religate. The digested and 
purified vector was incubated with 1 µl of FastAP thermosensitive alkaline phosphatase 
and 1X of 10X Fast AP buffer for 10 min at 37 °C. The enzyme was inactivated at 75 °C 
for 5 min. 
Due to a ligation reaction the insert was incorporated into the backbone of the target-
vector. DNA ligases join DNA fragments by forming phosphodiester bonds between a free 
5’-phosphate group and 3’-hydroxyl group. The ligation was performed using the Rapid 
DNA Ligation Kit (Roche, Basel, Switzerland). In detail, the insert was added to the vector 
backbone in a molar ratio of 3:1 with a maximum total DNA amount of 200 ng and filled up 
to 10 µl of DNA dilution buffer. 10 µl of T4 DNA ligation buffer and 1 µl of T4 DNA ligase 
were added and incubated for 10 min at room temperature. For the transformation of one 
shot TOP10 Escherichia coli cells 5 µl of the ligation reaction were used. The 
transformation was performed as described above for the gateway cloning system. 
2.2.7 Plasmid preparation 
Plasmid mini preparations were performed to identify positive clones after generation of 
expression constructs. Four clones per transformation were picked using sterile pipette 
tips and cultured overnight in 3 ml LB medium at 37 °C in a shaker. The medium was 
supplemented with either 3 µl of 100 mg/ml ampicillin or 3 µl of 50 mg/ml kanamycin 
depending on the selection marker of the cloned plasmid. Plasmid DNA was isolated 




according to the manufacturer’s protocol. The sequence of the isolated plasmid DNA was 
identified using Sanger sequencing (chapter 2.2.8). For larger DNA quantity, 100 ml LB 
medium was inoculated and cultured overnight in a shaker at 37 °C. Plasmid DNA was 
isolated using the PureLink® HiPure Plasmid Filter Midiprep Kit (Life Technologies, 
Darmstadt, Germany) according to the manufacturer’s protocol. The DNA concentration 
was determined using the NanoDrop ND-1000 spectrophotometer (PeqLab 
Biotechnologie GmbH, Erlangen, Germany). Plasmid DNA was stored at -20 °C for further 
usage. 
2.2.8 Sanger sequencing 
The precise order of nucleotides in all generated plasmids was determined by Sanger 
sequencing (166) using the BigDye Terminator v1.1 cycle sequencing Kit (Life 
Technologies, Darmstadt, Germany). 300 ng of plasmid DNA was mixed with 3.3 µM of a 
template-specific oligonucleotide, 1.5 µl of BigDye, 1 µl of 5X sequencing buffer and 4 µl 
PCR-grade water. During the following PCR, the fluorescent labeled ddNTPs were 
incorporated into the PCR products. The PCR program contained an initial denaturation 
step at 96 °C for 1 min, followed by cycling 30 times through a denaturation step at 96 °C 
for 10 sec, annealing phase at 50 °C for 5 sec and an elongation phase at 60 °C for 4 min. 
A laser of the 3730xl DNA Analyzer (Applied Biosystems, Carlsbard, USA) detected the 
fluorescence of the incorporated ddNTPs while passing through thin capillaries filled with 
a gel matrix for separation. DNA sequences were analyzed using the Sequencher 5.0 
software (Gene Codes Corporation, Ann Arbor, USA). 
2.3 Protein biochemical methods 
2.3.1 Total protein lysate preparation 
Total protein lysates were extracted to analyze the protein content of cells by applying the 
gel electrophoresis technique. Adhered cells in a 6-well plate were washed twice with 
ice-cold PBS and lyzed using 100 µl cold RIPA buffer, containing 1X HaltTM combined 
protease and phosphatase inhibitor (Thermo Scientific, Bremen, Germany). Lysates were 
stored on ice for 30 min to ensure complete cell lysis. Afterwards, lysates were centrifuged 
at 16000 g for 15 min at 4 °C to remove cell debris and genomic DNA. Supernatant was 
transferred to new 1.5 ml reaction tubes. Protein lysates were stored short-term at -20 °C 




2.3.2 Cell fractionation 
Cell fractionations were performed to isolate cytosolic, membrane and nuclear proteins. 
To this end, cells were washed with ice-cold PBS and incubated on ice for 10 min with cell 
fractionation buffer 1. Cells were scraped from their culture dish, lyzed by pushing them 
15 times through a 26G needle on a syringe and centrifuged at 1000 g for 10 min at 4 °C. 
The resulting cell pellet was resuspended using cell fractionation buffer 2 and incubated 
overnight on an end-over-end rotator at 4 °C. The suspension was centrifuged at 16000 g 
for 15 min at 4 °C to obtain the nuclear fraction. The supernatant from the first 
centrifugation step was further separated by centrifugation at 16000 g for 45 min at 4 °C. 
The resulting supernatant contained cytosolic proteins. The membrane containing pellet 
was resuspended in RIPA buffer. All buffers were supplemented with 1X HaltTM combined 
protease and phosphatase inhibitors. 
2.3.3 Protein concentration determination 
Protein concentration was determined using the Bio-Rad DC (detergent compatible) 
protein assay (Bio-Rad, Munich, Germany). The colorimetric assay is based on the Lowry 
method (167) where copper ions react with peptide bonds under alkaline conditions, 
leading to subsequent reduction of the folin reagent by the copper-treated proteins. This 
results in the development of a characteristic blue color with a maximum absorbance at 
750 nm. 5 µl of protein lysate were diluted with 5 µl of aqua bidest. and mixed with the 
assay reagents. After 15 min, absorbance of protein samples were determined and 
correlated with protein concentrations using a bovine serum albumin (BSA) standard 
curve. 
2.3.4 Gel electrophoresis of proteins  
The separation of proteins by their molecular weight was performed using either sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) or pre-cast NuPAGE® 
Bis-Tris gel electrophoresis (Life Technologies, Darmstadt, Germany).  
According to the Laemmli standard protocol (168) for SDS-PAGE, proteins were treated 
with the reducing agent dithiothreitol (DTT) to dissociate disulfide bonds. Additionally, the 
anionic detergent SDS denaturizes proteins and masked their intrinsic charges by 
negatively charged sulfate groups. Applying an electric field to the polyacrylamide gel 
matrix causes the separation of proteins by their molecular weight. The discontinuous gel 
for SDS-PAGE was composed of a stacking and a separating gel (Table 2.10). 




the polymerization of the polyacrylamide matrix in the gels. Electrophoresis was 
performed in two steps using Tris-glycine-SDS (TGS) buffer. During the first step, proteins 
concentrate at the interface of stacking and separation gel by applying a constant current 
of 15 mA and a maximum voltage of 300 V per gel for 30 min. In the second step, proteins 
were fractionated by their molecular weight in the separating gel at a constant current of 
30 mA and a maximum voltage of 300 V per gel. 
Table 2.10: Gel components for SDS-PAGE 
Gel component Stacking gel [µl] Separating gel [µl] 
Aqua bidest. 1950 2500 
4X Stacking buffer 750 - 
4X Separation buffer - 2500 
Polyacrylamide 300 5000 
10 % (w/v) APS 30 100 
TEMED 3 10 
 
The separation of a broad molecular weight range from 14 to 260 kDa was obtained by 
employing pre-cast gradient NuPAGE® 4-12% Bis-Tris protein gel electrophoresis (Life 
Technologies, Darmstadt, Germany). Pre-cast NuPAGE® Bis-Tris gels are made with Bis-
Tris/HCL buffer and do not contain SDS. These gels operate at a neutral pH during 
separation (169). 4-Morpholinepropanesulfonic acid (MOPS) running buffer enables 
chloride ion tailing towards the anode as the electric field is applied. The neutral pH of the 
pre-cast gel diminishes the reactivity of disulfide bonds. Pre-cast NuPAGE® gels were run 
in the XCell SureLock Mini Cell system (Life Technologies, Darmstadt, Germany). 
Separation of the proteins was achieved by applying a constant voltage of 160 V and a 
maximum current of 300 mA for 1 h. 
In both cases, protein lysates were mixed with 5X sample buffer and heated at 95 °C for 5 
min. An equal protein amount was loaded into the wells of the gels. The molecular weight 
of the proteins was estimated by the prestained PageRuler plus protein ladder 10-250K 
(Thermo Scientific, Bremen, Germany).  
2.3.5 Immobilization of proteins by immunoblot  
The immunoblot technique allows electrophoretic transfer of separated proteins from 
polyacrylamide gels to polyvinylidene difluoride (PVDF) membranes (170). This method 
enables immunodetection of proteins by specific antibodies. 
PVDF membranes (Bio-Rad, Munich, Germany) were activated with methanol for 10 sec, 




Rad, Munich, Germany) each was equilibrated in either anode buffer 1, anode buffer 2 or 
cathode buffer. After protein separation by gel electrophoresis, the blotting sandwich was 
assembled in the following way: thick blot paper soaked with cathode buffer, gel, PVDF 
membrane, thick blot paper soaked with anode buffer 1 and thin blot paper soaked with 
anode buffer 2. The electrophoretic transfer of the proteins was carried out using the 
Trans-Blot® TurboTM Transfer System (Bio-Rad, Munich, Germany) at a constant current 
of 0.1 A and a maximum voltage of 25 V for 30 min.   
2.3.6 Immunodetection of proteins 
The visualization of transferred proteins of interest was achieved by immunodetection with 
specific primary antibodies and horseradish peroxidase (HRP)-conjugated secondary 
antibodies. The HRP enzyme activity is detectable by incubating the membrane with an 
enhanced chemiluminescent (ECL) substrate (GE Healthcare, Freiburg, Germany). 
To prevent unspecific interactions of the PVDF membrane and the antibody, the PVDF 
membrane was blocked with either 5 % (w/v) non-fat dry milk or 5 % (w/v) BSA for 1 h. 
The membrane was incubated with a specific primary antibody at room temperature for 
one hour. Subsequently, the membrane was washed with TTBS three times for 10 min. 
The secondary antibody was incubated with the membrane for 30 min at room 
temperature. The secondary antibody was removed and the membrane was washed with 
TTBS three times for 15 min at room temperature. For detection, the membrane was 
treated with ECL substrate for 1 min, exposed to chemiluminescence hyperfilm and 
developed using an automated developer machine (Agfa, Mortsel, Belgium).  
For analyzing different proteins on one membrane, primary and secondary antibodies 
were removed by stripping. Therefore, membranes were incubated with stripping buffer at 
55 °C for 20 min and washed with TTBS three times for 10 min. Membranes were 
incubated with new primary antibodies after blocking with either 5 % (w/v) non-fat dry milk 
or 5 % (w/v) BSA for 1 h. 
2.3.7 Co-immunoprecipitation 
Co-immunoprecipitations (CO-IP) are widely used to identify physiologically relevant 
protein-protein interactions. Target-specific antibodies, which are mostly coupled to 
beads, capture intact protein complexes and allow to co-immunoprecipitate unknown 
members of the complex. For the identification of new interaction partners, co-precipitated 




In this study, CO-IPs were used to elucidate a potential interaction of ORMDL3 and 
ATF6α. ORMDL3 and ATF6α were co-transfected into 10 ml of HEK-293 cells (as 
described in chapter 2.1.2). After 24 h, the cells were lyzed using 500 µl RIPA buffer 
containing 1X HaltTM combined protease and phosphatase inhibitor and vortexed three 
times for 45 sec to achieve complete cell lysis. Cell debris were removed by centrifugation 
of the lysis suspension at 16000 g for 15 min at 4 °C. In the meantime 25 µl of magnetic 
dynabeads® coupled with protein G (Life Technologies, Darmstadt, Germany) were 
incubated for one hour with 1 µg of the target-specific antibody, which either detected HA- 
or FLAG-tagged proteins. Dynabeads coupled with a specific antibody were added to the 
cell lysate and incubated at 4 °C overnight for dynabead-antigen complex formation. This 
complex was washed three times using CO-IP binding and washing buffer to remove 
nonspecifically bound proteins. The complex was eluted from dynabeads by incubating 
the beads with 22 µl CO-IP elution buffer for 5 min at room temperature. Dynabeads were 
removed from the suspension by applying the samples to a magnetic field. The pH of the 
suspension was adjusted to 7.5 using 10 µl Tris buffer. After adding 7 µl 5X SDS-loading 
buffer and boiling the samples for 5 min at 95 °C, samples were resolved on a SDS-PAGE 
and used for immunoblotting to detect the presence of co-precipitated proteins.  
2.3.8 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assays (ELISA) were applied for quantification of the 
growth hormone (GH) or insulin-like growth factor 1 (IGF1) in the serum of Ormdl3-
deficient mice. The ELISA method involves antigen-specific capture antibodies 
immobilized to a plate. After adding the serum sample to the plate, antigens bind to the 
capture antibody. Enzyme-labeled antibodies are applied for detection. 
Quantification of GW was performed using the Rat/Mouse Growth hormone ELISA kit 
(EMD Millipore, Schwalbach, Germany). Serum concentrations of IFG1 were determined 
using the Mouse/Rat IGF1 quantikine ELISA kit (R&D systems, Minneapolis, USA). Both 
kits were performed according to the manufacturer’s protocol. 
2.3.9 Measurement of cytokine concentrations 
For the determination of cytokines levels from murine serum, the Bio-Plex ProTM Mouse 
Cytokine 23-plex immunoassay (Bio-Rad, Munich, Germany) was used. The multiplex 
magnetic bead-based assay enables the detection of 23 cytokines from 12.5 µl of serum. 
Blood was collected in lithium-heparin tubes, centrifuged at 10000 g for 5 min and the 
resulting serum was stored at -80 °C until further usage. The immunoassay measurement 




2.4 Generation, handling and treatment of mice 
2.4.1 Generation of Ormdl1 constitutive knockout mice (Ormdl1-/-)  
The role of Ormdl1 was studied in vivo using Ormdl1-deficient mice (Ormdl1-/-). The 
murine Ormdl1 gene is located on chromosome 1 and consists of 4 exons separated by 3 
introns. The knockout was achieved by deleting exon 2 with the translation initiation codon 
(NM_145517) in collaboration with genOway SA (Lyon, France). The targeting vector 
contained the cDNA of exon 2 flanked by bacteriophage P1-derived loxP sites and a 
neomycin resistance gene cassette flanked by flippase recognition target (FRT) sites in 
intronic sequences (Fig. 2.2). The targeting vector was electroporated into 129Sv 
embryonic stem cells and incorporation into the genome by homologous recombination. 
Positive recombined embryonic stem cells were microinjected into C57BL/6J blastocysts. 
Blastocysts were transferred into pseudo-pregnant mice and allowed to develop. The 
resulting male chimeras were breed to C57BL/6 Flp deleter mice (C57BL/6-Tg(CAG-
Flpe)2) for germline transmission and in vivo removal of selection markers by Cre 
recombinase. Ormdl1-/- mice were generated by breeding the mice to Cre deleter mice 
(C57BL/6-Gt(ROSA)26Sortm9(Cre/ESR1)) resulting in the deletion of exon 2 by recombination 
of the two loxP site. The obtained mice were backcrossed for nine generations to a 
C57BL/6J background at the Central Animal Facility of the Schleswig-Holstein University 
Hospital Kiel, Germany.  
 
Fig. 2.2: Targeting strategy for the generation of conditional and constitutive Ormdl1 knockout alleles. 
For Ormdl1 deletion a targeting vector was designed to flank exon 2 by loxP sites and a neomycin resistance 
cassette for positive selection. The neomycin resistance gene was excised in vivo by breeding with Flp deleter 
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2.4.2 Generation of Ormdl3 conditional mice  
In this study, Ormdl3 conditional and constitutive knockout mice were used to investigate 
the mode of function of Ormdl3 in vivo. In cooperation with TaconicArtemis GmbH 
(Cologne, Germany), the murine Ormdl3 gene (ensemble gene ID: 
ENSMUSG00000038150) was isolated to create the targeting vector (Fig. 2.3). Due to the 
fact, that exon 2 of Ormdl3 contains the translation initiation codon, exon 2 to 4 were 
flanked by loxP sites in intronic sequences. The sequence between the two loxP sites was 
deleted by Cre recombinase. Additionally, the targeting vector contained positive selection 
markers such as puromycin and neomycin resistances. The targeting vector was 
electroporated into C57BL/6N Tac embryonic stem cells. The sequence of the targeting 
vector was incorporated into the genome replacing the original sequence by homologous 
recombination. Embryonic stem cells with the incorporated modified sequence were 
isolated using double positive selection with puromycin and neomycin. Positive cells were 
microinjected into mouse blastocysts and transferred into pseudopregnant female mice. 
The resulting chimeras were bred with Flp deleter mice (C57BL/6-Tg(CAG-Flpe)2Arte) for 
germline transmission and removal of selection markers. The resulting Ormdl3 conditional 
mice allow the generation of conditional and constitutive knockout mice. 
 
 
Fig. 2.3: Overview of the targeting strategy for the generation of conditional and constitutive Ormdl3 
knockout alleles. 
The translation initiation codon of Ormdl3 is located on exon 2 and the coding region is from exon 2 to exon 4. 
The coding region was flanked by loxP sites and selection markers were flanked by either F3 sites (PuroR, 
puromycin resistance) or by FRT sites (NeoR, neomycin resistance). The targeting strategy enables the 
generation of conditional and constitutive Ormdl3 knockout mice, which is explained in detail in the chapters 
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2.4.3 Generation of Ormdl3 constitutive knockout mice (Ormdl3-/-)  
To study the effect of Ormdl3 on the entire organism, Ormdl3-deficient mice were 
generated by breeding Ormdl3 conditional mice to Cre deleter mice (C57BL/6-
Gt(ROSA)26Sortm9(Cre/ESR1)Arte). The loss of function of Ormdl3 was achieved by deleting 
the entire protein coding sequence from exon 2 to 4 after Cre-mediated recombinase, 
which is ubiquitously expressed under the control of the Gt(ROSA)26Sor gene on 
chromosome 6. The obtained mice with a constitutive knockout allele were bred with 
C57BL/6N wild-type mice to remove the Cre recombinase, which could cause unspecific 
side effects. Additional backcrossing was not needed, due to the generation of these mice 
in C57BL/6N Tac embryonic stem cells. For all experiments in this study, mice were bred 
heterozygously to generate Ormdl3-/- and their wild-type littermates.  
2.4.4 Generation of Ormdl3 conditional knockout mice (Ormd3ΔIEC)  
Since ORMDL3 had been identified as a susceptibility gene for CD and UC, Ormdl3 
conditional knockout mice were generated, where the lack of Ormdl3 is restricted to 
intestinal epithelial cells (IECs) of the villi and crypt cells of the small and large intestine 
(Ormdl3ΔIEC). For the generation of Ormdl3ΔIEC mice, Ormdl3 conditional mice were 
crossed with B6.SJL-Tg(Vil-cre)997Gum/J (villin-cre) mice. Villin-cre mice express the Cre 
recombinase under the control of the villin 1 promoter, which leads to Cre-mediated 
recombination of loxP sites resulting in a tissue-specific deletion of Ormdl3. Beside the 
mainly described expression of villin 1 in intestinal epithelial cells, villin 1 can also be 
found in cells of the kidney proximal tubulus and in the duct of pancreas and biliary 
system (171). In this study, mice were bred heterozygously for villin 1 in order to generate 
Ormdl3 ΔIEC and their wild-type littermates. 
2.4.5 Animal housing and animal care 
Mice were housed under specific pathogen-free conditions in individually ventilated cages 
at the Central Animal Facility of the Schleswig-Holstein University Hospital Kiel, Germany. 
Animals were maintained in a 12 h light-dark cycle under barrier conditions at 21°C ± 2°C 
and 60% ± 5% humidity and were provided with food and tap water ad libitum. All 
experiments were performed according to the german guidelines for animal care and 
protection. The animal research in this study was approved by the institutional review 





Table 2.11: License numbers for approved animal research 
License number Designated use 
V 312-7224.121-33 killing for tissue harvesting 
V 312-72241.121-33 (26-3/10) acute and chronic DSS-induced colitis 
V 312-7224.121-33 (77-6/13) tunicamycin treatment 
 
2.4.6 Genotyping 
Genotyping was performed to distinguish between heterozygous mice and homozygous 
wild-type or knockout mice by performing PCR analyses of genomic DNA. The genomic 
DNA was extracted from tail biopsies of three to four weeks old mice by boiling with 100 µl 
of 50 mM sodium hydroxide (NaOH) for 1 h. After centrifugation the genomic DNA-
containing supernatant was collected and submitted to two independent touch-down 
PCRs per mouse line. Therefore, GoTaq DNA polymerase (Promega, Mannheim, 
Germany) was applied. Components for the PCR reaction and profile are shown in (Table 
2.12). Applied oligonucleotides are listed in the supplementary information (Table 8.8). 
 
Table 2.12: PCR components and profile for genotyping 
Component Volume  Number of cycles  Temp [°C] Time 
DNA  1 µl 
 
1 95 2 min 
5X GoTaq Green Buffer  4 µl 
 10 
95 30 sec 
dNTPs (10 mM each)  0.5 µl 
 
65 to 55 (-1 °C/cycle) 5 sec 
Oligonucleotide for (10 µM)  0.25 µl 
 
72 4 min 
Oligonucleotide rev (10 µM)  0.25 µl 
 33 
95 10 sec 
GoTaq Polymerase  0.5 µl 
 
55 5 sec 
Nuclease-free water  13.5 µl 
 
72 4 min 
   
1 72 7 min 
   
1 4 ∞ 
 
The resulting amplicon lengths were determined by gel electrophoresis (as described in 
chapter 2.2.4) followed by exposure to UV light for visualization. The genotype of a mouse 
was determined by combining the received amplicon lengths of the two PCR analyses 
(Table 2.13).  
Table 2.13: Overview of expected amplicon lengths after genotyping PCR. 
 Ormdl1 Ormdl3     
Genotype PCR WT PCR KO PCR WT PCR KO  Genotype PCR cond PCR cre 
+/+ 1632 bp no band  194 bp no band 
 
Ormdl3fl/fl  388 bp no band 
+/- 1632 bp 2015 bp  194 bp  277 bp 
 
Ormdl3ΔIEC  388 bp 1000 bp 
-/-  no band 2015 bp  no band  277 bp 




Generic PCR product profiles of genotyping PCRs for Ormdl1-/-, Ormdl3-/- and Ormdl3ΔIEC 
mice are shown in Fig. 2.4. Sizes of the PCR amplicons were estimated using the 
SmartLadder MW-1700-10 (Eurogentec, Cologne, Germany). 
Fig. 2.4: Representative example of genotyping results obtained from Ormdl1-/- (A), Ormdl3-/-(B) and 
Ormdl3ΔIEC (C) mice. 
Genomic DNA was isolated from mouse tails to perform genotyping PCRs. PCR products were separated by 
agarose gel electrophoresis and the genotype was determined by interpreting the resulting amplicon sizes. 
L represents the molecular weight marker of the DNA SmartLadder MW-1700-10. 
 
2.4.7 Primary cell isolation 
Primary murine cells were isolated to investigate proteins at basal level or upon 
stimulation ex vivo. 
Bone marrow-derived macrophages (BMDMs) were obtained from femoral bone marrow. 
These cells were used for controlled studies of macrophages ex vivo. Cells were isolated 
from femur and tibia bones by flushing with 30 ml BMDM medium and plated for 
differentiation in a 150 mm dish at 37 °C and 5 % (v/v) CO2. The depleted medium was 
replaced with fresh warm BMDM medium after three days. After seven days of culturing, 
BMDMs were harvested, counted using the Cellometer Auto T4 Plus (PeqLab 
Biotechnologie GmbH, Erlangen, Germany) and seeded into culture dishes with a defined 
cell number for experiments according to Table 2.14. 
Primary murine splenocytes were isolated to study primary immune cells, such as T cells 
and B cells, ex vivo. The spleen was mashed through a 0.4 µm cell strainer into a 50 ml 
tube. Mixed splenocytes were isolated from the mashed spleen using mouse Biocoll 
(Biochrom, Berlin, Germany) by centrifugation without breaks at 1250 g for 20 min at room 
temperature. The resulting interphase was collected and washed 3 times with splenocyte 
medium by centrifugation at 300 g for 10 min. Cells were counted and seeded into culture 
dishes with the appropriate cell numbers (Table 2.14). 
Murine intestinal epithelial cells were isolated from PBS-flushed small intestine. Slices of 
the small intestine were incubated with 1.5 mM EDTA in HBSS for 20 min at 37 °C 
followed by vortexing for 30 sec. Supernatant was centrifuged at 300 g for 10 min. The 































































T4 Plus and seeded into culture dishes with the appropriate cell number in MEM 
supplemented with 20 % (v/v) FCS and 1 % (v/v) penicillin and streptomycin (Table 2.14).  
Table 2.14: Overview of cell culture formats for experiments with primary murine cells. 
cell culture dish cell number/well media volume [ml] 
 6-well plate  1 x 106  2 
 12-well plate  5 x 105  1 
 96-well plate  5 x 104  0.1 
 
IECs and cells from the lamina propria were isolated from small intestine and colon 
tissues using the Lamina Propria Dissociation Kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany). 10 weeks old mice were sacrificed and the intestine removed, flushed with 
PBS and cut longitudinally into pieces of approximately 0.5 cm length. Isolation and 
purification of intraepithelial lymphocytes and lamina propria cells was performed 
according to the manufacturer’s protocol. The fraction of intraepithelial lymphocytes also 
contained IECs. Due to this reason, this fraction was named IEC fraction in this study. 
2.4.8 Induction of acute colitis  
Experimental acute colitis was induced in 10 weeks old male mice by administration of 
2.5% (w/v) dextran sodium sulfate (DSS) in autoclaved drinking water for 6 days, followed 
by one day of regular drinking water. Mice were exposed to drinking water with or without 
DSS ad libitum. As recommended by Wirtz et al. (172), DSS-containing water was 
replaced on day three to prevent bacterial growth. Mice were monitored and weighted 
every day. Mice were sacrificed on day 8. 
2.4.9 Induction of chronic colitis 
Chronic colitis in 10 weeks old male mice was induced by three cycles of 1.5% (w/v) DSS 
in autoclaved drinking water for five days, followed by regular drinking water for five days. 
Mice were exposed to water with or without DSS ad libitum. DSS-containing water was 
replaced on day three to prevent bacterial growth. In every cycle, the mice were monitored 
and weighed at least every other day. Mice were sacrificed on day 30. 
2.4.10 Disease activity index (DAI) 
During DSS-induced colitis experiments, the course of the disease was monitored and 
scored using the disease activity index (DAI), a combined score of stool blood, stool 





Table 2.15: Scoring criteria for the determination of the disease activity index. 
Score Stool blood Stool consistency Body weight loss [%] 
0 Hemoccult negative formed 0 
1     1-4.99 
2 Hemoccult positive unformed 5-9.99 
3     10-19.99 




Hematoxylin and Eosin staining (HE staining) 
HE staining enables blue coloring of the nucleus by hemalaun, a complex formed of 
aluminium ions and oxidized hematoxylin, as well as red coloring of eosinophilic structures 
by Eosin.   
For histological studies, tissues were fixed in 10 % (v/v) PBS buffered formalin for 24 h 
followed by dehydration and embedding in paraffin wax. Tissues were cut into 3.5 µm 
sections using the Leica RM 2255 microtome (Leica Microsystems, Wetzlar, Germany) 
and mounted on microscope slides. Before staining, histological sections were 
deparaffined by applying a decreasing alcoholic dilution series using the xylol replacing 
reagent Roti®-Histol (Carl Roth, Karlsruhe, Germany) for 10 min, 3 times 100 % ethanol 
for 10 min, 2 times 96 % ethanol for 2 min, 70 % ethanol for 2 min and water for 5 min. 
Slides were stained with hemalaun for 5 min and exposed to tap water for blueing. After 
staining with Eosin G for 2 min, slides were shortly washed using aqua bidest. and dried 
by an increasing alcoholic series. Slides were coverslipped using Roti Histokit (Carl Roth, 
Karlsruhe, Germany).  
 
Histological scoring of colonic sections after DSS treatment 
Histological scoring of HE stained colonic sections were applied for the assessment of the 
severity of colitis. As described by Laroui et al. (173), images were scored blinded based 
on three parameters including infiltration of immune cells, crypt damage and ulceration 
(Table 2.16). Scores from each parameter were summed up to result in a maximum 






Table 2.16: Overview of the three histological scoring components 
Score Severity of inflammation Crypt damage Ulceration 
0 rare inflammatory cells in the 
lamina propria 
intact crypts absence of ulcer 
1 increased number of granulocytes 
in the lamina propria 
crypt loss of the basal 
one-third 
1 or 2 foci of 
ulterations 
2 confluence of inflammatory cells 
extending into the submucosa 
crypt loss of the basal 
two-third 
3 or 4 foci of 
ulterations 
3 transmural extension of the 
inflammatory infiltrate 
entire crypt loss confluent or 
extensive ulteration 
4   change of epithelial surface with erosion 
  
5   confluent erosion   
 
2.4.12 Tunicamycin injection 
For in vivo ER stress induction, a single intraperitoneal injection of 1 mg tunicamycin per 
kg body weight (BW) was applied for 8 h, 24 h, 48 h or 7 d. During the experiment, body 
weight and overall appearance of the mice was monitored daily. At the end of the 
treatment, mice were anaesthetized using 100 mg/kg BW Ketamin (Ketanest, Pfizer, New 
York, USA) plus 16 mg/kg BW Xylazin (Rompun, Bayer, Leverkusen, Germany) for final 
blood collection by cardiac puncture. Kidney and liver tissues were obtained and either 
fixed in 10 % (v/v) PBS buffered formalin for HE staining or snap-frozen in liquid nitrogen 
and stored at -80 °C for RNA and protein analyses. 
2.5 Statistical analysis  
The Student’s unpaired t-test was performed for all statistical analyses using the 
GraphPad Software (GraphPad Software Inc., La Jolla, USA). Data were plotted in 
GraphPad Prism 5 with mean and standard error of the mean (SEM). Significance levels 
were depicted as (*) for statistically significant with p≤0.05, (**) strongly significant with 
p≤0.01 and (***) for highly significant with p≤0.001. Statistical analysis was performed 





3.1 Expression analyses of human and murine ORMDL mRNA  
SNPs in close proximity to the human ORMDL3 gene were associated with a variety of 
diseases, including asthma and IBD. However, so far the impact of ORMDL proteins on 
the pathogenesis of these diseases is not fully elucidated. Moreover, molecular functions 
of ORMDL proteins, in this regard, are largely unknown (163).  
To get a first insight into the specific in vivo function of ORMDL proteins and to investigate 
whether these proteins have potential tissue-specific functions, mRNA expression 
analyses were performed. Human and murine mRNA levels of ORMDL1, ORMDL2 and 
ORMDL3 were studied on a variety of tissues by semi-quantitative endpoint PCR (Fig. 
3.1). Transcripts of the three genes showed ubiquitous expression patterns in the 
examined tissues. Interestingly, the largest variation in tissue-specific transcript levels was 
observed for ORMDL3. The highest mRNA level of the human ORMDL3 was detected in 
liver, spleen and pancreas (Fig. 3.1A). The murine Ormdl3 gene was additionally highly 
expressed in skeletal muscle (Fig. 3.1B).  
 
Fig. 3.1: Analyses of human and murine ORMDL transcripts investigated by endpoint PCR. 
Transcript levels of ORMDL1, ORMDL2 and ORMDL3 in various (A) human and (B) murine tissues were 
assessed by endpoint PCR. Water was used as no template control. GAPDH mRNA expression served as 
internal control for the applied cDNA amount. 
 
3.2 ER stress-induced tissue-specific expression of ORMDL proteins 
ORMDL proteins have been reported to be involved in the UPR (135). Typically, proteins 







































































































increased protein levels upon ER stress induction (86,174). For the investigation of 
ORMDL protein levels during ER stress, immortalized cell lines and primary cells were 
treated with the ER stress-inducing agents tunicamycin (TM) or thapsigargin (TG) and 
evaluated using immunoblotting analyses. Due to the close resemblance of the three 
ORMDL proteins with around 80 percent amino acid identity (135), antibodies cannot 
distinguish between ORMDL1, ORMDL2 and ORMDL3. Thus it has to be noted that 
immunoblotting analyses enables only the visualization of total ORMDL protein levels with 
all three members of the ORMDL family.  
Efficiency of ER stress induction was confirmed by increased GRP78 protein levels (Fig. 
3.2). 24 h of tunicamycin or thapsigargin treatment revealed increased protein levels for 
ORMDL in the murine RAW 264.7 macrophage cell line (Fig. 3.2A), primary murine 
macrophages (Fig. 3.2D) and primary murine mixed splenocytes (Fig. 3.2E). In contrast, 
ER stress in intestinal epithelial cells, such as cells from the human colon 
adenocarcinoma cell line HT-29 (Fig. 3.2B) or primary murine small intestinal cells (Fig. 
3.2F), resulted in reduced ORMDL protein levels. Interestingly, ORMDL protein levels 
were not altered in cells of the human embryonic kidney cell line HEK-293 after 24 h of 
tunicamycin or thapsigargin treatment (Fig. 3.2C). These findings indicate a diverse 
induction pattern of ORMDL proteins in various cell lines.  
 
Fig. 3.2: ER stress-inducing reagents alter ORMDL protein levels in vitro. 
Mouse macrophage cell line RAW 264.7 (A), human colon adenocarcinoma cell line HT-29 (B), human 
embryonic kidney cell line HEK-293 (C), primary murine bone marrow-derived macrophages (BMDMs) from 
wild-type  (C57BL/6) mice (C), primary murine splenocytes from wild-type mice (D) and primary murine small 
intestine cells from wild-type mice were treated with 20 µg/ml tunicamycin (TM) or 2 µM thapsigargin (TG) for 
24 h, unless otherwise indicated. Cell lysates were resolved on a SDS-PAGE and analyzed by immunoblotting 
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3.3 The effect of ORMDL proteins on the UPR 
The observed regulation of ORMDL protein levels during ER stress (Fig. 3.2) suggested 
that ORMDL proteins are involved in the UPR pathways. Promoter-mediated luciferase 
reporter assays, immunoblotting and FACS analysis were performed to investigate the 
effect of ORMDL proteins on the three major arms of the UPR including IRE1, ATF6 and 
PERK. Due to the association of ORMDL1 and ORMDL3 with a variety of diseases, the 
main focus of this study lies on these two members of the ORMDL protein family. 
3.3.1 ORMDL proteins inhibit the IRE1 pathway 
During ER stress, IRE1 gets autophosphorylated and induces mRNA splicing of the 
transcription factor XBP1. The spliced form of XBP1 functions as the main inducer of the 
UPRE promoter (86). To investigate the impact of ORMDL on the IRE1 pathway, mRNA 
splicing of XBP1 was monitored by FACS analyses using the XBP1ΔDBD-venus 
construct. In ORMDL3 overexpressing cells the fluorescence intensity was decreased, 
thus XBP1 splicing was significantly reduced already under normal conditions and even 
stronger after 24 h of tunicamycin treatment (Fig. 3.3A). A similar, but not significant, 
tendency was observed in HEK-293 cells overexpressing ORMDL1. In order to exclude 
transfection or overexpression artifacts of ER membrane proteins such as ORMDL 
proteins, HEK-293 cells were treated with a mix of siRNAs against ORMDL1, ORMDL2 
and ORMDL3 or a scrambled siRNA as a control (Fig. 3.3B). Confirming the findings from 
the overexpression experiments, siRNA knockdown of ORMDL1, ORMDL2 and ORMDL3 
resulted in increased fluorescence intensities in untreated as well as in tunicamycin- or 
thapsigargin-treated cells.  
As a consequence of XBP1 mRNA splicing, the URPE promoter gets activated. Promoter-
mediated luciferase reporter assays in ORMDL1 and ORMDL3 overexpressing HEK-293 
cells revealed reduced UPRE promoter activities after tunicamycin-treatment (Fig. 3.3C). 
This result was confirmed by siRNA treatment (Fig. 3.3D), where the knockdown of 
ORMDL proteins significantly induced the UPRE promoter activity. Upon tunicamycin and 
thapsigargin treatment, this effect was even reinforced. Taken together, the results of the 
UPRE promoter-mediated luciferase reporter assays were consistent with those from the 






Fig. 3.3: ORMDL proteins reduce XBP1 mRNA splicing and UPRE promoter activation. 
The effect of ORMDL1 or ORMDL3 overexpression (A) as well as siRNA-based ORMDL knockdown (B) on 
XBP1 mRNA splicing was evaluated using the life-cell XBP1 monitoring assay. HEK-293 cells were 
transfected as indicated and additionally transfected with pCAX-XBP1ΔDBD-venus. After 24 h, the cells were 
stimulated with 4 µl DMSO as a control, 20 µg/ml tunicamycin (TM) or 2 µM thapsigargin (TG) for additional 24 
h. The appearance of fluorescent XBP1-venus protein in the cells was monitored by flow cytometry and 
displayed as geometric mean fluorescence intensity. UPRE promoter activity was measured by promoter-
mediated luciferase reporter assays after ORMDL1 and ORMDL3 overexpression (C) or ORMDL knockdown 
using siRNA (D). HEK-293 cells were additionally co-transfected with a firefly luciferase reporter pGL3B-UPRE 
and Renilla luciferase as a transfection control. The cells were treated with 20 µg/ml of tunicamycin (TM) or 
2 µM thapsigargin (TG) for 24 h. Luciferase activities were determined by flow cytometry and relative 
luciferase units (RLU) were calculated. Assays were performed in quintuples. Error bars represent 




3.3.2 ORMDL proteins activate the ATF6α pathway 
ER stress induces the translocation of ATF6α from the ER to the Golgi apparatus, where it 
is cleaved by Site-1 protease (S1P) and Site-2 protease (S2P). The cleaved N-terminal 
fragment of ATF6α (ATF6α (N)) activates the ERSE promoter and, subsequently, the 
transcription of chaperones such as GRP78 and GRP94 (175). Besides the mainly 
described 50 kDa cleavage product of ATF6α (176), also 36 kDa and 60 kDa fragments of 





































































3.3.2.1 ORMDL proteins reduce p36ATF6α protein levels and induce the ERSE 
promoter  
The impact of ORMDL3 on the cleavage of endogenous ATF6α was determined by 
immunoblotting analyses. Commercially available antibodies against ATF6α solely 
detected protein bands with a size around 36 kDa. This 36 kDa fragment of ATF6α 
(p36ATF6α) was reduced in ORMDL3 overexpressing HEK-293 cells after 30 min, 1 h and 
3 h of tunicamycin treatment (Fig. 3.4A). Consistent with the overexpression data, the 
opposite effect was observed in cells treated with ORMDL1, ORMDL2 and ORMDL3 
siRNA (Fig. 3.4B). For siRNA-mediated knockdown, HT-29 cells were chosen, because of 
their high basal ORMDL protein levels compared to HEK-293 cells.   
In detail, knockdown of the three ORMDL homologues in HT-29 revealed increased 
p36ATF6α protein levels after 10 min, 30 min, 1 h and 3 h of tunicamycin treatment 






Fig. 3.4: ORMDL proteins 
regulate the p36ATF6α 
fragment. 
HEK-293 cells were transfected 
with an ORMDL3 expression 
plasmid (pCMV-HA-hORMDL3) 
(A) and HT-29 cells were treated 
with siRNA against ORMDL1, 
ORMDL2 and ORMDL3 (B). After 
24 h, cells were left untreated or 
treated using 5 µg/ml tunicamycin 
(TM) for indicated durations. Total 
cell lysates were resolved on a 
SDS-PAGE and analyzed by 
immunoblotting using antibodies 
against ATF6α, ORMDL1/2/3 or β-






Cleavage of ATF6α enables the resulting N-terminal fragment to enter the nucleus, where 
it induces the ERSE promoter and regulates the expression of ER chaperones (175,178). 
Cell fractionations were performed to investigate the effect of ORMDL3 on the 
translocation of p36ATF6α (Fig. 3.5A). ORMDL3 overexpressing cells showed increased 
p36ATF6α protein levels in the nuclear fraction upon ER stress. In addition, p36ATF6α 
disappeared from the cytosolic fraction only in ORMDL3 overexpressing cells after 10 h of 










































































































































































active ATF6α fragment was examined by ERSE luciferase reporter assay (Fig. 3.5B). In 
this experiment, HEK-293 cells overexpressing ORMDL1 and ORMDL3 revealed 
increased basal and ER stress-induced ERSE promoter activities. 
 
Fig. 3.5: ORMDL proteins induce translocation of p36ATF6α to the nucleus and activate the ERSE 
promoter. 
(A) Cell fractionations were performed using HEK-293 cells transfected with an ORMDL3 (pCMV-HA-
hORMDL3) or an EGFP (pCMV-HA-EGFP) expression plasmid. Cells were left untreated or treated using 5 
µg/ml tunicamycin (TM) for the indicated durations. Cytosolic and nuclear fractions were resolved on a 
SDS-PAGE and analyzed by immunoblotting using antibodies against ATF6α, or Histone H3, used as a 
loading control. (B) Effects of ORMDL1 and ORMDL3 overexpression on the ERSE promoter were measured 
by luciferase reporter assays. HEK-293 cells were co-transfected with a firefly luciferase reporter pGL3B-
ERSE, Renilla luciferase for normalization and pCMV-HA-EGFP, pCMV-HA-hORMDL1, or 
pCMV-HA-hORMDL3. After 24 h, cells were left untreated or treated with 20 µg/ml tunicamycin (TM) or 2 µM 
thapsigargin (TG) for additional 24 h. Error bars represent means ± SEM. Statistical analyses was performed 
by two-way ANOVA followed by Student’s t-test for unpaired samples. 
 
To investigate whether the effect of ORMDL proteins on p36ATF6α and ERSE promoter 
activity is S1P-dependent, cells were treated with the well established serine protease 
inhibitor 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) (179). AEBSF 
treatment resulted in reduced p36ATF6α protein levels in all observed cells independent 
of ORMDL proteins (Fig. 3.6A). This finding supports the hypothesis raised by Liu et al. 
(180) that p36ATF6α is a S1P-dependent ATF6α cleavage fragment. AEBSF stimulation 
equalized the p36ATF6α protein levels in HEK-293 cells transfected with ORMDL3 and 
EGFP. In line with this result, also the ERSE promoter activity remained unchanged after 
tunicamycin treatment in ORMDL1 and ORMDL3 overexpressing HEK-293 cells, which 













































































Fig. 3.6: The effect of ORMDL proteins on the p36ATF6α fragment is modulated by S1P. 
(A) HEK-293 cells were transfected with an ORMDL3  (pCMV-HA-hORMDL3) or an EGFP (pCMV-HA-EGFP) 
expression plasmid. Cells were left untreated or were pretreated for 1 h using 300 µM AEBSF prior to 
stimulation with 5 µg/ml tunicamycin (TM). Total cell lysates were resolved on a SDS-PAGE and analyzed by 
immunoblotting using antibodies against ATF6α, ORMDL1/2/3 or β-Actin as a loading control. (B) Effects of 
AEBSF and ORMDL1 or ORMDL3 overexpression on the ERSE promoter were measured by luciferase 
reporter assays. HEK-293 cells were co-transfected with a firefly luciferase reporter pGL3B-ERSE, Renilla 
luciferase for normalization and pCMV-HA-EGFP, pCMV-HA-hORMDL1, or pCMV-HA-hORMDL3. After 24 h, 
cells were left untreated or treated with 20 µg/ml tunicamycin (TM) for additional 24 h in the presence or 
absence of 300 µM AEBSF. Error bars represent means ± SEM. Statistical analyses was performed by two-
way ANOVA followed by Student’s t-test for unpaired samples. n.s. indicates not significant differences. 
 
3.3.2.2 ORMDL3 affects the ERSE promoter mainly through ATF6α cleavage 
To determine whether the effect of ORMDL3 on the ATF6α branch was influenced only by 
by ATF6α cleavage events or also by cross-talk events with other UPR mediators, an 
ERSE luciferase reporter assay was performed in presence or absence of UPR mediator-
specific siRNAs. The ERSE promoter activity has been reported to be mainly activated by 
ATF6α cleavage products (90). However, other UPR mediators, such as XBP1 (93) and 
ATF4 (181), are capable to bind the ERSE and function as transcription factors, but to a 
lesser extent.  
Knockdown of ATF6α in EGFP overexpressing HEK-293 cells validated the specificity of 
the ERSE luciferase reporter assay (Fig. 3.7A). In those cells, only a minor increase in 
ERSE promoter activity was detected after 24 h of tunicamycin treatment. As expected, 
cells treated with siRNA against ATF4, PERK, IRE1 or control siRNA revealed elevated 
ERSE promoter activations upon tunicamycin stimulations. A similar tendency for ERSE 
promoter activity was observed in ORMDL3 overexpressing HEK-293 (Fig. 3.7B). 
However, upon ER stress induction by tunicamycin, the ERSE promoter was more 
induced in cells treated with siRNA against ATF6α, indicating a weak cross-talk effect. 
Thus, the effect of ORMDL3 on the ERSE promoter activity is mainly, but not exclusively, 
mediated by the ATF6α pathway. 












































































Fig. 3.7: Effects of all UPR pathway mediators on the ERSE promoter activity. 
ERSE promoter activity was quantified by promoter-mediated luciferase reporter assays. HEK-293 cells were 
treated with siRNA as indicated and co-transfected with a firefly luciferase reporter pGL3B-ERSE, Renilla 
luciferase for normalization and a plasmid containing EGFP (A) or ORMDL3 (B). 24 h after transfection, cells 
were left untreated or treated with 5 µg/ml tunicamycin (TM) for additional 24 h and thereafter assayed using a 
luminometer. Assays were performed in quintuples. Error bars represent means ± SEM. Statistical analyses 
was performed by two-way ANOVA followed by Student’s t-test for unpaired samples. n.s. indicates not 
significant differences. 
 
3.3.2.3 N-linked glycosylation of ATF6α is ORMDL3-dependent 
Since commercially available antibodies did not recognize the full-length form of ATF6α 
(ATF6α FL), but overexpression of ORMDL3 revealed a distinct impact on the 
endogenous 36 kDa cleavage fragment of ATF6α (Fig. 3.4), ATF6α FL was investigated 
using a FLAG-tagged ATF6α expression construct. Immunoblotting analyses indicated an 
ORMDL3-dependent alteration of ATF6α FL (Fig. 3.8A). Untreated HEK-293 cells 
transfected with an ORMDL3 expression construct showed reduced protein levels for 
ATF6α FL and an emerging slightly smaller band of ATF6α. This smaller band has been 
described as the unglycosylated form of ATF6α (ATF6α UG), which exhibits a faster rate 
of constitutive transport to the Golgi apparatus and results in higher levels of 
transcriptionally active ATF6α in the nucleus (182). Tunicamycin treatment for 1, 3 and 6 h 
further enhanced the effect of ORMDL3 leading to reduced levels of ATF6α FL and 
increased levels of ATF6α UG. Most prominent, after 8 h of treatment, ATF6α FL even 
disappeared and in addition, as sign of an increased ATF6α activation, ATF6α UG was 
mitigated in ORMDL3 overexpressing cells compared to control cells.  
In order to investigate whether the effect of ORMDL3 on ATF6α FL especially depends on 
stimulations with a glycosylation inhibiting agent such as tunicamycin, cells were treated 
with thapsigargin (Fig. 3.8B). In contrast to tunicamycin, thapsigargin induces ER stress 
by blocking the ER calcium ATPase pump without affecting the glycosylation machinery. 





















































































































3 h of thapsigargin treatment, ORMDL3 overexpressing cells showed reduced ATF6α FL 
protein levels indicating an increased cleavage rate of ATF6α. Efficiency of ER stress 
induction by thapsigargin was confirmed by increased ATF4 protein levels. The effect of 
ORMDL3 on ATF6α FL was further validated by siRNA-mediated knockdown of ORMDL1, 
ORMDL2 and ORMDL3 (Fig. 3.8C). Down-regulation of ORMDL proteins revealed 
increased ATF6α FL protein levels compared to control siRNA-treated cells.  
 
Fig. 3.8: The full length form of ATF6α is affected by ORMDL3. 
Effects of pCMV-HA-hORMDL3 overexpression (A, B) and siRNA-based down-regulation of ORMDL1, 
ORMDL2 and ORMDL3 (siORMDL1/2/3) (C) on ATF6α FL were examined by immunoblotting analyses 
HEK-293 cells co-transfected with FLAG-ATF6α. After 24 h, cells were left untreated or treated using 5 µg/ml 
tunicamycin (TM) (A, C) or 0.5 µM thapsigargin (TG) (B) for indicated durations. Cell lysates were resolved on 
a SDS-PAGE and analyzed by immunoblotting using antibodies specific to FLAG, ORMDL1/2/3, ATF4 or 
β-Actin as a loading control. Anti-FLAG antibody was used to detect FLAG-tagged ATF6α. 
 
To ensure that the ATF6α UG fragment is the unglycosylated form of ATF6α FL, HEK-293 
cell lysates were treated with endoglycosidase H (Endo H) to reduce the N-glycans to a 










































































































































































































resulted in a protein band with a similar size as the band for ATF6α UG (Fig. 3.9). 
Interestingly, another N-linked glycoprotein, translocon-associated protein alpha (TRAPα), 
did not show increased unglycosylated bands in ORMDL3 overexpressing cells indicating 
a unique effect of ORMDL3 on ATF6α N-linked glycosylation 
 
Fig. 3.9: Effect of ORMDL3 on ATF6α functions 
independently of glycosylation processes. 
HEK-293 cells were co-transfected with FLAG-ATF6α and 
ORMDL3 or EGFP expression constructs. After 24 h, cells 
were left untreated or treated with 5 µg/ml tunicamycin (TM) 
for 6 h. Indicated cell lysates were incubated with 
endoglycosidase H (Endo H) and resolved on a SDS-Page. 
Immunodetection was performed using antibodies against 
FLAG, TRAPα, ORMDL1/2/3 or β-Actin as a loading control. 











3.3.2.4 ORMDL3 induces ATF6α cleavage 
To clarify the impact of ORMDL3 on ATF6α cleavage, FLAG-ATF6α was overexpressed 
in HEK-293 cells and ATF6α FL and its cleavage fragments were visualized with an 
anti-FLAG antibody. First, a dose-dependency was investigated, where increasing 
amounts of ORMDL3 were co-transfected with a constant concentration of an FLAG-
ATF6α expression construct (Fig. 3.10A). This experiment revealed increasing levels of 
ATF6α UG and a cleavage fragment ATF6α (N) with a molecular mass of 55 kDa in cells 
with rising concentrations of ORMDL3. Upregulation of the ATF6α (N) level after 3 h of 
tunicamycin treatment confirmed this fragment as a specific cleavage product of ATF6α 
FL. As expected from the above mentioned results, the effect of ORMDL3 on ATF6α 
cleavage was observed in untreated as well as tunicamycin-treated cells. Thus, ORMDL3 
overexpression is sufficient to induce ATF6α cleavage also in the absence of tunicamycin. 
Cleaved ATF6α (N) has been reported to enter the nucleus, where it functions as a 
transcriptional regulator of ER chaperones (175). Cell fractionations were performed to 
investigate the influence of ORMDL3 on the translocation of the ATF6α (N) fragment into 
the nucleus (Fig. 3.10B). Nuclear fractions show higher ATF6α (N) protein levels in 














































Fig. 3.10: Dose-dependent effect of ORMDL3 on ATF6α UG and ATF6α (N). 
(A) HEK-293 cells were co-transfected with FLAG-ATF6α and ORMDL3 (ORM3) or EGFP expression 
constructs, in increasing or decreasing amounts, respectively. (B) For cell fractionations HEK-293 cells were 
co-transfected with FLAG-ATF6α and ORMDL3 or EGFP expression constructs in equal amounts. After 24 h, 
cells were left untreated or treated with 5 µg/ml tunicamycin (TM) for indicated durations. Total cell lysates (A) 
or cell fractions (B) were resolved on a SDS-PAGE and analyzed by immunoblotting using antibodies specific 
to FLAG, ORMDL1/2/3, EGFP and β-Actin or Histone H3 as a loading control. Anti-FLAG antibody was used 
to detect FLAG-tagged ATF6α. 
 
ATF6α is constitutively synthesized and restores ATF6α FL after cleavage (105). For the 
investigation of the degradation rate of ATF6α FL, HEK-293 cells were treated with 
cycloheximide (CHX) to inhibit protein synthesis (Fig. 3.11). ATF6α FL protein levels were 
more rapidly decreased in ORMDL3 overexpressing cells compared to EGFP 
overexpressing cells.  
 
Fig. 3.11: CHX-treated ORMDL3 overexpressing cells display increased cleavage of ATF6α FL. 
HEK-293 cells were co-transfected with a FLAG-ATF6α and an ORMDL3 or an EGFP expression plasmid. 
After 24h, cells were treated with or without 50 µl/ml cycloheximide (CHX) in presence or absence of 5 µg/ml 
tunicamycin (TM) (A) or 0.5µM thapsigargin (TG) (B) for indicated durations. Cell lysates were resolved on a 
SDS-Page and analyzed by immunoblotting using antibodies against FLAG, ORMDL1/2/3 or β-Actin as a 































































































































































































3.3.2.5 ORMDL3 and ATF6α are located in close spatial proximity 
Due to the distinct effects of ORMDL3 on ATF6α cleavage and N-linked glycosylation, 
co-localization studies were performed. HeLa cells were co-transfected with EGFP-ATF6α 
and either RFP-ORMDL3 or RFP as a control. RFP-ORMDL3, in contrast to RFP (Fig. 
3.12A), was distributed in an ER-like structure similar to the structure of EGFP-ATF6α 
(Fig. 3.12B). Especially the enlargement of the images identified similar clustering of both 
proteins around the nucleus (Fig. 3.12C). By overlaying the images for EGFP-ATF6α and 
RFP-ORMDL3 a close spatial proximity of both proteins was demonstrated, suggesting a 
possible interaction of ORMDL3 and ATF6. 
 
Fig. 3.12:  ORMDL3 co-localizes with ATF6α. 
HeLa cells were co-transfected with plasmids for GFP-ATF6α and (A) RFP or (B) RFP-ORMDL3. 24 h after 
transfection, images were taken from viable cells. Bottom images (C) show an enlargement of the outlined 


















3.3.2.6 ORMDL3 interacts with ATF6α  
Co-immunoprecipitation (CO-IP) studies were performed using cells co-transfected with 
FLAG-ATF6α and HA-ORMDL3 or HA-EGFP. The first CO-IP approach used an anti-HA 
antibody, which recognizes HA-tagged ORMDL3 or EGFP as a control. In immunoblotting 
experiments, ATF6α was only detected in ORMDL3 overexpressing cells using an anti-
FLAG antibody (Fig. 3.13A). The interaction remained intact also after tunicamycin 
stimulation. The specificity of the interaction was confirmed by CO-IP using the opposite 
approach, where an anti-FLAG antibody was used (Fig. 3.13B). In this setting, 
FLAG-ATF6α precipitated only ORMDL3 and not EGFP. Both approaches revealed 
protein-protein-interaction of the ER-resident proteins ORMDL3 and ATF6α FL. 
 
Fig. 3.13: Interaction of ORMDL3 and ATF6α shown by co-immunoprecipitation. 
HEK-293 cells were co-transfected with plasmids for HA-ORMDL3, HA-EGFP and FLAG-ATF6α. After 24 h, 
cells were left untreated or treated with 5 µg/ml tunicamycin (TM) for 6 h. CO-IPs were performed using 
antibodies against either HA (A) or FLAG (B). Immunoprecipitates (IP) and cell lysates (3 % input) were 
resolved on a SDS-PAGE and analyzed by immunoblotting using antibodies to FLAG or HA. The anti-HA 




























































































































3.3.3 ORMDL proteins modulate the PERK pathway 
Activation of PERK by ER stress leads to phosphorylation of eIF2α (p-eIF2α), which 
mediates global repression of protein translation as well as activation of the transcription 
factor ATF4 and the pro-apoptotic factor CHOP (184). To investigate the effect of 
ORMDL1 and ORMDL3 on the promoter activity of ATF4, a promoter mediated luciferase 
reporter assay was used (Fig. 3.14A). For that reason, ORMDL1 and ORMDL3 were 
overexpressed in HEK-293 cells, which resulted in significantly increased ATF4 promoter 
activities already under unchallenged conditions. This effect of ORMDL1 and ORMDL3 
was even reinforced during ER stress induced by tunicamycin or thapsigargin treatment 
for 24 h. Interestingly, the ATF4 promoter activity was slightly more increased in HEK-293 
cells transfected with ORMDL3 compared to ORMDL1 overexpressing cells. Due to that 
finding, ORMDL3 overexpressing HEK-293 cells were chosen to investigate the PERK 
pathway on protein levels. Similar to the increased ATF4 promoter activities in these cells, 
the upstream regulator of ATF4 p-eIF2α was also affected. ORMDL3 overexpressing 
HEK-293 cells disclosed faster phosphorylation of eIF2α, especially after 1 and 3 h of 
tunicamycin treatment (Fig. 3.14B). After 6 h of treatment, ORMDL3 overexpressing cells 
elucidated lower amounts of p-eIF2α compared to EGFP overexpressing cells. 
Additionally, the pro-apoptotic factor CHOP, which is a downstream target of ATF4, was 
stronger upregulated in ORMDL3 overexpressing HEK-293 cells after 6 h of tunicamycin 
administration. After 24 h of tunicamycin treatment, protein levels of CHOP and p-eIF2α 
were reduced in ORMDL3 overexpressing HEK-293 cells, indicating a faster ER stress 
response followed by a more quickly removal of increased ER stress mediators during the 
recovery phases.  
The opposite approach using siRNA against ORMDL3 or against all ORMDL homologues 
disclosed confirming data. The ATF4 promoter activity was decreased in HEK-293 cells 
transfected with siRNA against all ORMDL homologues (Fig. 3.14C). This effect was 
reinforced after 24 h of tunicamycin- and thapsigargin-induced ER stress. Investigations of 
the protein levels confirmed the data obtained from the promoter mediated luciferase 
reporter assay (Fig. 3.14D).  Knockdown of all ORMDL homologues led to reduced CHOP 
protein levels after 6 h of tunicamycin treatment. Taken together, these results suggest 
that ORMDL proteins accelerate activation of the PERK pathway. This in turn might 





Fig. 3.14: ORMDL proteins modulate the PERK pathway. 
The effect of ORMDL1 (pCMV-HA-hORMDL1) or ORMDL3 (pCMV-HA-hORMDL3) overexpression (A) as well 
as siRNA-based ORMDL knockdown (C) on the ATF4 promoter activity was quantified by promoter-mediated 
luciferase reporter assay. HEK-293 cells were additionally co-transfected with a firefly luciferase reporter 
pGL3B-ATF4 and Renilla luciferase for normalization. 24 h after transfection, cells were left untreated or 
treated with either 20 µg/ml tunicamycin (TM) or 2 µM thapsigargin (TG) for additional 24 h and assayed using 
a luminometer. Assays were performed in quintuples. Error bars represent means ± SEM. Statistical analyses 
was performed by two-way ANOVA followed by Student’s t-test for unpaired samples. Protein levels were 
analyzed by immunoblotting of HEK-293 cells transfected with either an EGFP or ORMDL3 containing plasmid 
(B) or with siRNA against all three ORMDL homologues. Cells were left untreated or treated with 20 µg/ml 
tunicamycin (TM) for indicated durations. Cell lysates were resolved on a SDS-PAGE and probed by 
immunoblotting with antibodies against CHOP, p-eIF2α, ORMDL1/2/3 or β-Actin, used as a loading control.  
 
Due to the distinct impact of ORMDL proteins on ATF6α and its signaling pathway, an 
ORMDL3-dependent cross-talk effect of ATF6α on the PERK pathway was investigated 
(Fig. 3.15). HEK-293 cells treated with siRNA against ATF6α revealed no induction of the 
ATF6α target GRP78, indicating a sufficient down-regulation of this UPR branch. 
Interestingly, phosphorylation of eIF2α was more pronounced in EGFP and ORMDL3 
overexpressing cells treated with siRNA against ATF6α. However, in these cells CHOP 
protein levels were reduced, indicating a distinct cross-talk effect of ATF6α on CHOP. 
Also the impact of ORMDL3 on CHOP protein levels in cells treated with control siRNA 



















































































































































































Fig. 3.15: ORMDL3 promotes ATF6α-
dependent CHOP induction. 
HEK-293 cells were treated with control siRNA 
(scr. siRNA) or ATF6α-specific siRNA. After 
24 h, cells were transfected with a FLAG-
ATF6α and an ORMDL3 or an EGFP 
expression plasmid. Cells were left untreated 
or treated with 5 µg/ml tunicamycin (TM) for 
indicated durations. Cell lysates were resolved 
on a SDS-Page and analyzed by 
immunoblotting using antibodies against 
GRP78, p-eIF2α, CHOP, ORMDL1/2/3 or 


































































3.4 Characterization of Ormdl3-/- mice 
Due to the association of ORMDL3 with a variety of diseases, further investigation 
focused on the impact of ORMDL3 on the entire organism. Already the in vitro studies 
mentioned above revealed ORMDL3 as a regulator of the UPR pathways. However, the 
validity of in vitro studies is limited due to a great simplification of the system by using 
immortalized cell lines in an artificial environment. For that reason, Ormdl3-deficient 
(Ormdl3-/-) mice were generated to identify the role of ORMDL3 in a complex organism at 
baseline conditions as well as during challenging conditions such as DSS-induced colitis 
and tunicamycin treatment. Due to the association of ORMDL3 with IBD, DSS-induced 
colitis experiments were performed to elucidate the role and the mechanism of ORMDL3 
in the development of these diseases. Additionally, systemic administration of tunicamycin 
to Ormdl3-/- mice was used in order to gain insights into the effect of ORMDL3 on the ER 
stress homeostasis in vivo. 
3.4.1 Basal phenotype of Ormdl3-/- mice 
3.4.1.1 Analyses of ORMDL homologues in Ormdl3-/- mice 
Ormdl3 deficiency in mice was identified by genotyping (as described in chapter 2.4.6) 
and validated by mRNA expression analyses of liver and colon tissues (Fig. 3.16). In the 
investigated tissues of Ormdl3-/- mice no Ormdl3 transcripts were observed confirming the 
deletion of Ormdl3 in the whole organism. 
Due to the high amino acids homology of the three ORMDL proteins, the question arises, 
if the loss of ORMDL3 can be compensated by upregulation of the two other ORMDL 
proteins. To address this question, mRNA expression patterns of all three murine Ormdl 
genes in liver and colon tissues of Ormdl3-/- mice were analyzed by semi-quantitative 
endpoint PCR (Fig. 3.16A). The mRNA expression levels of Ormdl1 and Ormdl2 in the 
observed tissues of Ormdl3-/- mice revealed no obvious alterations compared to the 
mRNA expression levels in wild-type (Ormdl3+/+) mice. 
Additionally, protein levels of all three ORMDL homologues in liver and colon tissues were 
investigated by immunoblotting with a pan-specific ORMDL1/2/3 antibody (Fig. 3.16B). 
Similar to the investigated transcript levels, ORMDL protein levels were markedly reduced 
but not compensated by upregulation of ORMDL1 or ORMDL2 in the observed tissues of 






Fig. 3.16: mRNA expression and protein levels of ORMDL homologues in Ormdl3-/- mice. 
(A) Expression pattern of Ormdl1, Ormdl2 and Ormdl3 mRNA in liver (left) and colon (right) tissues from three 
Ormdl3+/+ and Ormdl3-/- littermate pairs were assessed by endpoint PCR. Water was used as control. Gapdh 
mRNA expression served as an internal control for the applied cDNA amount. (B) Total cell lysates of liver 
(left) and colon (right) tissues from two Ormdl3+/+ and Ormdl3-/- littermate pairs were resolved on a SDS-PAGE 
and analyzed by immunoblotting using antibodies against ORMDL1/2/3 or β-Actin as a loading control. 
 
 
3.4.1.2 Ormdl3 deficiency results in reduced body weight 
Homozygous Ormdl3-/- mice were viable, fertile and were born from heterozygous 
breeding pairs at the expected Mendelian ratio (22.7 %; n = 455 pups), indicating no 
embryonic lethality of this genotype. The overall behavior and coat were inconspicuous. 
However, the most obvious phenotype of these mice was their significantly reduced body 
weight (Fig. 3.17A). Analyses of body weights revealed that Ormdl3-/- mice were 
approximately 10 % lighter in weight than their wild-type littermates at an age of 10 weeks 



























































Fig. 3.17: Ormdl3-/- mice exhibit reduced body weight. 
(A) Representative example of a male Ormdl3+/+ (left) and Ormdl3-/- (right) littermate pair at 10 weeks of age. 
(B) Body weights of 10 weeks old mice based on 4 female Ormdl3+/+ and 4 female Ormdl3-/- mice (left) as well 
as 22 male Ormdl3+/+ and 24 male Ormdl3-/- mice (right). Two-tailed paired Student’s t-test was performed for 
statistical analysis. Data represents means ± SEM. 
 
Reduced body weights of Ormdl3-/- mice were investigated by analyzing the concentration 
of a major postnatal growth regulator, the growth hormone (GH). In the serum of Ormdl3-/-
mice levels of GH tend to be lower than in the serum of their wild-type littermates (Fig. 
3.18). The investigated trend was observed in female as well as in male mice at the age of 
4 weeks. Additionally, also 10 weeks old male Ormdl3-/- mice showed the same trend in 
the serum level of GH compared to their wild-type littermates. 
 
Fig. 3.18: Level of growth hormone in the 
serum of 4 and 10 weeks old wild-type 
and Ormdl3-/- mice. 
Levels of growth hormone in the serum of 4 
and 10 weeks old mice were determined by 
ELISA. Cohorts consisted of four to five mice 
per group. Two-tailed paired Student’s t-test 
was performed for statistical analysis. Data 




Another key component of the growth control pathway, the insulin-like growth factor 1 
(IGF1), is known to be reduced in the serum accompanied by diminished GH levels (185). 
In agreement with the tendency of reduced GH, also IGF1 was slightly reduced in the 
serum of Ormdl3-/- mice, which was most prominent in 4 weeks old female mice (Fig. 
3.19A). Due to the fact, that IGF1 is mainly produced in the liver in response to GH 
stimulation, liver IGF1 levels were investigated. In liver tissues of female and male 

















































Fig. 3.19: Effect of Ormdl3 deletion on serum IGF1 levels and liver Igf1 mRNA expression. 
(A) Serum insulin-like growth factor 1 (IGF1) concentrations of 4 and 10 weeks old mice were determined by 
ELISA. (B) The liver mRNA levels of Igf1 were quantified by qPCR and normalized against Gapdh mRNA 
expression. The cohorts consisted of four to five mice per group. Two-tailed paired Student’s t-test was 
performed for statistical analysis. Data represents means ± SEM. 
 
3.4.1.3 Histology of the lung, ileum and colon of Ormdl3-/- mice 
For further investigation, lung, ileum and colon tissues (Fig. 3.20A and Fig. 3.21A,B) were 
chosen due to the association of ORMDL3 with asthma (149), CD (137) and UC (138), 
respectively. Additionally, histological analyses were performed from liver tissues of 
Ormdl3-/- and wild-type mice (Fig. 3.20B), because the liver as vital organ for protein 
synthesis and detoxification is especially susceptible to ER stress (186). 
For this histological analysis, tissues of untreated 10 weeks old male mice were stained 
with hematoxylin and eosin. No obvious differences in histological appearance of all 
observed tissues were found between Ormdl3-/- mice and their wild-type littermates. In 
detail, lung tissues were composed of alveoli with similar structures in both genotypes 
(Fig. 3.20A). Similar structures were also obtained from liver tissues of Ormdl3-/- and wild-
type mice (Fig. 3.20B).  









































Fig. 3.20: Hematoxylin and eosin staining of lung and liver tissues from wild-type and Ormdl3-/- mice. 
Paraffin-embedded sections (3.5 µm) of formalin-fixed lung (A) and liver (B) tissues were stained with 
hematoxylin and eosin and visualized at 200x magnification. Scale bars represent 100 µm.  
Ileum tissues of Ormdl3-/- and wild-type mice showed comparable structures (Fig. 3.21A). 
Additionally, the thickness of the submucosa and the muscularis externa were not affected 
by the deletion of Ormdl3. Also colon tissues revealed unaltered crypt architectures in 
Ormdl3-/- mice (Fig. 3.21B). The investigated intestinal tissues were composed of similar 
numbers and appearances of Paneth cells and goblet cells in both genotypes. The 
appearance of the muscularis mucosae and the submucosa of colon tissues showed no 
genotype-mediated abnormalities. 
 
Fig. 3.21: Hematoxylin and eosin staining of ileum and colon tissues from wild-type and Ormdl3-/- 
mice. 
Paraffin-embedded sections (3.5 µm) of formalin-fixed ileum (A) and colon (B) tissues were stained with 




As a proxy for cell composition of the small intestine and the colon from Ormdl3-/- mice, 
mRNA expression analyses of indicator transcripts were examined (Fig. 3.22A-B). The 
mRNA expression levels of well established cell type markers such as villin (Vil), mucin 2 
(Muc2), leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) and 
lysozyme 1 (Lyz1) were analyzed by qPCR to measure the content of epithelial cells, 
goblet cells, intestinal stem cells and Paneth cells, respectively. Deletion of Ormdl3 did not 
alter mRNA expression levels of all mentioned genes, indicating that the cell composition 
in the small intestine as well as in the colon seems to be unaffected.  
 
Fig. 3.22: Ormdl3 deficiency does not affect marker transcripts in ileum and colon tissues. 
Total RNA was isolated from small intestine (A) and colon (B) of 10 weeks old Ormdl3-/- mice and their wild-
type littermates. The mRNA levels of Villin (Vil), Mucin 2 (Muc2), Leucine-rich repeat-containing G-protein 
coupled receptor 5 (Lgr5) and Lysozyme 1 (Lyz1) were quantified by qPCR and normalized against Gapdh 
mRNA expression. The qPCRs were performed using TaqMan probes. Cohorts consisted of six male mice per 
genotype. Data represents means ± SEM. 
 
3.4.1.4 Cytokine concentrations in Ormdl3-/- mice 
Due to the fact that cytokines play a vital role in the development of chronic diseases, 
such as asthma or IBD (187), cytokine levels were determined in the serum of Ormdl3-/- 
mice. The investigated cytokine concentrations of IL-1β, IL-10 and IL-12 p40 in the serum 
of Ormdl3-/- mice were comparable to those of their wild-type littermates (Fig. 3.23). 
Additionally, other determined cytokines such as IL-1α, IL-2, IL-6 and IL-13 were also not 
altered in the observed mice (data not shown). However, TNFα, IFNγ and IL-12 p70 
concentrations in the serum of Ormdl3-/- mice tend to be lower than in the serum of 
Ormdl3+/+ mice.  















































Fig. 3.23: Representative examples of serum cytokines of Ormdl3-/- and wild-type mice. 
Serum cytokine concentrations of 10 weeks old Ormdl3-/- mice and their wild-type littermates were determined 
by Bio-Plex ProTM Mouse Cytokine 23-plex immunoassay. The cohorts consisted of three male mice per 
genotype. Data represents means ± SEM. 
 
IFNγ levels were further explored, because IFNγ was described to induce proteolytic 
processing of ATF6α (189) and ORMDL3 was shown in the present study to modulate 
ATF6α cleavage. In addition, IFNγ is essential for regulation of the intestinal epithelial 
homeostasis (190). The tendency of reduced IFNγ concentration in the serum of Ormdl3-
deficient mice was additionally investigated by qPCR of liver, colon and spleen tissues. 
Interestingly, the mRNA levels of Ifnγ were significantly reduced in proximal colon tissues 
and slightly diminished in liver tissues of Ormdl3-/- mice (Fig. 3.24A-B). In spleen tissues 
no genotype-dependent Ifnγ alterations were observed (Fig. 3.24C). This indicates a 
tissue-specific Ifnγ mRNA expression in Ormdl3-/- mice with even significantly altered 
expression levels in the colon. 











































































































Fig. 3.24: Tissue-specific effect of Ormdl3 on Ifnγ mRNA levels. 
Total RNA was isolated from proximal colon (A), liver (B) and spleen (C) of 10 weeks old Ormdl3-/- mice and 
their wild-type littermates. The mRNA levels of Ifnγ were quantified by qPCR and normalized against Gapdh 
mRNA expression. The cohorts consisted of five male mice per genotype. Two-tailed unpaired Student’s t-test 
was performed for statistical analysis. Data represents means ± SEM. 
 
The effect of Ormdl3 deficiency on Ifnγ mRNA expression levels was further investigated 
in colon tissues. Lamina propria fractions were isolated from colon tissues using the 
lamina propria dissociation kit. Isolated cells were stained and measured using the 
FACScalibur to analyze IFNγ-specific cell surface targets such as MHC (major 
histocompatibility complex) class I (MHCI) and MHC class II (MHCII) molecules on 
CD11b+ cells (Fig. 3.25).   
Cell debris with low granularity (side scatter, SSC) and size (forward scatter, FSC) were 
excluded from further evaluation (Fig. 3.25A+C). To this end, only cells from the gated 
region 1 (R1) were investigated for cell-surface expression of CD11b and MHCI or MHCII. 
CD11b/MHCI double-positive cells were gated (R3) and examined for two mice per 
genotype. The percentage of CD11b/MHCI double-positive cells isolated from the lamina 
propria of Ormdl3-/- mice was lower compared to their wild-type littermates (Fig. 3.25B). A 
similar tendency was observed for the percentage of CD11b/MHCII double-positive cells 
(Fig. 3.25D). Thereby, the amount of CD11b+ cells was comparable between Ormdl3-/- and 
wild-type mice. These findings suggest Ormdl3-dependent alterations in IFNγ levels 
influencing MHCI and MHCII cell-surface expression on CD11b+ myeloid cells of the 

































































Fig. 3.25: Ormdl3-/- mice express less MHCI and MHCII on CD11b+ lamina propria cells. 
Lamina propria fractions were isolated from colon tissues of 10 weeks old Ormdl3-/- mice and their wild-type 
littermates. Cells were stained using specific antibodies for CD11b and MHCI (A+B) or MHCII (C+D). 
Representative SSC/FSC scatter dot plots and FACS profiles of CD11b and MHCI (A) or MHCII (C) cell-
surface expression pattern are given. The percentage of MHCI CD11b double positive cells (B) and 
CD11b/MHCII double positive cells (C) were determined in R3 and R2, respectively. Data show the 
mean ± SEM from two animals per group.  
 
3.4.2 Ormdl3-/- mice are more susceptible to acute DSS-induced colitis 
ORMDL3 had been identified by GWAS as a susceptibility loci for CD (137) and UC (138). 
However, under baseline conditions Ormdl3-/- mice do not show any signs of inflammation 
(Fig. 3.20 and Fig. 3.23). To investigate the role of ORMDL3 during intestinal 
inflammation, mice were challenged with 2.5 % DSS in their drinking water to induce an 
acute colitis. The severity of DSS-induced colitis was monitored daily by measuring body 
weight (Fig. 3.26A). Already on day one Ormdl3-/- mice lost weight but recovered again 
until day four, whereas wild-type littermates maintained their body weights until day four. 
After day four, body weights decreased faster in Ormdl3-deficient mice than compared to 
their wild-type littermates. Additionally, the course of the disease was monitored and 























































































scored using the disease activity index (DAI), a combined score of stool blood, stool 
consistency and body weight loss. On day one and six of DSS treatment, the course of 
the disease was significantly worse in Ormdl3-/- mice than in their wild-type littermates. In 
summary, the progression of the DAI showed a similar trend as the body weight loss.  
 
Fig. 3.26: Ormdl3 deficiency increases susceptibility to DSS-induced colitis. 
2.5 % DSS was administered in drinking water for six days and thereafter replaced by regular drinking water. 
(A) Body weight changes of treated littermates (n=4 for Ormdl3+/+; n=3 for Ormdl3-/-) are shown in percent of 
initial weights. (B) Clinical severity was assessed daily using the disease activity score (DAI). Two-tailed 
unpaired Student’s t-test was performed for statistical analysis. Data represents means ± SEM. 
 
Another indication for the severity of a DSS-induced colitis is the degree of colon 
shortening (191). DSS administration induced colon shortening in all treated mice, 
however, colon length of untreated and DSS-treated Ormdl3-/- mice were comparable to 
their wild-type littermates (Fig. 3.27A). In addition, reduced liver weight has been reported 
to correlate with the degree of colitis in DSS-treated hamsters (192). Ormdl3-/- mice 
showed significantly less liver weight than Ormdl3+/+ mice after DSS treatment, although 
the liver weight were comparable in untreated mice (Fig. 3.27A), indicating a more severe 
course of the disease in Ormdl3 deficient mice. 
 
Fig. 3.27: DSS-induced colitis affects colon length and liver weight of Ormdl3-/- and wild-type mice. 
Colon length (A) and the liver weight (B) of untreated (n=7-8) and DSS-treated littermates (n=4 for Ormdl3+/+; 
n=3 for Ormdl3-/-) were determined. Two-tailed unpaired Student’s t-test was performed for statistical analysis. 
Data represents means ± SEM. 














































































Distal colon tissues, which are most affected during DSS administration (191), were 
investigated by histological analysis of hematoxylin and eosin stained tissues. Colon 
tissues of both genotypes revealed strong effects of DSS administration. However, 
histological score analysis, which combines values for crypt damage, severity of 
inflammation and ulceration, showed slightly higher DSS injury scores for Ormdl3-/- mice 
than for wild-type mice (Fig. 3.28A). A higher score represented a more severe DSS-
induced colitis. Comparison of histological sections of an exemplary littermate pair 
showed more intense infiltrations of immune cells, crypt damage, crypt abscesses and 
crypt loss in Ormdl3-/- mice (Fig. 3.28B).  
 
Fig. 3.28: Histological scores and HE stainings of Ormdl3-/- and wild-type mice after DSS treatment. 
Paraffin-embedded sections (3.5 µm) of fixed colon tissues were stained with hematoxylin and eosin and 
visualized at 100x and 200x magnification. (A) The histological score, a combined score of crypt damage, 
severity of inflammation and ulceration, was evaluated in a blinded manner. Data represents means ± SEM. 
(B) Distal colon tissues from the distal part of a littermate pair are exemplary shown. The scale bars represent 
200 µm and 100 µm in the 100x and 200x magnifications, respectively. 
 
It has been shown, that the level of the pro-inflammatory cytokine IL-1β correlate with the 
severity of intestinal inflammation (193). Interestingly, DSS-treated Ormdl3-/- mice 
revealed significantly elevated IL-1β serum levels compared to wild-type mice (Fig. 
3.29A). Additionally, secretion of the pro-inflammatory cytokines IL-6 and TNFα was also 
slightly higher in the serum of Ormdl3-/- mice than in wild-type mice (Fig. 3.29B, C). 
However, serum concentration of the pro-inflammatory cytokine chemokine (C-X-C motif) 
ligand 1 (CXCL1) was not altered between the investigated genotypes (Fig. 3.29D). As for 
untreated Ormdl3-/- mice (Fig. 3.23), serum levels of the pro-inflammatory cytokine IFNγ 




















Secretion of the anti-inflammatory cytokine IL-10 showed an increased tendency in 
DSS-treated Ormdl3-/- mice compared to the wild-type mice (Fig. 3.29F). 
 
Fig. 3.29: DSS-induced cytokine secretion in Ormdl3-/- and wild-type mice.  
Ormdl3-/- and wild-type mice were treated for six days with 2.5% DSS in drinking water and an additional day 
with normal drinking water. Serum cytokine concentrations were determined by Bio-Plex ProTM Mouse 
Cytokine immunoassay (Bio-Rad). Cohorts consisted of 4 Ormdl3+/+ mice and 3 Ormdl3-/- mice. Two-tailed 
unpaired Student’s t-test was performed for statistical analysis. Data represents means ± SEM. 
 
 
Due to the fact, that ORMDL proteins are involved in the cellular UPR (135) and 
unresolved ER stress induces intestinal inflammation (51), mRNA expression pattern of 
components of the UPR were investigated by qPCR (Fig. 3.30). After DSS treatment, 
mRNA expression levels of Atf6α, Grp94, Atf4 and Chop in Ormdl3-/- mice were similar to 
those in wild-type mice. Although mRNA expression levels of Atf4 and Chop were 
comparable in both genotypes, mRNA levels of its target gene Gadd34 tend to be higher 
expressed in Ormdl3-deficient mice after DSS administration. In addition, spliced Xbp1 
was less expressed in colon tissues of Ormdl3-/- mice. 
Furthermore, mRNA expression levels of UPR mediators were also analyzed in liver and 






































































































Fig. 3.30: DSS-induced colonic mRNA 
expression of genes involved in the UPR 
in Ormdl3-/- and wild-type mice. 
Ormdl3-/- and wild-type mice were treated 
for six days with 2.5% DSS in drinking 
water and an additional day with normal 
drinking water. The mRNA expression in 
colon tissues were investigated by qPCR 
and normalized against Gapdh. Cohorts 
consisted of 4 Ormdl3+/+ mice and 3 
Ormdl3-/- mice. Two-tailed unpaired 
Student’s t-test was performed for statistical 
analysis. Data represents means ± SEM. 
 
At the end of the acute colitis experiment, both genotypes were affected by DSS, which 
might be the reason for molecular markers of the UPR not being significantly altered 
between the genotypes (Fig. 3.30). To further assess the UPR during the development of 
colitis, protein levels of colon tissues were investigated after short-term DSS-treatments 
ranging from two to four days. Immunoblotting analysis revealed prolonged 
phosphorylation of eIF2α (p-eIF2α) in colon tissues of DSS-treated Ormdl3-/- mice, 
although basal level of p-eIF2α was lower in these mice compared to its littermates (Fig. 
3.31A). However, the downstream target of p-eIF2α, ATF4, was not significantly altered 
between both genotypes. In liver tissues, which are affected by DSS already after one day 
of treatment (194), p-eIF2α was also prolonged upregulated in Ormdl3-/- mice after DSS 
treatment (Fig. 3.31B). This observation was supported by elevated levels of CHOP, a 
downstream target of p-eIF2α. Additionally, levels of ORDML proteins increased during 
the DSS treatment in the investigated tissues of Ormdl3-/- mice, indicating a protective role 
during colitis. 
 
Fig. 3.31: Short-term DSS treatment induces prolonged upregulation of p-eIF2α in Ormdl3-/- mice. 
Mice were left untreated or treated with 2.5 % DSS in drinking water for indicated durations. Total cell lysates 
of colon (A) and liver (B) tissues from Ormdl3+/+ and Ormdl3-/- littermate pairs were resolved on a SDS-PAGE 








































+ -/--/- -/- -/-Ormdl3 Ormdl3
























3.4.3 Tunicamycin injection induces prolonged UPR in Ormdl3-/- mice 
Several investigations pointed to an influence of ORMDL3 on ER stress pathways and 
brought the liver into focus. First, the earlier described in vitro results in HEK-293 cells led 
to the conclusion that ORMDL3 is involved in mechanisms which protect cells against 
ongoing stress. Second, challenging Ormdl3-/- mice with 2.5 % DSS for short durations 
revealed prolonged upregulation of p-eIF2α, indicating unresolved ER stress (Fig. 3.31). 
Third, a systemic ER stress effect of DSS-treated animals in the liver became prominent 
(Fig. 3.31). For these reasons and to investigate whether deficiency in Ormdl3 influences 
the susceptibility to chemically induced ER stress, Ormdl3-/- mice were challenged with a 
sublethal dose of tunicamycin (1 mg/g body weight). During the first five days, all mice lost 
weight continuously (Fig. 3.32). After day five, mice gained weight again, however Ormdl3-
/- mice recovered slightly slower than their wild-type littermates. All treated mice survived 
the tunicamycin challenge. 
 
Fig. 3.32: Effect of tunicamycin injection on body 
weight of Ormdl3-/- mice. 
Ormdl3-/- and Ormdl3+/+ mice were injected 
intraperitoneally with tunicamycin (TM; 1 mg/kg body 
weight) or vehicle. Body weight was determined daily 
and is represented after normalization to their initial 
body weights on day 0. The cohorts consisted of 
seven male mice per genotype. Two-tailed unpaired 
Student’s t-test was performed for statistical analysis. 




Intraperitoneally injection of tunicamycin primary affects liver and kidney (195). To gain a 
more detailed insight into tunicamycin-mediated molecular alterations, groups of mice 
were sacrificed after 8, 24, 48 h or 7 d of treatment. Dissections after 48 h of treatment 
disclosed obvious lighter liver colors in Ormdl3-/- mice compared to their wild-type 
littermates (Fig. 3.32A). To address the reason for the pale liver color, lipid accumulations 
were investigated using the cytosolic lipid protein marker adipose differentiation related 
protein (ADRP) (196). Immunoblotting analysis revealed a postponed kinetic of ADRP 
protein expression in Ormdl3-/- mice (Fig. 3.33B). In detail, protein levels of ADRP were 
increased in wild-type mice already after 8 h, whereas Ormdl3-/- mice showed no 
alterations of ADRP protein levels at that time point. After 24 h of tunicamycin 
administration, both genotypes expressed ADRP in approximately same amounts. 
However, after 48 h of tunicamycin treatment, ADRP protein levels decreased again in 
wild-type mice, whereas Ormdl3-/- mice still exhibited high ADRP protein levels. To 
validate this finding, liver protein lysates of all littermate pairs treated with tunicamycin for 























48 h were investigated by immunoblotting (Fig. 3.33C). Assessment of these liver tissues 
showed increased ADRP protein levels in three out of four Ormdl3-/- mice.  
Additionally, UPR signaling in tunicamycin-treated mice was investigated by monitoring 
ER stress mediators and chaperones. The ATF4 pathway was examined by 
immmunoblotting using antibodies to p-eIF2α and its target CHOP (Fig. 3.33B). In line 
with the ADRP protein expression pattern, the kinetic of eIF2α phosphorylation was 
postponed in Ormdl3-/- mice. These mice showed lower levels of p-eIF2α after 24 h of 
tunicamycin treatment compared to wild-type mice. However, after 48 h until the end of 
the experiment Ormdl3-/- mice exhibited prolonged eIF2α phosphorylation, whereas in 
wild-type mice p-eIF2α reached the baseline level. Interestingly, deletion of Ormdl3 
resulted in an increased protein expression of the pro-apoptotic factor CHOP after 8 and 
24 h of tunicamycin administration. 
ATF6α FL was also affected by intraperitoneally injection of tunicamycin. After 24 h of 
tunicamycin treatment, only wild-type mice showed reduced protein levels of ATF6α FL, 
indicating ER stress-induced ATF6α FL cleavage. At the same time point, Ormdl3-/- mice 
exhibited ATF6α FL protein levels comparable to those of untreated mice. Similar to the in 
vitro results (Fig. 3.8C), a protein band with a slightly lower kDa size of ATF6α appeared 
in wild-type mice after 24 h of tunicamycin treatment. This slightly lower protein band 
indicates the potentially unglycosylated form of ATF6α FL. Similar observations were 
made for the translocon-associated protein subunit alpha (TRAPα). TRAPα was initially 
investigated to confirm the efficacy of tunicamycin injection, which results in inhibition of 
glycosylation. Similar to ATF6α-/- mice (94), the protein levels of unglycosylated TRAPα 
(TRAPαUG) were lesser in Ormdl3-/- mice early after tunicamycin injection (24 h) but were 
augmented at later time points (48 h). After 7 days of treatment, liver tissues of Ormdl3-/- 
mice still showed a weak protein band of TRAPαUG, whereas wild-type mice revealed only 
the full length form of TRAPα and a not described protein band. The ATF6α targets, 
GRP78 and GRP94, were induced in all tunicamycin-treated mice over time. Alterations in 
GRP78 and GRP94 protein levels were observed only after 24 h of tunicamycin 
administration, where Ormdl3-/- mice showed a delayed onset of protein expression. 
However, expression of GRP78 and GRP94 proteins are not only induced by ATF6α but 
also by the spliced form of XBP1 (86). Therefore, Xbp1 mRNA splicing was monitored 
over time using semi-quantitative endpoint PCRs. In the early phase after only 8 h of 
treatment, both genotypes responded to tunicamycin by Xbp1 splicing (Fig. 3.33D). After 
this time point, wild-type mice restored the unspliced form of Xbp1, whereas Ormdl3-/- 
mice revealed persistent splicing of Xbp1 until the end of the experiment. In accordance 
with a potential protective role of ORMDL proteins, their protein levels were upregulated in 






Fig. 3.33:  ORMDL3 regulates ER stress-dependent chaperone expression in the liver upon 
tunicamycin injection. 
Ormdl3-/- and Ormdl3+/+ littermate mice were intraperitoneally injected with tunicamycin (1 mg/kg body weight) 
and sacrificed after 8, 24, 48 h or 7 d. (A) Livers of treated mice were dissected and photographed after 48 h. 
(B+C) Protein lysates from liver tissues were probed by immunoblot as indicated. (D) RNA was isolated from 
the same samples and analyzed for unspliced Xbp1 (Xbp1) and spliced Xbp1 (sXbp1) mRNA by semi-
quantitative endpoint PCR. Gapdh mRNA expression served as an internal control for the applied cDNA 
amount. 
 
Besides liver tissues, also kidney tissues were affected after intraperitoneal injections of 
tunicamycin. ADRP protein levels were prolonged upregulated in both organs of Ormdl3-/- 
mice after 48 h of tunicamycin treatment (Fig. 3.34A). Additionally, as already seen in liver 
tissues, the pro-apoptotic factor CHOP was prolonged upregulated in kidney tissues of 
Ormdl3-/- mice compared to their wild-type littermates. As expected from the literature, the 
high protein level of CHOP in kidney tissues was postponed for 24 h compared to liver 
tissues, indicating that kidneys were secondary affected organs by tunicamycin injection. 
Protein levels of the ER stress marker GRP78 increased during the experiment, but there 
were no significant alterations between the observed genotypes. Also mRNA splicing of 
Xbp1 did not show significant alterations between Ormdl3-/- and their wild-type littermates 
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Fig. 3.34: Ormdl3 deficiency prolongs upregulation of ADRP and CHOP in kidney tissues. 
Ormdl3-/- and Ormdl3+/+ littermate mice were intraperitoneally injected with tunicamycin (1 mg/kg body weight) 
and sacrificed after 8, 24, 48 h or 7 d. (A) Protein lysates of kidney tissues were probed by immunoblot as 
indicated. (B) RNA was isolated from the same samples and analyzed for unspliced Xbp1 (Xbp1) and spliced 
Xbp1 (sXbp1) mRNA by endpoint PCR. Gapdh mRNA expression served as an internal control for the applied 
cDNA amount. 
 
To investigate the pale liver (Fig. 3.33A) and prolonged upregulation of ADRP (Fig. 3.33B) 
in Ormdl3-/- mice in more detail, lipid contents in serum and liver of tunicamycin-treated 
mice were investigated. Upon tunicamycin injection mice exhibited increased hepatic 
triglycerides and decreased plasma lipids, including plasma triglycerides, cholesterol and 
high-density lipoprotein (HDL) cholesterol (197). Liver concentrations of triglycerides 
increased during the tunicamycin treatment as expected, however without any significant 
differences between the observed genotypes (Fig. 3.35A). Also concentrations of serum 
triglycerides showed no markedly differences between Ormdl3-/- and wild-type mice in 
response to tunicamycin administration (Fig. 3.35B). Interestingly, after 8 h of tunicamycin 
treatment, serum cholesterol concentrations decreased slightly faster in Ormdl3-/- mice 
than in wild-type mice (Fig. 3.35C). This tendency might be a result of the significantly 
decreased serum HDL cholesterol concentrations in Ormdl3-/- mice after 8 h of 
tunicamycin administration (Fig. 3.35D), as ER stress in metabolic disorders has been 
identified to reduce HDL biogenesis (198). These findings demonstrate that Ormdl3-/- mice 
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Fig. 3.35: Tunicamycin administration affects lipid contents in Ormdl3-/- and wild-type mice.  
Ormdl3-/- and Ormdl3+/+ littermate mice were intraperitoneally injected with tunicamycin (TM; 1 mg/kg body 
weight) and sacrificed after 8, 24, 48 h or 7 d. Concentrations of hepatic triglycerides (A) and serum lipids, 
including plasma triglycerides (B), cholesterol (C) and high-density lipoprotein (HDL) cholesterol (D) were 
determined. Two-tailed unpaired Student’s t-test was performed for statistical analysis. Data represents 


























































































3.5 Characterization of Ormdl3ΔIEC mice 
Due to the association of ORMDL3 as a potential risk variant for IBD, further investigation 
focused on the effect of Ormdl3 deficiency particularly in intestinal epithelia cells (IEC). 
For this reason, mice with an IEC-specific deficiency of Ormdl3 (Ormdl3ΔIEC mice) were 
investigated. 
3.5.1 Basal phenotype of Ormdl3ΔIEC mice 
Ormdl3ΔIEC mice were generated by applying the Cre-mediated homologous 
recombination technology as described in chapter 2.4.4. For the validation of the 
IEC-specific deletion of Ormdl3, mRNA expression levels of the three Ormdl homologues 
were investigated in IECs and lamina propria cells by semi-quantitative endpoint PCR.  As 
expected, Ormdl3 mRNA was not expressed in IECs of small intestinal and colon tissues 
isolated from Ormdl3ΔIEC mice whereas their wild-type (Ormdl3fl/fl) littermates exhibited 
normal mRNA expression levels of Ormdl3 (Fig. 3.36A-B). Similar to Ormdl3-/- mice, 
mRNA expression levels of the other two Ormdl homologues in IECs were comparable 
between the observed genotypes and did not compensate the loss of Ormdl3 by 
upregulation of Ormdl1 or Ormdl2. In addition, mRNA expression of Ormdl3 remained 
unaffected in lamina propria cells of Ormdl3ΔIEC mice. Interestingly, small intestine and 
colon tissue of the wild-type mouse revealed a higher Ormdl3 mRNA expression level in 
lamina propria cells than in IECs. 
 
Fig. 3.36: mRNA expression levels of Ormdl homologues in Ormdl3ΔIEC and wild-type mice. 
Intestinal epithelial and lamina propria cells were isolated from small intestine (A) and colon (B) tissues of one 
Ormdl3fl/fl mouse and two Ormdl3ΔIEC littermate mice. Total mRNA was isolated and expression patterns of 
Ormdl1, Ormdl2 and Ormdl3 were assessed by semi-quantitative endpoint PCR. Water was used as control. 






































































































Characterization of Ormdl3ΔIEC mice also comprised the breeding behavior and physical 
appearance. These mice showed normal longevity and fertility. No overt behavioral or 
physical abnormalities were observed. Body weights (Ormdl3fl/fl 25.44 ± 0.42 g; Ormdl3ΔIEC 
25.21 ± 0.51 g; n = 15 each) were inconspicuous.  
Histological analysis of kidney and colon tissues was performed for further assessment of 
Ormdl3ΔIEC mice. Kidney tissues were additionally investigated, because beside the mainly 
describes expression of villin 1 in intestinal epithelial cells, villin 1 was also found in cells 
of the renal proximal tubulus (171). Tissues of 10 weeks old male mice were stained with 
hematoxylin and eosin. No obvious differences in histological appearance of all observed 
tissues were found between Ormdl3ΔIEC mice and their wild-type littermates (Fig. 3.37). 
 
Fig. 3.37: HE stainings of kidney and colon tissues of wild-type and Ormdl3ΔIEC mice. 
Paraffin-embedded sections (3.5 µm) of formalin-fixed kidney (A) and colon (C) tissues were stained with 
hematoxylin and eosin and visualized at 200x magnification. Scale bars represent 100 µm.  
 
3.5.2 Ormdl3ΔIEC are less susceptible to chronic DSS-induced colitis 
Ormdl3ΔIEC mice were challenged with three cycles of DSS in their drinking water to 
assess the effect of Ormdl3 deletion in IECs during chronic colitis. In each cycle mice 
were treated with 1.5 % DSS in their drinking water for five days, followed by five days 
consumption of normal drinking water. After the first cycle of DSS treatment, body weight 
of wild-type and Ormdl3ΔIEC mice reduced similarly (Fig. 3.38). However, Ormdl3ΔIEC mice 
gained faster weight than their wild-type littermates during the first regeneration phase. 
This difference in body weight remained during the second cycle of DSS administration. 




Ormdl3ΔIEC mice compared to their wild-type littermates. The faster recovery of Ormdl3ΔIEC 
mice led to a significantly higher body weight during the third cycle of DSS treatment. 
Surprisingly though, the third DSS administration was less effective with just little body 
weight loss for both genotypes. At the end of the experiment, Ormdl3ΔIEC mice showed 
slightly higher body weight than wild-type mice, indicating that Ormdl3ΔIEC mice tend to be 
less susceptible to a DSS-induced chronic colitis.  
 
Fig. 3.38: Body weight assessment of 
Ormdl3ΔIEC mice during chronic 
DSS-induced colitis. 
Chronic colitis was induced by three 
cycles of 1.5 % DSS treatment for five 
days, followed by administration of 
normal drinking water for five days. Body 
weight changes were calculated for each 
mouse as percentage of initial body 
weight on day zero. Cohorts consisted of 
15 male mice per genotype. Two-tailed 
unpaired Student’s t-test was performed 
daily for statistical analysis. Data 
represents means ± SEM. 
 
Colon length and spleen weight were determined to evaluate the disease severity at the 
end of the chronic colitis (Fig. 3.39A). Shortening of the colon, which has been identified 
as an indicator of colitis (199), were observed in a similar manner for both DSS-treated 
genotypes. Additionally, DSS-induced chronic colitis is characterized by increased spleen 
weights (199). This extraintestinal manifestation was equally pronounced in Ormdl3ΔIEC 
mice and wild-type mice (Fig. 3.39B).  
 
Fig. 3.39: Colon length and spleen weight in Ormdl3ΔIEC and wild-type mice during chronic colitis. 
Colon length (A) and spleen weight (B) of untreated (n=5 of each genotype) and DSS-treated mice (n=15 of 
each genotype) were determined. Two-tailed unpaired Student’s t-test was performed for statistical analysis. 





























































DSS-induced colitis affects mostly the distal colon (191). For this reason, a more detailed 
investigation of distal colon tissues was performed by histological analysis using 
hematoxylin and eosin staining. Histological score analysis was performed fully blinded 
based on the severity of inflammation, ulceration and crypt damage (as explained in 
chapter 2.4.11). DSS-treated colon tissues of Ormdl3ΔIEC mice revealed significantly lower 
histological scores than Ormdl3fl/fl mice (Fig. 3.40A), indicating less affected colon tissues 
during DSS-induced colitis. Histological sections of an exemplary littermate pair 
demonstrates a more intense infiltrations of immune cells and crypt disorder in the colon 
of Ormdl3fl/fl mice compared to Ormdl3ΔIEC mice (Fig. 3.40B).  
 
 
Fig. 3.40: Histological scores and HE stainings of Ormdl3ΔIEC and Ormdl3fl/fl mice after DSS treatment. 
Paraffin-embedded sections (3.5 µm) of formalin-fixed colon tissues were stained with hematoxylin and eosin 
and visualized at 100x and 200x magnification. (A) The histological score, a combined score of crypt damage, 
severity of inflammation and ulceration, was evaluated in a blinded manner. Cohorts consisted of 15 male 
mice per genotype. Two-tailed unpaired Student’s t-test was performed for statistical analysis. Data represents 
means ± SEM. (B) Distal colon tissues of a littermate pair are exemplary shown. Scale bars represent 200 µm 
and 100 µm in the 100x and 200x magnifications, respectively. 
 
Due to significant differences in histological analysis between Ormdl3ΔIEC and their 
Ormdl3fl/fl littermates, further investigation was performed. Therefore, serum cytokine 
concentrations were determined by Bio-Plex ProTM Mouse Cyctokine immunoassay. 
Typically, during chronic DSS-induced colitis the disease severity correlates positively with 
increased serum concentrations of IL-1β, IL-6, TNFα, CXCL1, IFNγ and IL-10 (200). IL-6 
tends to be less secreted into the serum of Ormdl3ΔIEC mice compared to their wild-type 
littermates (Fig. 3.41B). All other investigated serum cytokine concentrations were 






Fig. 3.41: DSS-induced cytokine secretion in Ormdl3 ΔIEC and Ormdl3fl/fl mice.  
Cytokine concentrations in the sera of Ormdl3ΔIEC and Ormdl3fl/fl mice were determined by Bio-Plex ProTM 
Mouse Cytokine immunoassay after three cycles of DSS administration, where each cycle composed five 
days consumption of drinking water containing 1.5 % DSS followed by five days consumption of normal 
drinking water. Cohorts consisted of fifteen male mice per genotype. Two-tailed unpaired Student’s t-test was 













































































































3.6 Characterization of Ormdl1-/- mice 
Besides ORMDL3, also ORMDL1 showed significant in vitro effects on the three pathways 
of the UPR. Due to these observed effects and the high homology to Ormdl3, 
Ormdl1-deficient mice were assessed under basal conditions as well as upon induction of 
DSS-induced colitis. 
3.6.1 Basal phenotype of Ormdl1-/- mice 
Deletion of Ormdl1 was validated by genotyping (as described in chapter 2.4.6). Levels of 
mRNA of all three Ormdl homologues were investigated by semi-quantitative endpoint 
PCR. Liver as well as colon samples of Ormd1-/- and their wild-type littermates were 
subjected to mRNA expression analysis. In contrast to Ormdl3-/- mice, Ormdl1-/- mice were 
generated by deleting only exon two on which the start codon is located. For that reason, 
the deletion of the first two and the last two exons were investigated by semi-quantitative 
endpoint PCR. Investigations of exon one and two revealed no transcript levels, 
confirming the deletion of the start codon (Fig. 3.42). However, mRNA of exon three and 
four was still expressed. The deletion of exon two of Ormdl1 was not compensated by an 
upregulation of Ormdl2 or Ormdl3 mRNA expression levels. 
 
Fig. 3.42: mRNA expression levels of Ormdl homologues in Ormdl1-/- mice. 
The mRNA expression patterns of Ormdl1, Ormdl2 and Ormdl3 mRNA in liver (A) and colon (B) tissues from 
two Ormdl1+/+ and Ormdl1-/- littermate pairs were assessed by endpoint PCR. Water was used as control. 
Gapdh mRNA expression served as an internal control for the applied cDNA amount.  
 
Additionally, levels of all three ORMDL proteins in liver and colon tissues were 
investigated by immunoblotting (Fig. 3.43). Ttotal protein levels of ORMDL1, ORMDL2 







































Fig. 3.43: Protein levels of ORMDL1, ORMDL2 and ORMDL3 in Ormdl1-/- and wild-type mice. 
Total cell lysates of liver (A) and colon (B) tissues from two Ormdl1+/+ and Ormdl1-/- littermate pairs were 
resolved on a SDS-PAGE and analyzed by immunoblotting using antibodies against ORMDL1/2/3 or β-Actin 
as a loading control. 
 
Basal phenotyping revealed that Ormdl1 deficiency in mice did not affect lifespan or 
fertility. Physical appearance and body weight of ten weeks old mice (Ormdl1+/+ 
25.92 ± 0.50 g; Ormdl1-/- 26.16 ± 0.23 g; n = 9 each) were inconspicuous. Behavioral 
abnormalities were not detected. 
Due to the high amino acid identity of ORMDL1 and ORMDL3 and the association of 
ORMDL3 with IBD, ileum and colon tissues of Ormdl1-/- mice were examined by 
histological analysis (Fig. 3.44). The probed tissues of Ormdl1-/- and wild-type mice 
showed similar morphological appearances and no genotype-specific differences. 
 
Fig. 3.44: HE staining of ileum and colon tissues of wild-type and Ormdl1-/- mice. 
Paraffin-embedded sections (3.5 µm) of formalin-fixed ileum (A) and colon (B) tissues were stained with 


























3.6.2 Ormdl1 deficiency causes no significant differences in acute DSS-induced 
colitis  
Ormdl1-deficient mice were subjected to an acute DSS-induced colitis to investigate the 
effect of Ormdl1 deficiency during intestinal inflammation. The acute colitis was induced 
by providing mice with drinking water containing 2.5 % DSS. During this phase, no 
significant difference in body weight change occurred between Ormdl1-/- mice and their 
wild-type mice (Fig. 3.45). After five days of DSS administration, the DSS containing water 
was replaced by normal drinking water to facilitate the regeneration phase. During this 
second phase, Ormdl1-/- mice started to recover on day eight, whereas the body weight of 
their wild-type littermates further decreased. However, the observed differences in body 
weight changes were not significant. This experiment had to be terminated on day nine, 
because three wild-type mice reached the critical body weight. 
 
 
Fig. 3.45: Comparable body weight loss in Ormdl1-/- 
and wild-type mice during DSS-induced colitis. 
Acute DSS-colitis in Ormdl1-/- and wild-type littermate 
mice was induced by 2.5 % DSS in drinking water for 
five days, followed by normal drinking water for four 
additional days. Body weights were monitored daily and 
the changes were calculated for each mouse as a 
percentage of initial body weight on day zero. Cohorts 
contained three Ormdl1-/- or four wild-type mice. Two-
tailed unpaired Student’s t-test was performed for 
statistical analysis. Data represents means ± SEM.  
 
 
In order to assess the severity of the acute colitis, typically affected organs such as colon, 
liver and spleen were investigated in more detail. Shortening of colon length is widely 
used as a parameter to reflect DSS-induced colitis in mice, which was observed in 
DSS-treated Ormdl1-/- as well as wild-type mice (Fig. 3.46A). However, wild-type mice 
revealed larger reductions in colon length than Ormdl1-/- mice, indicating less intestinal 
inflammation in the knockout mice. By contrast, oral DSS administration induced a greater 
increase in spleen weight of Ormdl1-/- mice compared to wild-type mice (Fig. 3.46B). This 
phenomenon of enlarged spleens is known to correlate with the progress of inflammation 
(199). Liver weights remained similar in both genotypes treated with DSS (Ormdl1+/+ 
1.008 ± 0.057 g; Ormdl1-/- 1.081 ± 0.120 g). 























Fig. 3.46: Colon length and spleen weight of Ormdl1-/- mice after acute DSS-induced colitis. 
Acute colitis was induced by oral administration of 2.5 % DSS for five days followed by four days of normal 
drinking water. Colon length (A) and the spleen weight (B) of untreated (n=5 of each genotype) and DSS-
treated mice (Ormdl1+/+ n=4; Ormdl1-/- n=3) were determined. Two-tailed unpaired Student’s t-test was 
performed for statistical analysis. Data represents means ± SEM. 
 
Histological analysis of DSS-treated colon tissues of Ormdl1-/- and their wild-type 
littermates revealed similar tissue damages with comparable histological scores (Fig. 
3.47). Colon tissues of both genotypes showed similar manifestations of immune cells 
infiltration, partial epithelial loss and ulceration of crypts. 
 
 
Fig. 3.47: Histological scores and HE stainings of Ormdl1-/- and Ormdl1+/+ mice after DSS treatment. 
Ormdl1-/- and Ormdl1+/+ mice were treated with 2.5 % DSS in drinking water for five days followed by normal 
drinking water for additional four days. Paraffin-embedded sections (3.5 µm) of formalin-fixed colon tissues 
were stained with hematoxylin and eosin and visualized at 100x and 200x magnification. (A) The histological 
score was evaluated in a blinded manner. Cohorts consisted of four wild-type and three Ormdl1-/- mice. Two-
tailed unpaired Student’s t-test was performed for statistical analysis. Data represents means ± SEM. (B) 
Distal colon tissues of a littermate pair are exemplary shown. The scale bars represent 200 µM and 100 µM in 











































































IBD, with its two most common forms CD and UC, is characterized by chronic or recurring 
immune activation and inflammation of the gastrointestinal tract. Although recent 
approaches increased the knowledge on genetic background and, thus, etiology of IBD, 
the exact functional effects of most genetic risk loci are yet unknown. Among those risk 
loci is ORMDL3 (50,51). Even though ORMDL3 was identified as one of the strongest 
known eQTL for CD (137), the causative role and mechanism of ORMDL3 in the 
pathogenesis of IBD is unclear. Nevertheless, recent publications found ORMDL proteins 
to be involved in the regulation of ER stress response (146,149) and since Xbp1ΔIEC mice 
suffer from ER stress and display spontaneous enteritis (51), the hypothesis at the begin 
of this study was that ORMDL proteins may also regulate ER stress-associated intestinal 
inflammation. This study investigates for the first time effects of ORMDL proteins on all 
three UPR branches. Additionally, this study comprises the first mouse models to analyze 
the in vivo function of ORMDL proteins during chemical-induced ER stress and colitis. 
4.1 Tissue-specific expression patterns of ORMDL homologues  
Approximately a decade after the first description of the three human ORMDL proteins 
(135), their function remains still largely unknown (163). Investigation of the expression 
pattern is often used to suggest functional differences of a gene in individual tissues (201). 
This study reveals that human and murine ORMDL homologues are expressed in all 
examined tissues under baseline conditions (Fig. 3.1), suggesting that ORMDL proteins 
exert their function in various tissues. However, mRNA expression levels of the three 
ORMDL homologues point out some tissue-specific differences. In contrast to unaltered 
ORMDL1 mRNA levels, ORMDL2 and ORMDL3 mRNA levels varied throughout the 
investigated tissues, suggesting a more pronounced tissue-specific function of ORMDL2 
and ORMDL3 than ORMDL1. Interestingly, the highest level of the human ORMDL3 
mRNA was detected in liver, spleen and pancreas, which may indicate an important role 
of ORMDL3 in highly secretory and immune relevant cells. Similar to ORMDL proteins, 
also other UPR members had been described to be differently expressed in various 
tissues, indicating tissue and cell type specialization of the UPR, which is poorly 




4.2 ER stress induces a tissue-specific expression pattern of ORMDL 
proteins 
Typically, proteins involved in the UPR, such as CHOP and GRP94, are upregulated 
during ER stress conditions (202). Also ORMDL protein levels are elevated in RAW 264.7 
macrophage cells, primary macrophages and primary murine splenocytes upon ER stress 
induction (Fig. 3.2). In accordance with these findings, Miller et al. showed ER 
stress-induced upregulation of ORMDL3 mRNA expression levels in RAW 246.7 
macrophage cells and A549 lung epithelial cells (149). This upregulation supports the 
hypothesis that ORMDL proteins play a vital role in the UPR of immune relevant cells and 
are elevated in order to cope with ER stress. In contrast to macrophages and splenocytes, 
ER stress suppresses ORMDL protein levels in intestinal epithelial cells (Fig. 3.2). 
Although reduced ORMDL protein levels had not been described so far, unchanged 
ORMDL mRNA expression levels were observed in peripheral blood neutrophils treated 
with Alternaria allergen (149), which is known to induce ER stress (203). Taken together, 
ORMDL proteins seem to function in an up to now unknown cell type-specific manner 
during ER stress conditions. 
It can be hypothesized, that tissue-specific alterations of ORMDL protein levels upon ER 
stress induction could be caused by different susceptibility rates of various cell types. Due 
to their natural environment intestinal epithelial cells are continuously challenged by many 
foreign stimuli, whereas bone marrow derived macrophages are not directly in contact 
with challenging or ER stress inducing agents. This could be a reason for the different 
types of replies of various cell types to ER stress-inducing reagents. However, ER stress-
induced tissue-specific expression pattern of ORMDL proteins may point to functional 
differences of ORMDL proteins between several cell types under challenging conditions. 
Recent investigations identified cell type-specific expression patterns also for some novel 
UPR components, including the old astrocyte specifically induced substance (OASIS) 
(204) and the cAMP responsive element-binding protein (CREBH) (205). For example, 
OASIS transcript levels are upregulated in C6 glioma cells upon thapsigargin treatment, 
whereas in mouse embryonic fibroblasts OASIS transcript levels are reduced after this 
treatment (204). This indicates that UPR components, such as OASIS and ORMDL 
proteins, can be differently regulated during ER stress. Even though there is no detailed 
explanation for the ER stress-induced cell type-specific expression patterns, these 
regulations may enable specialized cells a proper ER stress response according to their 
needs. Altered expression levels of ORMDL proteins may also have different functions in 
individual tissues during pathophysiological conditions and affect the disease outcome. 




mice treated with tunicamycin or DSS to determine the impact of ER stress on liver tissue 
or the intestine, respectively. These experiments are discussed in chapter 4.7 and 4.8. 
Interestingly, the identified risk variant of ORMDL3 is thought to regulate its expression 
level as illustrated by in vitro experiments (136). However, in ileal and colonic biopsies of 
CD and UC patients no influence on ORMDL3 expression level was observed (143). A 
possible explanation of unaffected mRNA expression level in IBD patients might be that 
ORMDL3 is differently expressed in distinct cell types as observed in this study. For that 
reason, future studies are needed to investigate ORMDL3 expression levels of IBD 
patients in separated cell types. 
4.3 ORMDL proteins function as a regulator of the UPR 
The UPR, with its three signaling branches, is a cellular stress response to maintain and 
restore the ER homeostasis after being in contact with ER stress-inducing agents or 
conditions. To cope with ER stress cells activate several cytoprotective pathways, which 
are fundamental for cell survival. However, during prolonged ER stress the aim of the 
UPR changes to induce apoptotic cell death. The role of ORMDL proteins on the three 
UPR branches are examined in this study. A major finding of the present work is that 
ORMDL proteins regulate all three branches of the UPR differently. Thereby, as discussed 
in the following chapters, ORMDL proteins facilitate activation of the ATF6α and PERK 
pathwas, but repress the IRE1 pathway.  
4.3.1 ORMDL proteins activate the ATF6α pathway 
Under ER stress conditions the ATF6α pathway gets activated and ATF6α undergoes 
S1P- and S2P-dependent cleavage resulting in cleavage fragments with sizes of 50 to 70 
and 36 kDa (206). The present study elucidates for the first time a direct effect of ORMDL 
proteins on the ATF6α pathway and the involved cleavage events. Despite surprisingly 
reduced levels of p36ATF6α in whole cell lysates (Fig. 3.4A), increased ERSE promoter 
activity and nuclear localization of p36ATF6α were detected in ORMDL3 overexpressing 
HEK-293 cells (Fig. 3.5). The elevated ERSE promoter activities are confirmed by a study 
of Miller et al. using A549 lung epithelial cells (149), indicating a general mechanism of 
ORMDL3 activating the ERSE promoter in different cell types.  
In line with an increased ERSE promoter activity, ORMDL3 overexpression induces 
ATF6α cleavage and results in elevated p50ATF6α fragments (Fig. 3.9). In addition, 
ORMDL3 affects the glycosylation status of ATF6α FL. The glycosylation status of ATF6α 




starvation (207). Not properly glycosylated proteins accumulate in the ER, which induces 
the ERSE promoter and synthesis of ER chaperones. Interestingly, overexpression of 
ORMDL3 reveals unglycosylated bands for ATF6α (Fig. 3.8A,B), which has not been 
described so far. However, other studies support these results of the present work by 
demonstrating faster transport rates of the unglycosylated form of ATF6α to the Golgi 
apparatus, increased nuclear translocations of its cleavage products and elevated ERSE 
promoter activities (182,208). Comparable to ORMDL3 also other proteins, such as the 
ribosome-associated membrane protein 4 (RAMP4), were identified to control the 
glycosylation status of various proteins through specific interaction sequences and, as a 
consequence, regulate the activity of its targets (209,210). Thus, the investigated impact 
of ORMDL proteins on the N-linked glycosylation status of ATF6α may function as an 
initial regulatory response mechanism for ATF6α activation, which is especially important 
during challenging conditions in order to rapidly respond to changing environmental 
conditions. Future investigation should determine how ORMDL3 affects the glycosylation 
status of ATF6α and whether the effect of ORMDL3 is specific for ATF6α or whether 
ORMDL3 also influences the glycosylation status of other proteins with similar structures.  
The impact of ORMDL3 on ATF6α suggests that both proteins are in close spatial 
proximity to each other. Indeed, ATF6α and ORMDL3 are localized in the ER (87,135) and 
show overlapping expression sites (Fig. 3.12). Furthermore, co-immunoprecipitation 
studies suggest a relevant physical interaction between ORMDL3 and ATF6α (Fig. 3.13). 
This interaction may stimulate the activity and translocation of ATF6α, comparable to the 
enhanced activation of ATF6α through its interaction with Ying Yang 1 (YY1) (175). 
Mingqing et al. speculates about the co-activating function of YY1 on ATF6α during ER 
stress, which could be caused by anchoring the protein complex to the ERSE or by 
inducing other proteins to activate ATF6α (175). However, the interaction of ORMDL3 with 
ATF6α could also cover the glycosylation sites of ATF6α, which may impede the 
glycosylation. Interestingly, some protein interactions were shown to be sensitive to 
altered levels of glycosylation as observed for GRP94 and lectin osteosarcoma amplified 
9 (OS-9) (211), which was not the case for ORMDL3 and ATF6α, indicating a relevant 
physical interaction during normal as well as ER stress conditions.  
In conclusion, ORMDL3 affects the ATF6α pathway by regulating the glycosylation status 
of ATF6α and thus its cleavage. This impact is most likely caused through the interaction 
of ORMDL3 with ATF6α. In context of IBD, these findings suggest a supporting effect of 
ORMDL3 on the ATF6α activity and its target genes, which is potentially involved in the 
pathogeneses of UC and CD since alterations in the ATF6α pathway were demonstrated 




4.3.2 ORMDL proteins facilitate the PERK pathway activation 
Elevated ORMDL3 protein levels also facilitate PERK pathway activation, indicated by 
increased ATF4 promoter activity and elevated CHOP protein level in ORMDL3 
overexpressing HEK-293 cells (Fig. 3.14A,B). In line with these findings, eIF2α 
phosphorylation is induced by ORMDL3, which was confirmed by a study of Cantero-
Recasens et al. using HEK-293 cells (146). The effect of ORMDL proteins on the PERK 
pathway is additionally supported by siRNA-mediated ORMDL1/2/3 knockdown 
approaches in the present work (Fig. 3.14C,D). In contrast to this study and the work of 
Cantero-Recasens et al. (146), Hsu et al. observed no alterations of p-eIF2α levels or 
CHOP transcript levels in SV40-transformed normal airway epithelial cells treated with 
siRNA against ORMDL3 (125). These inconsistent findings might be due to different 
investigated cell types.  
The obtained results of the PERK pathway investigation suggest an in vivo impact of 
ORMDL proteins during ER stress conditions, which may influence the pathogenesis of 
IBD. Interestingly, also intestinal epithelial cells of IBD patients revealed elevated p-eIF2α 
and CHOP levels (212,213). Taken these observations into account, increased expression 
levels of ORMDL3, as they are described for IBD patients (137), and the subsequent 
increase in p-eIF2α might negatively affect the intestinal homeostasis and promote the 
development of intestinal inflammation.  
4.3.3 ORMDL proteins reduce the activity of the IRE1 pathway 
In contrast to the induction of ATF6α and PERK, ORMDL proteins repress the IRE1 
pathway, indicated by reduced XBP1 mRNA splicing and UPRE promoter activation under 
baseline as well as ER stress conditions (Fig. 3.3A,B). These results are supported by 
studies of McGovern et al. using HEK-293 cells (138). However, Miller et al. found no 
obvious alterations of XBP1 splicing in the lung epithelial cell line A549 transfected with 
ORMDL3 (149). These divergent results again indicate cell type-specific differences 
similar to those observed for the PERK pathway. Possibly endogenous ORMDL protein 
levels are uniquely regulated in the investigated cell types and therefore affect all three 
UPR pathways differently. Interestingly, differently regulated IRE1 and ATF6α pathways 
were identified also during hepatitis C virus infection, which is known to induce ER stress 
(214). Hepatitis C virus infections suppress the IRE1 pathway to reduce ERAD, whereas 
the ATF6α pathway is upregulated to stimulate protein folding (215). This example 
illustrates the possibility of differentially regulated UPR signaling pathways during ER 




In the context of IBD, the impact of ORMDL3 on the IRE1 pathway might directly affect the 
intestinal homeostasis. In humans, several genetic variants within XBP1 were identified as 
potential genetic risk factors for IBD and colonic tissue of IBD patients show increased 
levels of spliced XBP1, suggesting that altered XBP1 splicing is involved in chronic 
intestinal inflammation (212). Thus, altered ORMDL3 levels influencing XBP1 splicing may 
negatively affect the intestinal homeostasis. 
4.3.4 Cross-talk events between the three UPR branches 
ER stress is generally thought to induce all three branches of the UPR in parallel. 
However, the timing of these signaling pathways and their cross-talk events are highly 
dynamic mechanisms depending on the ER stress duration as well as on the type and 
concentration of the stimulus (63). In addition, many target genes are not exclusively 
induced by only one UPR branch. For example, activation of ATF6α is not only crucial for 
ERSE-induced transcription of ER chaperones but also facilitates transcription of XBP1 
and CHOP (105). Furthermore, in vivo studies showed that alterations or depletions of 
several UPR components in murine IECs induce components of other UPR branches 
possibly by cross-talk events (51,130). To this end, cross-talk events enable cells to 
compensate the loss of a UPR component by up-regulating other pathway members. 
However, the complex mechanisms of cross-talk events between the UPR branches are 
not fully understood. 
Due to the variety of molecular cross-talk events, it is difficult to determine the impact of 
ORMDL proteins on only one of the three UPR branches. In this study, cross-talk effects 
influencing ATF6α activation are determined using ERSE promoter-mediated luciferase 
reporter assays in combination with siRNA-mediated knockdowns of several UPR 
components (Fig. 3.7). Only siRNA-mediated knockdown of ATF6α results in strongly 
reduced ERSE promoter activities during ER stress, demonstrating a high specificity of 
the ERSE promoter assay. However, the ERSE activity in ORMDL3 overexpressing cells 
is still higher than in EGFP overexpressing cells after tunicamycin treatment, which might 
be due to the activation of the other two UPR branches mediated by ORMDL3. In this 
context, components of the PERK pathway are known to facilitate ATF6α cleavage and 
thus activate the ERSE promoter (181). For example, diminished ATF6α activation in 
response to ER stress was identified in murine liver tissue lacking Perk, which indicates 
that the PERK pathway also facilitates activation of the ATF6α pathway and the ERSE 
promoter (181). In line with this, ORMDL3 might additionally trigger the ERSE promoter 




However, an substantial role of ATF6α in the UPR was suggested by Wu et al., showing 
that genes containing either ERSE or UPRE sequences in their promoters require ATF6α 
binding for their full activation (94). In addition, ATF6α was demonstrated to co-regulate 
the PERK pathway member CHOP (109,216), which may be the primary effect 
responsible for the induction of the PERK pathway by ORMDL proteins. Thus, the results 
of this study indicate that the regulation of the three UPR branches by ORMDL3 is a 
complex mechanism, which allows a flexible ER stress response with cross-talk events 
depending on the type, duration and strength of the stimulus. For further investigation it 
would be of great interest to clearly identify the mode of action of these cross-talk events 
between the three UPR branches mediated by ORMDL proteins. This would help to 
explore the functional mechanism of ORMDL proteins in a complex multicellular system 
like the human body.  
4.3.5 Proposed mechanisms of ORMDL3 on the UPR pathways 
Summarizing the in vitro results of this study, ORMDL proteins regulate the three UPR 
branches differently (Fig. 1.1). Elevated levels of ORMDL3 facilitate the activation of the 
ATF6α and the PERK pathways, but repress the IRE1 pathway. 
The most distinct impact of ORMDL3 was observed on the ATF6α pathway. ORMDL3 
interacts with ATF6α and suppresses the glycosylation of the full length form of ATF6α. 
This unglycosylated form of ATF6α exhibits faster transport rates to the Golgi apparatus, 
increased cleavage rates and, as a consequence, triggers the ERSE promoter activity. 
The induced ATF6α cleavage by ORMDL3 influences also directly CHOP protein levels 
with no need of affecting the phosphorylation of eIF2α. Independently of its impact on 
ATF6α, ORMDL3 is capable to facilitate the phosphorylation of eIF2α and the activation of 
the ATF4 promoter. In contrast to that, ORMDL3 suppresses the IRE1 pathway, which is 
demonstrated by reduced mRNA splicing rates of XBP1 and diminished UPRE promoter 





Fig. 4.1: Proposed mechanisms of ORMDL3 on the UPR pathways. 
See text for detailed explanations. 
4.4 Embryonic development is unaffected by ablation of either Ormdl1 or 
Ormdl3 
The UPR plays a crucial role during embryonic and postnatal development. Especially 
during embryonic development many UPR mediators are indispensable. Complete 
deletion of either the UPR sensor IRE1α (encoded by Ern1) or its target gene Xbp1 results 
in embryonic lethality in mice at day 12.5 (217) or day 14.5 of gestation (218), 
respectively. Also the knockout of the major ER chaperone Grp78 in mice leads to lethality 
prior embryonic day 7.5 (219). Furthermore, genomic excision of Grp94, which is an 
important target gene of ATF6α (65), induces embryonic lethality in mice as early as on 
day 7 of gestation (220). Although GRP94 is mainly induced by ATF6α (85), Atf6α-
deficient mice develop normally. Mice with a deletion of the other closely related ATF6 
isoform, Atf6β, disclosed no abnormalities (94). Even though the transcriptional activity of 
ATF6α is substantially higher than that of ATF6β, both isoforms are required for proper 
adjustment of ER chaperones (221). For that reason, genetic depletion of both, Atf6α and 
Atf6β, causes embryonic lethality in mice, indicating essential overlapping functions during 
early stages of development (85). Interestingly, some members of the PERK pathway, 
such as PERK itself (222), CHOP (223) and GADD34 (224), are expendable during 
embryonic development. However, mice with a deletion of Atf4, another member of the 
PERK pathway, are partial lethal during embryonic development (225,226). These 
different outcomes in the embryonic development of components of the PERK branch 





















and ORMDL proteins, the development of any Ormdl knockout in mice has never been 
elucidated. Interestingly, similar to Atf6α-/- mice and to mouse models with a deletion of 
genes involved in the PERK pathway, Ormd1-/- and Ormdl3-/- mice are born at the 
expected Mendelian ratio. This indicates that neither ORMDL1 nor ORMDL3 alone is 
required for organogenesis and embryonic development, at least if the remaining ORMDL 
homologues are intact. The double or triple knockout of Ormdl genes could affect 
synergistically embryonic development, as reported for the double knockout of the Atf6 
homologues, Atf6α and Atf6β (85). Nevertheless, it is hard to speculate about the 
phenotype of double or triple knockout Ormdl mice, because at least partial functional 
redundancies of the ORMDL homologues are conceivable due to the shown phenotype 
rescue using the human ORMDL3 in ORM1/2 double knockout yeast (135). Thus, the 
effect of a double or triple knockout of Ormdl genes in regard to embryonic development 
and organogenesis in mammals remains to be elucidated, and is subject of ongoing 
investigation. 
4.5 ORMDL3 modulates body growth by affecting IGF1 production 
The present study identifies for the first time that genetic deletion of Ormdl3 causes 
postnatal growth retardation in mice (Fig. 3.17) without affecting organ development (Fig. 
3.20, Fig. 3.21). Postnatal growth in mammals is mainly regulated by the coordinated 
action of GH and IGF1 (227). IGF1 expression levels are significantly reduced in muscle 
tissues of 4 weeks old Ormdl3-/- mice (Fig. 3.19B), whereas circulating GH levels are just 
slightly diminished (Fig. 3.18). This may indicate that the main regulatory effect of 
ORMDL3 on growth is mediated through IGF1 and takes place in the first weeks after 
birth, because at that early time point IGF1 is almost exclusively responsible for postnatal 
growth (228). The early growth deficit of Ormdl3-/- mice continues throughout their ageing 
(Fig. 3.17). The hypothesis of reduced growth due to altered IGF1 production in Ormdl3-/- 
mice is supported by studies showing that Igf1-/- mice are born 35 % smaller than their 
wild-type littermates (229) and continue to grow with retarded rates reaching only 30 % of 
normal body weights (230), whereas mice deficient for GH or GH receptor grow normally 
during the first two weeks after birth before reaching growth retardation (228,231). 
Interestingly, genetic deletions of several other UPR components also result in growth 
abnormalities. Especially members of the ATF6 and PERK branches, which are down-
regulated in cells lacking ORMDL proteins, are fundamental for postnatal growth. For 
example, the ATF6α target GRP94 is essential for local IGF1 production, which was 




growth caused by inhibited local IGF1 production (232,233). In addition, Perk-/- mice 
exhibit neonatal growth retardation with a 50 % reduction in body weight at the age of 3 
weeks, which is attributed to low IGF1 levels derived from liver tissue (234,235). Thus, 
these findings demonstrate a link between UPR components, body growth and altered 
IGF1 levels, which is also shown for ORMDL3 in the present study. 
Although Ormdl1 and Ormdl3 have high sequence homologies, Ormdl1-/- mice develop 
and grow without any abnormalities (Fig. 3.44). For that reason, ORMDL1 is thought to be 
expendable during developmental and growth processes. This exchangeable role of 
ORMDL1 may result in only slight effects of Ormdl1 deficiency on total ORMDL protein 
level, whereas ablation of Ormdl3 in mice results in a significant reduction (Fig. 3.43; Fig. 
3.16). This clear impact on total ORMDL protein level may cause a more pronounced 
phenotype of Ormdl3-/- mice. On the other hand, it can be speculated that the three 
ORMDL proteins may function differently or in a cell type-specific manner with ORMDL3 
depicting a profound role in cells producing hormones responsible for body growth, such 
as IGF1-producing liver cells. 
In contrast to the observed growth retardation in mice with an ablation of Ormdl3, a single 
knockout of one of the two ORMDL homologues ORM1/2 in yeast is not sufficient to 
induce growth abnormalities (135). However, ORM1/2-deficient yeast are retarded in cell 
growth, clearly demonstrating that each of the two yeast homologues is capable to 
compensate the loss of the other ORM gene. Interestingly, IGF1 signaling exits also in 
yeast and may be responsible for growth abnormalities caused by ORM1/2 deficiency. 
Together with the findings of the present study this may indicate that through evolutionary 
processes the regulation of growth processes are incorporated into the ORMDL3 gene in 
particular. In summary, this study provides evidence that ORMDL3, but not ORMDL1, is 
required for normal postnatal growth by regulating local IGF1 production.  
4.6 Ormdl3 deficiency in mice reduces IFNγ levels and its targets 
Inflammatory cytokines are of crucial importance for the intestine because they regulate 
the gut homeostasis during unchallenged conditions as well as during intestinal 
inflammation (236). Out of 23 investigated cytokines only IFNγ, TNFα and IL-12 p70 
display reduced levels in the serum of unchallenged Ormdl3-/- mice (Fig. 3.23). In addition, 
Ifnγ is significantly lower expressed in colon tissue of Ormdl3-/- mice. However, spleen 
tissue reveal unaffected Ifnγ expression levels (Fig. 3.24), suggesting organ-specific 
effects of ORMDL3 on Ifnγ expression. Interestingly, ORMDL3 protein levels are also 




indication that ORMDL3 fulfills distinct functions in the colon and the spleen (Fig. 3.2). 
Thus, the gained results support the hypothesis of cell type-specific functions of ORMDL3, 
which affects Ifnγ expression. 
It may be speculated that in IBD patients perturbed ORMDL3 expression could lead to 
changes in IFNγ levels, which in turn may facilitate inflammation or interfere with epithelial 
function. Especially CD is mainly driven by a chronic T helper 1 (Th1)-driven immune 
response leading to increased production of proinflammatory cytokines, such as IFNγ and 
IL-12 (237–239). Nevertheless, the functional link between ORMDL3 and IFNγ has not 
been investigated yet. In the murine system a substantial role of IFNγ in colitis is 
highlighted by the phenotype of Ifnγ-/- mice, which are less susceptible to DSS-induced 
colitis (240). In CD patients IFNγ is abundantly produced by intestinal lamina propria cells 
(241). Together with the results of the present study, it can be proposed that altered 
ORMDL3 expression levels in specialized immune cells may result in variations of IFNγ 
expression levels, which then promotes the pathogenesis of IBD.  
In accordance with down-regulated Ifnγ mRNA expression in colon tissue of Ormdl3-/- 
mice, also cell-surface expression levels of IFNγ targets, such as MHCI and MHCII 
molecules, are significantly reduced in myeloid cells isolated from the lamina propria (Fig. 
3.25). MHC molecules are highly important for immune response by binding peptide 
fragments from extra- and intracellular pathogens and displaying them for the recognition 
by CD4+ and CD8+ T cells, respectively (242). Especially epithelial MHCII cell-surface 
expression levels are highly upregulated in CD patients (243,244). This may indicate that 
ablation of Ormdl3 and the resulting reduced cell-surface expression of MHC molecules 
on CD11b+ lamina propria cells function as a protective mechanism for the intestinal 
homeostasis. Future investigations should explore whether the impact ORMDL3 on MHC 
molecules is a primary effect or a secondary effect through the regulation of IFNγ 
expression levels.  
Interestingly, ORMDL3 is associated with both IBD and asthma (136,245). Asthma and 
UC are described to be mainly driven by Th2 cells, which are present during acute 
exacerbations of the disease and induce the expression of Th2-type cytokines, such as 
IL-4, IL-5 and IL-13 (246,247). The presence of the same risk factor in Th1 (CD) and Th2 
driven disorders is puzzling from classical immunology textbook knowledge. Th1 cells 
secrete IFNγ, which is crucial for the resolution of allergy-related immunopathologies 
(248). However, UC patients respond to anti-TNF treatment, which blocks a hallmark Th1 
cytokine. In addition, IFNγ-producing Th1 cells were identified in airways of asthmatics 




level of IFNγ (249). Furthermore, lung-targeted overexpression of IFNγ in the airway 
enhances airway hyperresponsiveness and non-eosinophilic inflammation, while Ifnγ-/- 
mice are protected from allergen-induced asthma (250). The findings demonstrate effects 
of IFNγ in both IBD and asthma patients, which may be mediated by ORMDL3. 
4.7 The role of ORMDL1 and ORMDL3 during intestinal inflammation 
4.7.1 Deletion of Ormdl1 or Ormdl3 leaves intestinal homeostasis unaffected 
Under physiological conditions, Ormdl1-/- and Ormdl3-/- mice reveal no signs of 
spontaneous enteritis or colitis, indicated by inconspicuous histological scores (Fig. 3.21, 
Fig. 3.44) and unchanged serum cytokine concentrations (Fig. 3.23). The normal 
phenotype of these mice indicate that either Ormdl1 or Ormdl3 are expendable for the 
homeostasis of the intestine, which might be due to compensatory effects of the other two 
remaining ORMDL homologues. In line with this hypothesis, the total ORMDL protein level 
is unchanged in the liver and colon of Ormdl1-deficient mice compared to their wild-type 
littermates (Fig. 3.43). In contrast, the overall ORMDL protein level is reduced in Ormdl3-/- 
mice (Fig. 3.16). However, upon DSS treatment the ORMDL protein level increases in the 
colon of Ormdl3-/- mice suggesting a compensatory regulation of the remaining two 
ORMDL homologues under pathological conditions (Fig. 3.31). Similar compensatory 
effects occur in yeast, where ORM1 or ORM2 single knockout strains are equally affected 
by toxic compounds as the wild-type strain, while double knockout mutants are highly 
sensitive to these agents (135,147). Interestingly, the human ORMDL3 is able to rescue 
the phenotype of ORM1/2-deficient yeast (135), indicating a conserved function even 
throughout different species. This compensatory effect was also demonstrated in vitro 
using mammalian cell culture, showing that the single knockdown of ORMDL3 is not 
sufficient to regulate serine palmitoyltransferase (SPT) activity, whereas the knockdown of 
all three ORMDL homologues affects the SPT activity (251,252). These findings clearly 
illustrate that the altered function of one ORMDL gene can usually be overcome by the 
presence of the two remaining ORMDL homologues, which may protect Ormdl1-/- and 
Ormdl3-/- mice from spontaneous intestinal inflammation. In addition, also genetic deletion 
of other UPR components, such as Atf6α or Chop, did not result in intestinal inflammation 
(127,131), indicating that a deletion of one of those UPR components is expendable and 
the remaining UPR components are sufficient to maintain the intestinal homeostasis under 




4.7.2 Mice lacking Ormdl3 are more susceptible to an acute DSS-induced colitis 
An intact UPR is important for the intestinal homeostasis, especially under challenging 
conditions (127). Due to the ascertained impact of ORMDL proteins on the UPR, the 
function of ORMDL1 and ORMDL3 during intestinal inflammation was investigated by 
challenging Ormdl1-/- and Ormdl3-/- mice with DSS to induce an acute colitis. DSS 
treatment initiates inflammatory response in the gut, which in part resembles human IBD 
and is a broadly applied model (253). The common opinion of the mode of action of DSS 
is that oral administration of this agent is toxic to colonic epithelial cells and causes 
defects in the barrier integrity (194). In addition, DSS was identified to induce ER stress in 
IECs (127). During DSS treatment, mice with a genetic deletion of Ormdl1 reveal a similar 
course of disease as their wild-type littermates, as suggested by comparable amounts of 
body weight loss and similar histological scores (Fig. 3.45, Fig. 3.47). Thus, the outcome 
of this treatment indicates that ORMDL1 has no marked impact on the intestinal 
homeostasis during DSS-induced intestinal inflammation.  
In contrast to the results obtained in Ormdl1-/- mice, Ormdl3-/- mice are more susceptible to 
acute DSS-induced colitis, as demonstrated by more pronounced body weight loss and 
increased DAI (Fig. 3.26). Additionally, DSS-treated Ormdl3-/- mice disclose significantly 
elevated serum levels of IL-1β (Fig. 3.29), which is one of the main drivers of inflammation 
in IBD (254,255). Further signs indicate increased sensitivity of Ormdl3-/- mice to 
DSS-induced colitis, including increased histological scores in the colon and significantly 
reduced liver weight (Fig. 3.28, Fig. 3.27B). Reduced liver weight was also identified in 
hamsters as a result of DSS treatments (192), which in the case of Ormdl3-/- mice 
suggested a more severe disease progression of the entire organism upon DSS 
administration. Interestingly, also IBD patients show disorders of the hepatobiliary system, 
which is a relatively common extra-intestinal manifestation and is probably caused by a 
shared pathogenesis with IBD or due to the effect of chronic inflammation (256). In 
summary, the results of this study suggest that ORMDL3 is more important for the 
intestinal homeostasis and immune responses than ORMDL1. 
For investigation of the mechanistic effect of ORMDL3 during the development of colitis, 
Ormdl3-/- mice were treated with DSS for short durations of two to four days. During this 
treatment, colonic tissues of Ormdl3-/- reveal higher and prolonged levels of p-eIF2α, 
indicating ongoing ER stress over several days in Ormdl3-/- mice, whereas wild-type mice 
are able to restore the UPR homeostasis (Fig. 3.31). Prolonged ER stress has been 
identified to cause cellular damage followed by barrier defects, as demonstrated in 




are more susceptible to DSS-induced colitis, which is accompanied by increased p-eIF2α 
in IECs (133). Additionally, elevated p-eIF2α was also observed in colonic tissue of IBD 
patients (212), which supports the hypothesis of an increased sensitivity of Ormdl3-/- mice 
to DSS-induced colitis based on their upregulated colonic p-eIF2α levels. Interestingly, 
increased p-eIF2α occurs also in liver tissue of DSS-treated Ormdl3-/- mice, whereas the 
hepatic p-eIF2α level was not altered in wild-type mice (Fig. 3.31B), demonstrating that 
more tissues than just the colon are affected by the intestinal barrier defect. In addition, 
the protein level of the p-eIF2α target CHOP is upregulated in the liver of Ormdl3-/- mice 
(Fig. 3.31B). The results of the present study indicate that increased levels of p-eIF2α and 
of the pro-apoptotic factor CHOP might be the reason for significantly reduced liver weight 
in Ormdl3-/- mice at the end of the acute DSS colitis experiment. Interestingly, the outcome 
of various genetic deletions of UPR components indicate that dysregulation of the URP 
deteriorates the ability to cope with intestinal inflammation upon DSS treatment 
(51,130,131), which may also be the case for ORMDL3. Summing up the results of the 
acute DSS-induced colitis experiment, molecular-biological changes in Ormdl3-/- mice 
support the assumption that ORMDL3 is needed for fine-tuning of the ER stress response. 
4.7.3 Deletion of Ormdl3 in IEC has a protective effect during chronic DSS-induced 
colitis 
ER stress in IECs functions as an originator and perpetrator of intestinal inflammation 
(257). Ormdl3ΔIEC mice with a genetic deletion of Ormdl3 particularly in IECs were 
investigated due to the central role of IECs in not only providing a physical barrier against 
invasive intestinal pathogens, but also in maintaining the intestinal homeostasis through 
secretion and regulation of commensal microorganisms and the host immune response 
(21). The importance of IECs is underlined by studies reporting that intestinal inflammation 
causes ER stress especially in epithelial cells and that functional impairment of IECs 
might contribute to IBD (68,258). Similar to Ormdl3-/- mice, Ormdl3ΔIEC mice show no 
apparent abnormalities under physiological conditions (Fig. 3.37). Interestingly, Ormdl3ΔIEC 
mice are less susceptible to the DSS-induced chronic colitis, indicated by less body 
weight loss and a faster regeneration rate, especially during the end of the second cycle 
and the beginning of the third cycle of DSS treatment (Fig. 3.38). However, at the end of 
the experiment, body weight, spleen weight and serum concentration of various cytokines 
are not significantly altered between the two groups (Fig. 3.39, Fig. 3.41). This is most 
probably owing to the low DSS concentration that resulted in only weak effects on body 
weight during the treatment. Nevertheless, DSS-treated Ormdl3ΔIEC mice disclose 
significantly lower histological scores than their wild-type littermates at the end of the 




a protective effect during chronic intestinal inflammation, whereas genetic deletion of 
Ormdl3 in all cell types revealed contrary findings during acute DSS-induced colitis (Fig. 
3.26). These opposite findings may be explained by the tissue-specific function of ORMDL 
proteins. It will be of great interest to determine, whether mice with a knockout in cells that 
respond with an ORMDL induction during tunicamycin treatment (e.g. monocytes; Fig. 
3.2) display a more severe phenotype during DSS treatment. Thus, further investigation 
with a monocyte/macrophage-specific knockout of Ormdl3 may elucidate the function of 
ORMDL3 in immune relevant cells, because especially macrophages actively produce 
inflammatory cytokines in response to invading bacteria. However, the different responses 
of Ormdl3ΔIEC and Ormdl3-/- mice to DSS treatment may also arise from the duration, 
concentration and frequency of DSS administration. Interestingly, the activation of some 
UPR mediators, such as ATF6α, are differently regulated during acute and chronic stress 
conditions (94). This suggests that the function of ORMDL3 and the disease outcome may 
depend also on the duration of ER stress conditions. 
4.8 ORMDL3 protects from prolonged ER stress in vivo 
The dysregulated UPR homeostasis in Ormdl3-/- mice during intestinal inflammation 
indicates that ORMDL3 plays a crucial role in regulating cellular stress conditions. To 
further investigate the function and the mechanism of ORMDL3 during ER stress in vivo, 
Ormdl3-/- mice were intraperitoneally injected with a single sublethal dose of the chemical 
ER stress inducer tunicamycin, which primarily affects the liver. All mice survived the 
tunicamycin challenge, demonstrating that ORMDL3 is expendable during persistent ER 
stress conditions at least for survival at the given tunicamycin concentration (Fig. 3.32). In 
contrast, deletion of Atf6α, which encoded protein was found to be modulated by 
ORMDL3, results in high mortality rates during a comparable treatment regime (259). 
Although the effect of Ormdl3 deletion is less pronounced compared to the genetic 
deletion of Atf6α, Ormdl3-/- mice showed similar, but attenuated, molecular-biological 
changes during tunicamycin treatment. Tunicamycin-treated Ormdl3-/- mice display a mild 
form of acute fatty liver degeneration, which is notable by a pale liver color and an 
increased level of the cytosolic lipid protein marker ADRP after 48 h of treatment (Fig. 
3.33). The kidney is as a secondary time-displaced affected organ and shows likewise 
prolonged upregulation of ADRP level (Fig. 3.34). In addition, serum level of the protective 
HDL cholesterol decreases significantly faster in Ormdl3-/- mice than in wild-type mice 
(Fig. 3.35), which has been shown as a sign of hepatic steatosis (197). This indicates that 
Ormdl3-/- mice are more susceptible to tunicamycin treatment. However, it is unclear, 




causes UPR signaling or the other way around. Since ORMDL3 was found to interact with 
ATF6α and to influence its cleavage, the resulting assumption is that the phenotype of 
Ormdl3-/- mice during tunicamycin treatment is primarily caused by a dysregulated UPR, 
which in turn influences the cholesterol metabolism. Interestingly, genetic deletion of other 
UPR mediators, such as Atf6α, p58IPK or a liver-specific excision of Ire1α, result in 
phenotypes comparable to the one seen in Ormdl3-/- mice (260,261), demonstrating that 
defects in the UPR can lead to hepatic steatosis upon tunicamycin administration. In case 
of tunicamycin-treated Ormdl3-/- mice, the often postulated link between ER stress and 
lipid metabolism could be confirmed with the present work (262). 
During tunicamycin treatment, Ormdl3-/- mice disclose dysregulated UPR signaling as 
expected from the in vitro results obtained in this study. Similar to prolonged upregulation 
of ADRP, also some UPR mediators, such as the pro-apoptotic factor CHOP, p-eIF2α or 
spliced Xbp1, are prolonged upregulated in liver and kidney of tunicamycin-treated 
Ormdl3-/- mice (Fig. 3.33, Fig. 3.34), reflecting ongoing ER stress and defects in the UPR 
signaling pathway. Comparable results of permanently elevated CHOP levels and 
prolonged Xbp1 splicing were observed also in tunicamycin-treated Atf6α-/- mice (94), 
supporting the connection of ORMDL3 and ATF6α. In addition, also during short-term 
DSS treatment prolonged upregulated p-eIF2α protein levels in liver and colon of Ormdl3-/- 
mice appears (Fig. 3.34), indicating similar systemic effects during locally administrated 
DSS and artificial, systemic ER stress induction by tunicamycin injection. Taking this into 
account, the results of the present study suggest that alterations in the UPR signaling 
caused by Ormdl3 deletion may modulate either liver steatosis or intestinal inflammation 
depending on the type and the site of action of the ER stress stimulus.  
Furthermore, genetic deletion of Ormdl3 in mice affects the glycosylation status of ATF6α 
during ER stress indicated by a delayed appearance of the unglycosylated band of ATF6α 
upon tunicamycin injection (Fig. 3.8, Fig. 3.33). A similar mode of action of ORMDL 
proteins on ATF6α glycosylation was observed in HEK-293 cells treated with siRNA 
against the three ORMDL homologues (discussed in chapter 4.3.1). These consistent in 
vitro and in vivo results clearly demonstrate the impact of ORMDL3 on ATF6α and 
reinforce the identified interaction of ORMDL3 and ATF6α. Additionally, the 
unglycosylated band of the ATF6α target GRP94 and the glycosylation status marker 
TRAPα are prolonged detectable in the liver of Ormdl3-/- mice, indicating a general effect 
of ORMDL3 on the glycosylation machinery during ER stress conditions. Improper 
glycosylation affects not only the activity of ATF6α, but also of GRP94 (211). Thus, the 
ORMDL3-dependend mechanism affecting ATF6α glycosylation may enable fine-tuning of 




on ATF6α glycosylation and activation might negatively affect the rapidity of the UPR 
signaling, which results in an increased sensitivity of Ormdl3-/- mice to chemically induced 
ER stress. Interestingly, the unglycosylated form of ATF6α has been identified as an 
inducer of diseases, such as cystic fibrosis (263), indicating the importance of the impact 
of ORMDL3 on the glycosylation status of ATF6α. With regard to the development of 
diseases, tissues of liver steatosis and IBD patients should be investigated with respect to 
their glycosylation status of ATF6α and analyzed for a correlation between glycosylation 
and ORMDL3 levels.  
In summary, the results of the present study indicate that ORMDL3 influence the UPR 
signaling during ER stress mainly by interacting with ATF6α and affecting its glycosylation 
status, which induces the activation of this pathway by increased ATF6α cleavage. 
Furthermore, ORMDL3 facilitates the PERK pathway activation and represses the IRE1α 
pathway. In addition, cross-talk events between the ATF6α and the PERK pathways are 
identified. Thus, from this study it can be suggested that loss of Ormdl3 primary 
dysregulates UPR signaling, which secondarily might cause defective lipid homeostasis, 
as illustrated by e.g. altered ADRP and HDL levels. These findings lead to the speculation 
that the detected molecular link between ORMDL, the UPR and lipid homeostasis is of 
strong importance for the development and progression of several ER stress-coupled 




4.9 Future prospects 
The results of the present study provide insights into the complex role of ORMDL proteins 
in the regulation of the UPR and their importance for the intestinal and liver homeostasis, 
especially during challenging conditions. Based on these findings, new open questions 
arise. 
Deletion of genes involved in the UPR signaling pathways revealed their implication 
during embryonic and postnatal development. This study disclosed a negative effect of 
Ormdl3 deficiency on murine body growth. However, the embryonic development is not 
affected by Ormdl3 deletion, which might be due to a compensatory effect of the other 
remaining ORMDL homologues. To elucidate possible overlapping functions between all 
three ORMDL proteins, the generation of Ormdl1/2/3(-/-) triple-knockout mice appears 
reasonable. In the case that triple-knockout mice are viable, further investigation should 
examine whether their organs are structurally and functionally intact. Additionally, 
spontaneous intestinal inflammation might occur, as seen in mice with a tamoxifen-
induced deletion of the ATF6α target gene Grp94. Furthermore, investigation of the 
phenotype of Ormdl1/2/3(-/-) triple-knockout mice during challenging conditions, such as 
DSS-induced colitis or intraperitoneal injection of tunicamycin, could elucidate whether the 
ORMDL proteins have compensatory functions. In addition, these mice would also enable 
to examine the impact of Ormdl1/2/3 deficiency on the ATF6α pathway in more detail. 
Ormdl1/2/3(-/-) triple-knockout mice may reveal whether the genetic deletion of Atf6α and 
the lack of all ORMDL proteins result in a similar phenotype during ER stress condition, 
which would support the hypothesized connection of these proteins. Thus, the triple-
knockout of Ormdl1/2/3 in mice may gain the understanding of ORMDL proteins in the 
whole organism. However, the present study already identified the impact of ORMDL3 on 
the intestinal and liver homeostasis during challenging conditions, which may be 
transferred into humans to improve the treatment of IBD and its extra-intestinal 
manifestations. 
Apart from this, prospective research may address the cellular and molecular mechanism 
of ORMDL3 during the pathogenesis of asthma, since ORMDL3 has been associated with 
both IBD and asthma. The question arises whether the identified effect of ORMDL3 on the 
intestinal homeostasis also influences lung homeostasis in mice during challenging 
conditions. In particular, the shown impact on the UPR gives additional insights into the 
function of ORMDL3, which may also improve research in the field of asthma. Thus, the 
present study increases the knowledge of ORMDL3 and may serve as a starting point for 





Unresolved and prolonged endoplasmic reticulum (ER) stress has been shown to be 
involved in the pathogenesis of inflammatory bowel disease (IBD). ER stress describes 
the condition of an excessive accumulation of unfolded or misfolded proteins in the ER 
that invokes an essential pathway to restore the function of the ER, termed the unfolded 
protein response (UPR). Especially hepatocytes and intestinal epithelial cells, including 
Paneth and goblet cells, strongly depend on a well-functioning UPR due to their high 
demand on secretory proteins. Unresolved ER stress has been found in inflamed 
intestinal epithelial cells and genome wide association studies identified UPR-associated 
genes, such as ORM1-like protein 3 (ORMDL3), as potential risk factors for IBD. 
However, the role and the functional mechanism of ORMDL3 in vitro and in vivo with 
regard to the pathogenesis of chronic intestinal inflammation as well as extra-intestinal 
manifestations have not been investigated so far. The aim of this study was to explore the 
effect of ORMDL proteins on the three UPR signaling branches and its impact on the 
intestinal and systemic homeostasis under physiological and challenging conditions. 
The present work provides the first evidence of a cell type-specific protein expression 
pattern of ORMDL proteins upon ER stress, which may point to functional differences of 
ORMDL proteins between various cell types under challenging conditions. Additionally, 
this study demonstrates for the first time, a distinct impact of ORMDL3 on each of the 
three UPR signaling branches, where ORMDL3 activates the ATF6α and the PERK 
pathways, but represses the IRE1 pathway. A strong effect of ORMDL3 on the ATF6α 
pathway was demonstrated, whereby overexpression of ORMDL3 suppresses the 
glycosylation of the full length form of ATF6α. The unglycosylated form of ATF6α has 
been described to facilitate ATF6α cleavage and to activate ATF6α target genes. In line 
with this, ORMDL3 promotes the cleavage of ATF6α and, as a consequence, increases 
the promoter activity of the ER stress response element (ERSE). In addition, 
co-immunoprecipitation studies in the present work suggest a physical relevant interaction 
between ORMDL3 and ATF6α. An inducing effect of ORMDL proteins also occurs on the 
PERK pathway, which is mainly caused by crosstalk effects between the ATF6α and 
PERK signaling branches. In addition, overexpression of ORMDL3 results in increased 
ATF4 promoter activities and elevated protein levels of the pro-apoptotic transcription 
factor CHOP. In contrast to the inducing effect of ORMDL3 on the ATF6α and the PERK 
pathways, splicing of XBP1 and the activity of the UPRE promoter is diminished as a 
consequence of ORMDL3 overexpression. These regulatory mechanisms of ORMDL3 
may enable a proper ER stress response through precisely coordinated activations of 




In addition to the mentioned in vitro findings, this study investigated for the first time the in 
vivo impact of ORMDL by examining Ormdl1- and Ormdl3-deficient mice. Interestingly, the 
depletion of Ormdl3, but not Ormdl1, leads to reduced body weight as a result of 
decreased local insulin-like growth factor 1 production in muscle tissue. Although genetic 
variants in close proximity of the human ORMDL3 gene have been identified as a 
potential risk factor for Crohn’s disease (CD) and ulcerative colitis (UC), genetic deletion 
of Ormdl1 or Ormdl3 reveal no signs of spontaneous inflammation in mice. Indeed, 
Ormdl3-deficient mice, but not Ormdl1-deficient mice, are more susceptible to DSS-
induced colitis, as demonstrated by a severe body weight loss, more pronounced crypt 
damage and significantly increased serum level of the pro-inflammatory cytokine IL-1β. In 
addition, short-term DSS-treatment causes prolonged unresolved ER stress in colon and 
liver of Ormdl3-deficient mice. Prolonged unresolved ER stress also appears in the liver of 
Ormdl3-deficient mice upon injection of a sublethal dose of the chemical ER stress 
inducer tunicamycin. Both experiments indicate that ORMDL3 is crucial to protect against 
prolonged unresolved ER stress.  
In summary, this study provides evidence that ORMDL proteins are crucial regulators of 
the UPR, with a particular impact on the ATF6α branch. Especially, ORMDL3 is relevant 
for maintaining the homeostasis in the ER and the intestinal epithelium. The findings of 
this study indicate a beneficial regulatory function of ORMDL3 during ER stress conditions 










Kontinuierlicher Stress im Endoplasmatischen Retikulum (ER-Stress) ist mit der 
Pathogenese von chronisch entzündlichen Darmerkrankungen (CED) assoziert. 
ER-Stress wird durch die übermäßige Akkumulation von falsch- oder ungefalteten 
Proteinen im ER hervorgerufen und induziert dadurch einen für die Wiederherstellung der 
ER-Homöostase essenziellen Signalweg, die sogenannte ungefaltete Proteinantwort 
(UPR; engl. unfolded protein response). Insbesondere intestinale Epithelzellen, wie zum 
Beispiel Paneth- und Becherzellen, sind aufgrund ihres hohen Bedarfs an sekretorischen 
Proteinen auf eine intakte UPR angewiesen. Diesbezüglich konnten Studien sowohl im 
murinen als auch humanen System bereits  zeigen, dass während einer Entzündung 
ER-Stress in intestinalen Epithelzellen vermehrt auftritt. Zusätzlich identifizierten 
genomweite Assoziationsstudien Gene, die in der UPR involviert sind, als potentielle 
Risikofaktoren für CED. Eines dieser Gene ist ORMDL3, dessen Funktion in Bezug auf 
die Pathogenese von CED und extraintestinalen Manifestationen jedoch bisher nicht 
untersucht ist. Aus diesem Grund hatte die vorliegende Arbeit das Ziel, den Effekt von 
ORMDL Proteinen auf die drei UPR-Signalwege und dessen Auswirkung auf die 
intestinale und systemische Homöostase zu untersuchen. 
Diese Studie liefert erstmals Hinweise auf zelltypspezifische Expressionsprofile von 
ORMDL Proteinen als Reaktion auf ER-Stress und weist somit auf funktionelle 
Unterschiede in verschiedenen Zelltypen unter belastenden Bedingungen hin. Zusätzlich 
verdeutlicht diese Studie zum ersten Mal die verschiedenen Auswirkungen von ORMDL3 
auf jeden der drei UPR-Signalwege. Dabei aktiviert ORMDL3 den ATF6α- und den PERK-
Signalweg, wohingegen der IRE1-Signalweg inhibiert wird. Den stärksten Effekt zeigt 
ORMDL3 auf den ATF6α-Signalweg, wobei die Überexpression von ORMDL3 die 
glykosylierte Form von ATF6α reduziert. In der Literatur finden sich bereits Hinweise, dass 
die unglykosylierte Form von ATF6α zunächst zu dessen Spaltung und Aktivierung sowie 
die sich anschließende Expression von ATF6α Zielgenen führt. Die in dieser Studie 
untersuchte Überexpression von ORMDL3 und die damit einhergehende verstärkte 
Spaltung von ATF6α sowie die erhöhte Induktion des ERSE-Promotors unterstützen dies. 
Zusätzlich konnte in dieser Arbeit erstmals die Interaktion von ORMDL3 und ATF6α 
mittels Co-Immunopräzipitationsstudien nachgewiesen werden. Eine induzierende 
Funktion von ORMDL Proteinen konnte auch für den PERK-Signalweg beobachtet 
werden, welche primär auf eine Verknüpfung der beiden genannten Signalwege 
zurückzuführen ist. Dies konnte anhand der vermehrten ATF4-Promotoraktivität sowie der 




Überexpression verdeutlicht werden. Im Gegensatz zu der induzierenden Wirkung von 
ORMDL3 auf den ATF6α- und PERK-Signalweg, konnte in der vorliegenden Arbeit in 
Folge einer Überexpression von ORMDL3 eine reduzierte Spaltung von XBP1 und eine 
verminderte Aktivierung des UPRE-Promotors beobachtet werden. Diese vielfältigen 
regulatorischen Mechanismen von ORMDL3 ermöglichen spezialisierten Zellen eine 
geeignete ER-Stressantwort entsprechend ihrer Anforderungen. 
Darüber hinaus wurde in dieser Arbeit erstmals die Auswirkung einer Deletion von jeweils 
einem ORMDL Gen mittels Ormdl1- und Ormdl3-defizienter Mäuse untersucht. Durch die 
Deletion von Ormdl3 kommt es zu einer Reduktion des Körpergewichts infolge einer 
verringerten lokalen Produktion des insulinähnlichen Wachstumsfaktors 1 (engl. Insulin-
like growth factor 1) in den Muskeln dieser Tiere. Obwohl genetische Veränderungen von 
ORMDL3 im Menschen als potentieller Risikofaktor für Morbus Crohn und Colitis Ulcerosa 
identifiziert wurden, hat die Deletion von Ormdl1 oder Ormdl3 keine spontane intestinale 
Entzündung im murinen Organismus zur Folge. Hingegen zeigen Ormdl3-defiziente, nicht 
aber Ormdl1-defiziente, Mäuse eine erhöhte Anfälligkeit für eine DSS-induzierte Kolitis, 
welches sich in einer stärkeren Gewichtsreduktion, einer vermehrten Bildung von 
Kryptabzessen sowie einer erhöhten Serumkonzentrationen des pro-inflammatorischen 
Zytokins IL-1β äußert. Die Verabreichung von DSS über einen kürzeren Zeitraum führt 
ebenfalls zu vermehrtem ER-Stress im Kolon und in der Leber von Ormdl3-defizienten 
Mäusen. Zudem konnten erhöhte ER-Stress-Level im Lebergewebe von 
Ormdl3-defizienten Mäusen nach einer subletalen Dosis des chemischen ER-
Stressinduktors Tunicamycin festgestellt werden. Beide in vivo Versuche weisen auf einen 
positiven Effekt von ORMDL3 auf die Rekonstitution der Homöostase im ER hin. 
Zusammenfassend verdeutlicht die vorliegende Arbeit, dass ORMDL Proteine als 
bedeutende Regulatoren der UPR einen starken Einfluss insbesondere auf den 
ATF6α-Signalweg ausüben. Zudem konnte gezeigt werden, dass ORMDL3 relevant für 
die Aufrechterhaltung der Homöostase im ER und im intestinalen Epithel ist. Die 
Ergebnisse dieser Arbeit weisen erstmals auf eine regulatorische Wirkung von ORMDL3 
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8.1 List of abbreviations 
ADRP adipose differentiation related protein 
AGR2 encoding the anterior gradient protein-2 
APS ammonium persulfate 
ATCC American Type Culture Collection 
ATF4 activating transcription factor 4 
ATF6 activating transcription factor 6 
ATF6α(N) N-terminal fragment of ATF6α 
ATG16L1 autophagy-related protein 16-1 
BMDM bone marrow-derived macrophages 
BSA bovine serum albumin 
BW body weight 
Ca2+ calcium 
CD Crohn’s disease 
cDNA complimentary DNA 
CHOP CCAAT-enhancer-binding homologous protein 
CHX cycloheximide  
CO-IP Co-immunoprecipitations 
CREBH  cAMP responsive element-binding protein 
CXCL1 chemokine (C-X-C motif) ligand 1 
DAI disease activity index 
DBD DNA-binding domain 
DMSO dimethylsulfoxid  
DNA deoxyribonucleic acid 
DSS  dextran sulfate sodium 
DTT ditriothreitol  
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
eIF2α eukaryotic translation initiation factor 2α 
eIF2αA/A_IEC nonphosphorylatable Ser51A1a mutant of eIF2α in IECs  
ELISA Enzyme-linked immunosorbent assays  
EndoH endoglycosidase H 
eQTL expression quantitative trait loci 
ER  endoplasmic reticulum 
ERAD ER-associated protein degradation 
ERN endoplasmic reticulum to nucleus signaling  
ERSE ER stress response element 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
FL full length 
FRT flippase recognition target 




GADD34 growth-arrest DNA damage gene 34 
GH growth hormone 
GRP78 78-kDa glucose-regulated protein 
GRP94 94-kDa glucose-regulated protein 
GWAS genome-wide association studies 
HDL high-density lipoprotein 
HE hematoxylin and eosin 
HERC2 probable E3 ubiquitin-protein ligase 
HRP horseradish peroxidase 
IBD inflammatory bowel disease 
IEC intestinal epithelial cell 
IFNγ interferon gamma 
IGF1 insulin-like growth factor 1 
IHC immunohistochemistry 
IL interleukin 
IRE1 inositol-requiring kinase 1 
IRES internal ribosome entry site 
JNK c-Jun-N-terminal kinase 
kDA kilodalton 
KO knockout 
L DNA SmartLadder 
LCB long-chain base 
Lgr5 leucine-rich repeat-containing G-protein coupled receptor 5 
Lyz1 lysozyme 1 
Mbtps1 membrane-bound transcription factor S1P-encoding gene 
MEF mouse embryonic fibroblasts 
MHC major histocompatibility complex 
MOPS 4-Morpholinepropanesulfonic acid 
mRNA messenger ribonucleic acids 
Muc2 mucin 2 
NeoR neomycin resistance 
NFY nuclear transcription factor 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NOD2 nucleotide-binding oligomerization domain-containing protein 2 
NRF2 nuclear factor erythroid 2-related factor 
OASIS  old astrocyte specifically induced substance 
ORMDL orosomucoid 1 (Saccharomyces cerevisiae)-like protein 
Ormdl1-/- Ormdl1-deficient mice 
Ormdl3-/- Ormdl3-deficient mice 
Ormdl3ΔIEC IEC-specific Ormdl3 deficiency 
OS-9 lectin osteosarcoma amplified 9 
p36ATF6α 36 kDA fragment of ATF6α 
p50ATF6α 50 kDA fragment of ATF6α 
p58IPK protein kinase inhibitor of 58 kDa 
PBA 4-phenylbutyrate 




PCR polymerase chain reactions 
p-eIF2α phosphorylated form of eIF2α 
PERK 
double-stranded RNA-activated protein kinase (PKR)-like ER 
kinase 
PP1 protein phosphatase 1 
PTPN2 tyrosine-protein phosphatase non-receptor type 2 
PuroR puromycin resistance 
PVDF polyvinylidene difluoride 
qPCR quantitative real-time PCR 
RAMP4 ribosome-associated membrane protein 4 
RIDD regulated IRE1-dependent decay of mRNA 
RLU relative light units 
RT reverse transcriptase 
S1P site 1 protease 
S2P site 2 protease 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
SERCA2b sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
siRNA small interfering RNA 
SNP single nucleotide polymorphisms 
SPT serine palmitoyltransferase  
SPTLC1 serine palmitoyltransferase, long chain base subunit 1 
SSC side scater 
STAT3 signal transducer and activator of transcription 3 
TEMED tetramethylethylenediamine  
TG thapsigargin 
Th1 T helper 1 
Th2 T helper 2 
TLR Toll-like receptor 
TM tunicamycin 
TNBS trinitrobenzene sulfonic acid 
TNFα tumor necrosis factor alpha 
TRAF2 tumor necrosis factor receptor-associated factor 2 
TRAPα translocon-associated protein alpha 
TUDCA tauroursode-oxycholate 
UC ulcerative colitis 
UG unglycosylated  
untr untreated 
UPR unfolded protein response 
UPRE unfolded protein response element 
WT wild-type 
XBP1 X-box binding protein 1 
XBP1s spliced XBP1 
Xbp1ΔIEC IEC-specific Xbp1 deficiency 






8.2 Applied buffers and solutions  
Table 8.1: List of applied buffers or solutions 
Buffer or solution Composition or company 
10x TAE buffer Carl Roth, Karlsruhe, Germany, cat. nr. T845.2 
10x TBS 200 mM Tris (pH 7.6), 1.37 M sodium chloride 
10x TGS buffer 25 mM Tris (pH 8.3), 192 mM glycine, 0.1 % (w/v) SDS 
5x SDS loading dye 250 mM Tris (pH 6.8), 10 % (w/v) SDS,  50 % (v/v) 
glycerol, 500 mM DTT 
Anode buffer 1  30 mM Tris, 20 % (v/v) methanol 
Anode buffer 2  300 mM Tris, 20 % (v/v) methanol 
Blocking solution 5 % (w/v) non-fat dry milk in TTBS 
Cathode buffer  25 mM Tris, 20 % (v/v) methanol, 40 mM 6-amino-n-
caproic acid 
Cell fractionation 1  10 mM HEPES (pH 7.9), 10 mM potassium chloride, 
1.5 mM magnesium chloride, 10 mM sodium floride 
Cell fractionation 2  20 mM HEPES (pH 7.9), 420 mM sodium chloride, 1.5 
mM magnesium chloride, 0.2 mM EDTA, 25 % (v/v) 
glycerol, 10 mM sodium fluoride 
CO-IP binding and washing buffer PBS, 0.02 % (v/v) Tween20 
CO-IP elution buffer 50 mM Glycin (pH 2.8) 
DNA loading dye 50 % (v/v) glycerol, 0.1 % (w/v) bromophenol blue, 0.1 
% (w/v) xylene cyanol 
ECL substrate GE Healthcare, Freiburg, Germany, cat. nr. RPN2109 
FCS PAA Laboratories/ GE Healthcare, Freiburg, Germany, 
cat. nr. PAA A15-151 
FWB 0.5 % (w/v) BSA in PBS 
Ketanest S 25mg/ml, 10ml Pfizer, New York, USA  
Loading gel 0.5 M Tris (pH 6.8), 0.4 % (w/v) SDS 
MOPS SDS Running Buffer (20X) Novex/Life Technologies, Darmstadt, Germany, cat. 
nr. NP001 
OPTI-MEM Gibco/Life Technologies, Darmstadt, Germany, cat. nr. 
31985-047 
PBS 8 g/l sodium chloride, 0.2 g/l potassium chloride , 
1.56 g/l disodium phosphate, 0.24 g/l monopotassium 
phosphate, pH 7.4 
RIPA  150 mM sodium chloride, 1 % (v/v) NP40, 0.5 % (w/v) 
deoxycholic acid, 0.1 % (w/v) SDS, 50 mM Tris 
(pH 8.0) 
Rompun Bayer, Leverkusen, Germany 
Separation buffer 1.5 M Tris (pH 8.8), 0.4 % (w/v) SDS 
SmartLadder  Eurogentec, Cologne, Germany, cat. nr. MW-1700-10 
Stacking buffer 0.5 M Tris (pH 8.8), 0.4 % (w/v) SDS 
Stripping buffer 62.5 mM Tris (pH 6.8), 2 % (w/v) SDS 
SYBR Safe DNA gel stain Life Technologies, Darmstadt, Germany cat. nr. 
S33102 
TE 10 mM Tris, 1 mM EDTA 





Table 8.2: List of applied media  
Media Composition or company 
BMDM medium 50 % (v/v) Mouse Macrophage medium, 50 % (v/v) DMEM, 
250 µg/ml Amphotericin, 1x Penicillin/Streptomycin 
DMEM Gibco/Life Technologies, Darmstadt, Germany cat. nr. 
41966-029 
LB Agar  10 g/l tryptone, 5 g/l yeast extract, 5 g/l sodium chloride, 15 
g/l agar agar 
LB Medium  10 g/l tryptone, 5 g/l yeast extract, 5 g/l sodium chloride 
Mouse Macrophage medium Life Technologies, Darmstadt, Germany,cat. nr. 12065-074 
RPMI Gibco/Life Technologies, Gibco/Life Technologies, 
Darmstadt, Germany, cat. nr. 52480-025 
S.O.C medium Life Technologies, Darmstadt, Germany, cat. nr. C4040-10 
 
8.4 Chemicals 
Table 8.3: List of applied chemicals 
Chemical Company 
2-Mercaptoethanol Sigma-Aldrich, Munich, Germany 
6-amino-n-caproic acid Sigma-Aldrich, Munich, Germany 
Acrylamide Bis Sol.30% Bio-Rad, Munich, Germany 
Ammonium persulfate (APS)  Sigma-Aldrich, Munich, Germany 
Amphotericin PAA Laberatories/ GE Healthcare, Freiburg, 
Germany 
Ampicillin Sigma-Aldrich, Munich, Germany 
Bovine serum albumin (BSA) Carl Roth, Karlsruhe, Germany 
Bromophenol blue  Sigma-Aldrich, Munich, Germany 
Deoxycholic acid Sigma-Aldrich, Munich, Germany 
Dimethylsulfoxid (DMSO)  Sigma-Aldrich, Munich, Germany 
Dithiothreitol (DTT) Th. Geyer, Renningen, Germany 
DSS reagent grade, molecular weight 
36000-50000 
MP Biomedicals, Illkirch Cedex, France 
Dynabeads Protein G Life Technologies, Darmstadt, Germany 
EDTA Sigma-Aldrich, Munich, Germany 
Ethanol Merck, Darmstadt, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Carl Roth, Karlsruhe, Germany 
HEPES  Sigma-Aldrich, Munich, Germany 
Isopropanol Merck, Darmstadt, Germany 
Kanamycin Merck, Darmstadt, Germany 
LE Agarose Biozyme, Hessisch Oldendorf, Germany 
Magnesium chloride Merck, Darmstadt, Germany 
Methanol Merck, Darmstadt, Germany 





Non-fat dry milk (NFDM) Bio-Rad, Munich, Germany 
Nonidet p 40 substitute Sigma-Aldrich, Munich, Germany 
Penicilin/Streptomycin Life Technologies, Darmstadt, Germany 
Potassium chloride Sigma-Aldrich, Munich, Germany 
Potassium dihydrogen phosphate  Merck, Darmstadt, Germany 
RNase-free water  Qiagen, Hilden, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
Sodium fluoride Sigma-Aldrich, Munich, Germany 
Sodium phosphate dibasic Sigma-Aldrich, Munich, Germany 
SYBR safe  Life Technologies 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Munich, Germany 
TRIS Merck, Darmstadt, Germany 
Triton-X Sigma-Aldrich, Munich, Germany 
Tween20 Carl Roth, Karlsruhe, Germany 
Xylene cyanol Sigma-Aldrich, Munich, Germany 
 
8.5 Enzymes and inhibitors 
Table 8.4: List of applied enzymes 
Enzyme Company 
FastDigest BamHI Thermo Scientific, Bremen, Germany 
FastDigest BglII Thermo Scientific, Bremen, Germany 
FastDigest EcoRI Thermo Scientific, Bremen, Germany 
FastDigest KpnI Thermo Scientific, Bremen, Germany 
Gateway® BP Clonase® II enzyme mix Life Technologies, Darmstadt, Germany 
GoTaqTM polymerase Promega, Mannheim, Germany 
Proteinase K Thermo Scientific, Bremen, Germany 
RNase-free DNase Set  Qiagen, Hilden, Germany 
Trypsin/EDTA Life Technologies 
 
Table 8.5: List of applied inhibitors 
Inhibitor Company 
AEBSF (4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride) 
Calbiochem, Darmstadt, Germany 
HaltTM combined protease and 
phosphatase inhibitor  
Thermo Scientific, Bremen, Germany 
Cycloheximide (CHX) Sigma-Aldrich, Munich, Germany 
Thapsigargin (TG) Calbiochem, Darmstadt, Germany 





Table 8.6: Overview of applied kits 
Kit Composition 
BigDye Terminator v1.1.Cycle Sequencing Kit  Applied Biosystems, Darmstadt, Germany 
BigDye® Terminator v1.1 cycle sequencing Kit Life Technologies, Darmstadt, Germany 
Dual-luciferase® reporter assay system Promega, Mannheim, Germany 
GeneJET Plasmid Miniprep Kit  Thermo Scientific, Bremen, Germany 
Lamina Propria Dissociation Kit  Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Maxima H Minus First Strand cDNA Synthesis 
Kit 
Thermo Scientific, Bremen, Germany 
Mouse/Rat IGF-1 quantikine ELISA kit R&D systems, Minneapolis, USA 
PureLink® HiPure Plasmid Filter Midiprep Kit  Life Technologies, Darmstadt, Germany 
QIAquick Gel Extration Kit Qiagen, Hilden, Germany 
QIAquick PCR Purification kit Qiagen, Hilden, Germany 
QIAshredder Qiagen, Hilden, Germany 
Rapid DNA Ligation Kit Roche, Mannheim, Germany 
Rat/Mouse Growth hormone ELISA kit EMD Millipore, Schwalbach, Germany 
RNeasy Mini Kit  Qiagen, Hilden, Germany 
Roti Histokit Carl Roth, Karlsruhe, Germany 
SYBR® Select Master Mix Life Technologies, Darmstadt, Germany 
TOP10 chemically competent E. coli Life Technologies, Darmstadt, Germany 
 
8.7 Plasmids and oligonucleotides 
Table 8.7: Plasmid names and their origin or production method 
Plasmid name Generated by 
p3xFLAG-ATF6 Chen et al., 2002; purchased from Addgene, Cambridge, USA, 
cat. nr.11975 
pCAX-XBP1delDBD Iwawaki et al., 2003 
pCMV-HA-EGFP Gateway cloning 
pCMV-HA-hORMDL1 Gateway cloning 
pCMV-HA-hORMDL3 Gateway cloning 
pDEST53 purchased from Life Technologies, Darmstadt, Germany, cat. nr. 
12288-015 
pDEST53-hORMDL3 Gateway cloning 
pDONR221 purchased from Life Technologies, Darmstadt, Germany, cat. nr. 12536-017 
pGL3-ATF4 restriction enzyme based cloning using BglII and KpnI 
pGL3-Basic purchased from Promega, Mannheim, Germany, cat. nr. E1751 
pGL3-ERSE restriction enzyme based cloning using BglII and KpnI 
pGL3-UPRE Wu et al., 2007; purchased from Addgene, Cambridge, USA, cat. nr. 11976 




All oligonucleotides were generated and desalted by Microsynth AG (Balgach, 
Switzerland). All sequences are shown from 5’ to 3’ direction. 
Table 8.8: List of applied oligonucleotides with their sequences 















murine CTTCATCCGTTGTTGCTTGC TCCCCTACAGATCTCCTGAGG 
Ormdl3 
PCR KO 
murine CTTCATCCGTTGTTGCTTGC TCACAGTGCCAGTAGGAAACC 
Ormdl3 
PCR cond 






Ormdl1 murine ACTCACTGGGAACAGCTGGA ATTCCAAAGATGCGAACACC 
Ormdl2  murine CTTTTGACACATTGGGAGCA GGTAGCTTAGGCAGCAGCAC 
















Il-6 murine GACAACTTTGGCATTGTGG ATGCAGGGATGATGTTCTG 
Il-10 murine TGCTATGCTGCCTGCTCTTA TTTTCACAGGGGAGAAATCG 
Cxcl1 murine GCTGGGATTCACCTCAAGAA TGGGGACACCTTTTAGCATC 
Tnfα murine TCACACTCAGATCATCTTCTC AGACTCCTCCCAGGTATATG 
Atf6α murine ATGCCAGTGTCCCAGCAAAA TCCCCCAGTGACTGCAAGAA 
Grp94 murine TGGGTCAAGCAGAAAGGAGG TCTCTGTTGCTTCCCGACTTT 
Atf4 murine ATGGCCGGCTATGGATGAT CGAAGTCAAACTCTTTCAGATC
CATT 
Chop murine CTGCCTTTCACCTTGGAGA CGTTTCCTGGGGATGAGATA 
Gadd34 murine CTGCAAGGGGCTGATAAGAG AGGGGTCAGCCTTGTTTTCT  
ORMDL1 human CTGACCAGGGTAAAGCAAGG TCCAAAGATCCGAACACCAT 
ORMDL2 human CATACGGTGAAAGGGACACC CGGCAGCAGTACACTTAGCA 
ORMDL3 human GTGGCATCTGGCTCTCCTAC TGAGCACAAAATGGATCTGG 






Table 8.9: Overview of applied TaqMan probes 
Target Species Company Catalog number 
Vil murine Life Technologies, Darmstadt, Germany 00457074 
Muc2 murine Life Technologies, Darmstadt, Germany 00458299 
Lgr5 murine Life Technologies, Darmstadt, Germany 00438905 
Gapdh murine Life Technologies, Darmstadt, Germany 99999915 
Lyz1 murine Life Technologies, Darmstadt, Germany 00657323 
 
8.8 Antibodies 
All antibodies used for western blotting were diluted in TTBS containing either 5 % (w/v) 
bovine serum albumin (BSA) or 5 % (w/v) non-fat dry milk (NFDM). Table 8.10 shows all 
employed primary antibodies. All used secondary antibodies are listed in Table 8.11. 
Secondary antibodies were linked with horseradish peroxidase (HRP) to enable detection 
using ECL substrate. 
Table 8.10: Detailed overview of applied primary antibodies  
Antibody Species, 
clonal 












Cell Signaling Technology, 












Cell Signaling Technology, 
Leiden, The Netherlands  
5554 




























Santa Cruz Biotechnology, 






Cell Signaling Technology, 



























Table 8.11: Detailed overview of applied secondary antibodies 





Amersham Biosciences, Glattbrugg, 
Switzerland 
NA931V 
rabbit HRP 1:2500 Amersham Biosciences, Glattbrugg, 
Switzerland 
NA934V 
goat HRP 1:1000 Sigma-Aldrich, Munich, Germany  A5420 
rat HRP 1:1000 Sigma-Aldrich, Munich, Germany  A9037 
 
Table 8.12: List of applied FACS antibodies 
Antibody Fluorophore Isotype Dilution Company Catalog 
number 
MHCI APC mouse 
IgG2a 
1:75 eBioscience, Frankfurt a. 
Main, Germany 
17-5958 
CD11b PE rat 
IgG2b 














1:100 eBioscience, Frankfurt a. 
Main, Germany 
12-4031 
MHCII PE rat 
IgG2b 
1:100 eBioscience, Frankfurt a. 
Main, Germany 
12-5322 
CD11b APC rat 
IgG2b 

























8.9 Devices and consumables 
Table 8.13: Overview of used devices 
Devices Company 
7900 HT Fast Real-Time PCR System Applied Biosystems/Life Technologies, 
Darmstadt, Germany 
96-well thermocycler Applied Biosystems/Life Technologies, 
Darmstadt, Germany 
ABI PRISM® 3700 sequencer  Applied Biosystems/Life Technologies, 
Darmstadt, Germany 
Analytic balance 870-15 Kern, Balingen, Germany 
Assistent Mini-Centrifuge SPROUT Heathrow Scientific, Nottingham , United 
Kingdom 
Automated developer machine Agfa, Mortsel, Belgium 
Axio Imager.Z1 Zeiss, Jena, Germany 






Centrifuge for 15/50 ml tubes: Megafuge 
16R 
Thermo Scientific, Bremen, Germany 
Centrifuge for Eppendorf tubes: Fresco 
21 
Thermo Scientific, Bremen, Germany 
Certomat MV, vortex mixer  B. Braun Biotech Internat., Melsungen, 
Germany 
ChemiDoc XRS Imaging System Bio-Rad, Munich, Germany 
Confocal microscope: TCS SP5 Leica Microsystems, Wetzlar, Germany 
Electronic pipet filler  Eppendorf, Hamburg, Germany 
Eppendorf Research®, adjustable-
volume pipette  
Eppendorf, Hamburg, Germany 
FACSCalibur flow cytometer BD Biosciences, Heidelberg, Germany 
GeneAmp PCR System 9700 Applied Biosystems/Life Technologies, 
Darmstadt, Germany 
Gentle-MACSTM Dissociator Miltenyi Biotec, Bergisch Gladbach, Germany 
Incubator for cell lines Binder, Tuttlingen, Germany 
Incubator for E.coli in media: Orbital 
Incubator SI50 
Stuart Equipment, Staffordshire, United 
Kingdom 
Incubator for E.coli on agar plates: 
Incucell 111 
MMM Group, Planegg, Germany 
Laminar flow workbench HERASafe KS Thermo Scientific, Bremen, Germany 
Leica RM 2255 microtome  Leica Microsystems, Wetzlar, Germany 
Magnetic stirrer C-MAG HS 7 IKAMAG IKA, Staufen, Germany 
Microwave R-239 SHARP, Hamburg, Germany 
Mini-Sub Cell GT Bio-Rad, Munich, Germany 
Molecular Imager ChemiDoc XRS 
Imaging System 
Bio-Rad, Munich, Germany 
NanoDrop ND-1000 spectrophotometer  PeqLab Biotechnologie GmbH, Erlangen, 
Germany 
Power Pac 300 Bio-Rad, Munich, Germany 
SympHony Benchtop Meters VWR, Darmstadt, Germany 
Tecan Infinite F200 pro plate reader  Tecan, Männedorf, Switzerland 
Thermomixer compact 5350 Eppendorf, Hamburg, Germany 
Trans-Blot® TurboTM Transfer System Bio-Rad, Munich, Germany 
Tube roller SRT6 Stuart Equipment, Staffordshire, United 
Kingdom 
Vortex-Genie 2 Variable Speed Sartorius, Göttingen, Germany 
Water bath 1003 GFL, Burgwedel, Germany 
Water purification system TKA, Niederelbert, Germany 
Wide Mini ReadySub-Cell GT Bio-Rad, Munich, Germany 









Table 8.14: List of applied consumables 
Consumable Company 
0.5 ml, 1.5 ml and 2 ml reaction tubes  Sarstedt, Nümbrecht, Germany 
1 ml syringes   
100 ml culture flasks  Schott, Mainz, Germany 
15 ml and 50 ml tubes  Sarstedt, Nümbrecht, Germany 
26G needles  B. Braun, Melsungen, Germany 
Blot paper Bio-Rad, Munich, Germany 
Chemiluminescence hyperfilm Applied Biosystems/Life Technologies, Darmstadt, 
Germany 
Glass beads Carl Roth, Karlsruhe, Germany 
HistoBond Paul Marienfeld GmbH& Co. KG 
MicroAmp Optical 384-Well Reaction 
Plates  
Applied Biosystems 
Microvette 500 (Potassium-EDTA) Sarstedt, Nümbrecht, Germany 
NuPAGE® Bis-Tris gel Life Technologies, Darmstadt, Germany 
Pipette tips and filter tips  Sarstedt, Nümbrecht, Germany 
Pipette tips for electronic pipette  Biohit, Göttingen, Germany 
Polyvinylidene difluoride (PVDF) 
membranes 
Bio-Rad, Munich, Germany 
Rotilabo 0.22 μm syringe filter  Carl Roth, Karlsruhe, Germany 
Serological pipettes Sarstedt, Nümbrecht, Germany 
Surgical disposable scalpels  B. Braun, Melsungen, Germany 
Tissue culture dishes 96-, 24- and 6-
well  
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